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THESIS ABSTRACT 
Introduction 
In November 2016, the International Conference on Harmonsation (ICH) published a 
requirement for sponsors to develop a systematic, prioritised, risk-based approach 
to monitoring clinical trials. This process is more commonly known as Risk Based 
Monitoring (RBM). However, evidence suggested that a gold standard validated 
approach to RBM did not exist and it was unclear how sponsors would introduce RBM 
into their clinical trials units (CTUs).  
In 2014, Ireland, unlike countries such as Switzerland and the UK, did not have a 
national strategy to support the introduction of RBM into its publicly funded, 
academic-led CTUs. The absence of a national strategy and gold standard RBM 
approach meant it was not clear how RBM would be implemented in CTUs. 
Therefore, the overarching aim of this thesis was to develop, implement and evaluate 
a quality improvement intervention to support the introduction of RBM into 
academic-led clinical trials in Ireland. 
Methods  
This thesis employed a multi-method research strategy directed by the Knowledge 
to Action (KTA) framework over four years from October 2014 to October 2018. The 
KTA framework is a conceptual framework to assist the translation of knowledge into 
sustainable, evidence-based interventions. This thesis used a range of research 
methods, implemented in four separate sequential phases, to address different 
components of the KTA framework which primarily involve knowledge creation and 
knowledge translations.  
The four phases first involved systematically reviewing the existing evidence of RBM 
methods. Then, in a mixed method study, I explored the attitudes, and perceived 
barriers and facilitators to the implementation of RBM in academic-led clinical trials 
in Ireland. Next, I did a document analysis study to examine the experience of 
monitoring in a clinical trial. Finally, I developed the quality improvement study by 
combining the results of the three earlier phases to identify the most appropriate 
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quality improvement intervention to support RBM use in academic led clinical trials 
in Ireland. 
Results  
The systematic review showed several tools exist to support the implementation of 
RBM. The mixed methods study showed a need for training and regulatory endorsed 
guidelines to support the implementation of RBM in academic-led clinical trials.  The 
document analysis showed that on-site and centralised monitoring can be used 
simultaneously to fulfil ICH GCP’s seventeen monitoring requirements. The findings 
of these three studies were combined and a brief, face-to-face, interactive education 
workshop was identified as an effective way to encourage RBM tool usage among 
clinical researchers working in academic-led clinical trials in Ireland.  
Conclusion: Applying the KTA framework to empirical data has led to an intervention 
that is implementable in clinical practice and has the potential to positively change 
monitoring practices of clinical researchers. This thesis provides critical evidence on 
the complexities associated with implementing RBM in academic-led clinical trials. It 
provides practical recommendations to guide clinical researchers who wish to 
perform RBM.  
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Chapter 1. Introduction  
1.1 Chapter overview 
The National Institute of Health defines clinical trials as research studies in which one 
or more human subjects are prospectively assigned to one or more interventions to 
evaluate the effects of those interventions on health-related biomedical or 
behavioral outcomes.(1). Such interventions include new medicines, but also new 
therapies, devices, diagnostic techniques and surgical procedures, as well as 
optimising existing medicinal products and procedures to promote better health and 
welfare(1, 2). Globally, each year, millions of Euros, time and resources are spent 
conducting thousands of clinical trials that aim to discover new treatments for 
diseases as well as new ways to detect, diagnose, and reduce the risk of disease(3-
5). These clinical trials are only possible thanks to the thousands of participants who 
volunteer to take part in these trials(6).  
 
Fortunately, most clinical trial participants, experience mild or no adverse events 
during their time in a trial(7). However, there have been cases where clinical trial 
participants have been hurt by the intervention or trial procedure(8, 9). This is 
inevitable as clinical trials involve the testing of new medicines and therapies with 
unknown safety profiles that may unexpectedly harm trial participants(2, 10). 
Therefore, to ensure the rights and wellbeing of participants are protected, it is 
essential that trial activity is adequately monitored, and the trial complies with 
relevant regulation and the approved trial protocol(11, 12).   
 
Clinical trial can be divided into Clinical Trials of Investigational Medicinal Products 
(CTIMPs) and non CTIMPs(13). Food trials, social and psychological interventions that 
target complex social and behavioural problems are examples of non -CTIMPs. Unlike 
CTIMP, which are subject to clinical trial regulations that require some degree of 
monitoring, non-CTIMPs, do not legally require monitoring. Primarily for this reason, 
most of the existing literature and guidelines for safety monitoring and reporting of 
adverse events focuses on CTIMPs(13, 14). Consequently, there is little monitoring 
guidance for investigators conducting non- CTIMPs (social and behaviour trials)(15). 
15 
 
 
However, despite the lack of a legal obligation and guidance, participant safety and 
data integrity are of extreme importance in non CTIMPs(14).  Like CTIMPs, risks such 
as participants entering non- CTIMPs without giving fully informed consent and 
implications of incomplete and inaccurate study data, exist in non-CTIMP trials (14). 
In recent years, many researchers have started to acknowledge the risks associated 
with non -CTIMPs and are employing the use of Data and Safety Monitoring Boards 
(DSMBs) to monitor the progress and quality of these trials(16). It is claimed that the 
safety of study participants in non-CTIMPs has increased due to the activity of 
DSBMs(16).  
 
However, this Thesis will only focus on the  monitoring of CTIMPs trials which is  
enforced under the EU Clinical Trial Directive(17).Traditionally, clinical trial 
monitoring involved intensive on-site monitoring visits at clinical trial sites and 
exhaustive source data verification of clinical trial data (12, 18-20). In recent years 
clinical researchers have questioned the validity and necessity for traditional 
monitoring methods (19, 20). Many consider it to be an expensive, time-consuming 
and resource heavy activity that does not improve the quality of clinical trial data or 
the protection of trial participants (21, 22). Regulatory agencies, such as the 
International Committee for Harmonization and the Food and Drug Administration, 
are now advising clinical researchers to stop automatically applying the traditional 
100% source data verification approach and instead use risk-based monitoring 
(RBM)(12, 23, 24).  It is suggested that RBM will reduce clinical trial costs by reducing 
the use of unnecessary traditional monitoring activity that has little impact on the 
safety or quality of a clinical trial(25). 
 
The RBM method is founded on the premise that each trial is different with its own 
risks that require a bespoke monitoring strategy(12).  It focuses on the individualized 
prevention or mitigation of likely sources of error or potential harm within each 
individual trial(12, 26). As such, the RBM approach is an adaptive approach to clinical 
trial monitoring that focuses monitoring on the identified areas which have the most 
potential to impact participant safety and data quality(26). Accordingly,  a RBM plan 
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must be tailored to the risk profile of each clinical trial(10). To do this, first, before a 
trial begins a robust risk assessment of the trial must be conducted to identify risks 
within a trial(10, 26). Once the risks have been identified  comprehensive, accurate 
monitoring guidelines are needed to guide the mitigation of the identified risks(10, 
26).   RBM tools and methodologies have been developed to guide the development 
of an RBM plan(27, 28). However, their effectiveness and usability has not been 
proven and so a gold standard approach to RBM does not exist(27).  
 
The non-prescriptive nature of RBM, lack of evidence-based methodology and lack 
of evidence to show its superiority to traditionally monitoring has hindered its 
widespread adoption(29, 30). Consequently academic sponsors are struggling to 
implement RBM in their trials (29, 31, 32). Furthermore, in Ireland, unlike countries 
such as Switzerland and the UK, a national strategy to support the introduction of 
RBM into its publicly funded, academic-led clinical trials units does not exist (23). The 
aim of this Thesis is to develop, implement and evaluate a quality improvement 
intervention to support the introduction of RBM into academic led clinical trials in 
Ireland. 
 
The aim of this chapter is to discuss the evolution of RBM and challenges regarding 
its implementation into academic led clinical trials. This chapter will also discuss the 
overall aim of the Thesis and provide an overview of the subsequent Thesis chapters. 
1.2 Clinical trials – phases, staff and academic trials  
1.2.1 Clinical trial phases 
One of the first documented clinical trials was conducted in 1747, by Dr James Lind. 
The aim of his trial was to find a cure for scurvy among an unrandomized, unblinded, 
convenient study sample of twelve sailors(1, 33). In the last three centuries, clinical 
trial methodology has greatly evolved(1). Major developments include the 
introduction of the placebo concept in 1863 to compare the effect of an active 
treatment to a dummy remedy(1). To the 1940s, when the Medical Research Council 
(MRC) in the UK, developed the double-blind controlled trial and random allocation 
process(1, 33). Then, by the 1970s randomized controlled trials were widely 
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recognized as the gold standard for establishing the safety and efficacy of medical 
interventions(33).  
Randomised clinical controlled trials involve the comparison of the action of an 
experimental treatment to the untreated progression of an illness in a patient under 
study(33). To generate unbiased, accurate and generalisable findings from a 
randomised clinical controlled trial, the study is conducted under tightly controlled 
conditions. Under these conditions, it is possible to conclude that an improvement 
or deterioration in a patient’s illness is caused by the treatment being 
administered(2). For findings of the randomised clinical controlled trial to be 
considered accurate, it is vital that the administration of the experimental treatment 
is the sole difference between the experimental (group that receives the study drug) 
and the control group (group that receives the placebo or standard care)(33). This is 
facilitated by the random, concealed  allocation of the intervention to study 
participants (34). Accordingly, patients’ entering a trial are assigned to either the 
experimental or the control group following a non-predictable, chance-based 
procedure, and the patient, the investigators and the participating physicians are 
ideally  blinded to which group (experiment or control) the patient has been 
assigned(35). The procedure of random and concealed allocation of study groups has 
the primary objective of removing subjective interferences, for instance, the 
possibility that investigators assign healthier patients to one arm of the study leading 
to allocation bias(34, 35). 
The scientific quality of the randomised clinical controlled trial methodology is 
currently considered the gold standard in treatment evaluation(33). Over the past 
several decades, randomised clinical controlled trial have prevailed over clinical 
judgement, case reports, and observational studies as evidential standards in 
medicine development and evaluation(33). Furthermore, during this time frame, 
randomised clinical controlled trial became a crucial part of the regulatory process 
whereby a new medicine could only gain marketing authorisation and access to the 
drug market after its safety and effectiveness was proven in typically 2 substantial 
Clinical Trial of an Investigational Medicinal Product (CTIMP)(36).  
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Currently, randomised , controlled clinical trials are large and tightly regulated 
projects that must comply with ethical and regulatory requirements while at the 
same time maintaining high scientific standards(11, 37). The clinical trial process is 
long, expensive and resource intensive. It can take up to fifteen years and sometimes 
over a billion dollars to get an Investigational Medicinal Product (IMP) approved for 
patient use (38, 39). Clinical trials of new IMPs are conducted in four separate clinical 
trial phases (I-IV) that follow an orderly and deliberate progression that build on one 
another (Table 2)  (38, 39). Each phase is designed to answer certain questions about 
the IMP under investigation. For example, the aim of a Phase I trial is to examine the 
safety profile of an IMP on a small number of study participants(40). While the aim 
of a Phase III trial is to determine if the IMP, now with a preliminary safety profile, 
has a therapeutic effect(40). 
Table 1: Clinical trial phases  
 
Phase  
 
Purpose  
I First stage of IMP testing in human participants. Designed to determine 
the maximum amount of the IMP that can be given to healthy 
volunteers (between 2-100) before adverse effects become intolerable 
or dangerous 
II Designed to evaluate whether the IMP has any biological activity or 
effect and continue phase I safety assessments, performed on between 
100-300 participants  
III Designed to assess how effective an IMP is in practice. They are the 
most expensive, time-consuming and difficult trials to design and run. 
They require many participants with a specific medical condition (300–
3,000) and are often multi-centre, international clinical trials 
IV Designed to monitor the safety of an IMP after it has received 
marketing authorisation by the appropriate regulatory agencies such 
as the European Medicine Association (EMA) in the EU or the FDA in 
the US. Marketing authorization permits the sale of an IMP on the open 
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market.  Typically, a phase IV trial is conducted over a minimum of two 
years, to monitor the safety of the IMP on the open market(40) 
 
All clinical trials, regardless of their phase, pose a risk to participant’s health as each 
trial is trying to establish the safety and efficiency of a pharmaceutical molecule by 
administering it to human subjects(12, 28). Depending on the characteristics of a 
clinical trial, its risks might be trivial causing only mild temporary discomfort; or 
serious causing long-term consequences(41). Side effects of a clinical trial can be 
physical (death, disability, infection), psychological (depression, anxiety) and 
economic (job loss)(42, 43). Therefore, before clinical researchers can start a clinical 
trial, they must first conduct a risk assessment analysis to ensure that the potential 
patient and societal benefits of a trial are proportionate to, or outweigh, the risks 
imposed on study participants(11, 41).  For example, most CTIMPs are designed to 
exclude women of childbearing age, pregnant women, or women who could become 
pregnant during the study(44, 45). In some cases, the male partners of these women 
are also excluded or required to take birth control measures(44, 45). These is because 
researchers do not know what impact the IMP would have on a fetus and so the risks 
of including women of childbearing age in a trial far outweighs the potential 
benefits(44, 45). 
Once a trial begins, it is vital that all four clinical trial phases are adequately 
monitored as safety risks for participants are present throughout all phases(38, 39). 
The purpose of monitoring as specified in GCP clearly highlights the need to ensure 
the three following aspects are achieved: the safety and well-being of the patient, 
the quality of the data and compliance with regulatory requirements(11). However, 
it must be noted that monitoring is limiting and cannot overcome inherent quality 
issues in a clinical trial(46). Clinical trial monitoring is defined by the International 
Conference on Harmonisation as ‘the act of overseeing the progress of a clinical trial, 
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and ensuring that it is conducted, recorded and reported in accordance with the 
protocol, SOPs, Good Clinical Practice (GCP), and the applicable regulatory 
requirements’, and aims to protect the rights and well-being of trial participants, 
while ensuring protocol compliance and data integrity(11). However, there are many 
well documented cases of research misconduct involving the deliberate fabrication 
or falsification of clinical trial data that were not detected by clinical trial monitoring 
(47, 48).  For example, in 1999, the Food and Drug Administration in the USA,  granted 
marketing authorisation for rofecoxib, a nonsteroidal anti-inflammatory drug(49). 
This meant that doctors could prescribe rofecoxib to their patients(49). However in 
2004, during the phase IV follow up trial, rofecoxib was withdrawn from the market 
as researchers identified an increased risk of heart attack and stroke associated with 
patients long term use, high dosage use of rofecoxib (49).  These risks had been 
overlooked during phase I–III trials(49). 
Conducting a clinical trial involves a diverse group of stakeholders including research 
sponsors (industry, academia), clinical investigators, patients, study nurses, 
pharmacists, laboratory technicians, physicians, and regulators. Each stakeholder 
offers a different set of tools to support an essential component of a clinical trial(47). 
Along with time, money, materials (e.g., medical supplies), support systems 
(informatics) and a clear plan for completing the necessary steps in a trial.  Therefore 
monitoring cannot be expected to correct clinical trial errors created by incompetent 
study teams, lack of resources such as budget and inadequate protocol design (47, 
48).    
1.2.2 Clinical trial staff 
All four clinical trial phases follow a formal trial protocol which describes the 
objectives, design, monitoring requirements, statistical considerations and aspects 
related to the organization of that  trial(50). Effective design and implementation of 
a trial protocol requires the involvement of many different types of research staff 
and medical professionals(51). Consequently, clinical trial staff are one of the most 
important, yet expensive, components of a clinical trial (50, 52). A typical clinical trial 
team will include a sponsor, principle investigator, study nurses, data manager, 
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monitor, biostatistician, administration staff ,pharmacists and most importantly 
study participants  (11, 53) (Table 2). As stated by ICH GCP guideline, ‘everyone 
involved in conducting research should be qualified by education, training and 
experience to perform his or her respective task(s)’(11).  
Table 2: Roles and responsibilities of a clinical trial team(11, 52) 
Role Responsibility 
Sponsor Institution, organisation or group of organisations with overall 
responsibility for initiation, management, insurance and 
financing arrangement for the trial  
Principal 
Investigator (PI) 
Responsible for the ethical conduct of the trial and for 
compliance with relevant legislation and ICH GCP guideline  
Trial 
coordinator 
Manages and conducts the day-to-day study activities in 
accordance with the protocol, applicable regulations and ICH 
GCP requirements. 
Study 
participant 
Comply with study requirements and fulfil other obligations 
they undertake when they make an informed choice to enrol in 
the trial  
Research nurses Provide clinical care for the participant, obtain participant’s 
informed consent and ensure the protocol is being followed at 
each step of the trial 
Data managers Oversee development of data collection tools based on the 
clinical trial protocol. Ensures trial data is collected, validated, 
and stored security. 
Trial monitor Ensure the trial team complies with the protocol by checking 
clinical site activities during on-site visits and communicates 
findings with the PI 
Sub-investigators 
such as 
clinicians  
Individuals authorized to make medical judgments and 
decisions regarding study participants   
Statistician  Design protocol and Statistical Analysis Plan (SAP) to describe 
the statistical techniques for study analysis in detail.  
Pharmacists Ensure IMPs are appropriate for use and are procured, handled, 
stored and used safely and correctly. 
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Overall, responsibility for protocol compliance and safety of study participants is 
shared between the local site Principle Investigators (if different from the sponsor), 
the various Research Ethics Committees that supervise the trial and the regulatory 
agency for the country where the IMP will be authorized(23). Each Principle 
Investigator must be qualified by training and experience and should have adequate 
resources to properly conduct their trial(54).  A Principle Investigator completes 
this role by formally delegating trial tasks to appropriately trained individuals 
and ensures that these individuals have the required GCP and protocol-specific 
training required for their specific roles and responsibilities(54, 55). In 
addition, a Principle Investigator must document and monitor all staff duties 
in an up to date, accurate and complete delegation log(23, 55).  
The trial sponsor is responsible for ensuring that formal processes are in place 
to maintain oversight of all delegated functions in a clinical trial(56, 57).  They 
take responsibility for the management and financing of a clinical trial but in some 
cases may not conduct the trial(23, 56). ICH GCP guideline, section 5.1.1 states 
that a sponsor is responsible for selecting the investigator(s) and/or institution(s) 
that manage the day to day running of a trial(23). It is also the sponsor’s 
responsibility to establish an independent data-monitoring committee (IDMC) to 
assess the progress of a clinical trial, including the safety data and the critical efficacy 
endpoints at intervals, and to recommend to the sponsor whether to continue, 
modify, or stop a trial(58).  
1.2.3 Academic clinical trials  
Historically academic institutions initiated, sponsored and managed the first clinical 
trials (51). Unlike pharmaceutical sponsored trials, academic clinical trials are usually 
motivated by public health need and scientific opportunities that would not offer 
substantial monetary gains(59).  Primarily, academic sponsored studies mostly 
involved the assessment and evaluation of the therapeutic effects, safety and socio-
economic implications of both new indications for licenced IMPs and innovative 
treatment within the real conditions of the health systems(60). However with the 
development of large global pharmaceutical companies and with the enormous costs 
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of drug development, there has been a progressive decrease in academic regulated 
clinical trial activity (61-63).  
In recent years, Irish academic institutes have united to increase the number of 
academic sponsored clinical trials been conducted in Ireland. Since 2012, the five 
largest Irish Universities; University College Cork, National University of Ireland 
Galway, Royal College of Surgeons Ireland, University College Dublin and Trinity 
College Dublin, have taken on the role of clinical trial sponsor(64). Accordingly, they 
have the legal authority to oversee the financial and management responsibilities of 
academic sponsored or led clinical trials(64). The five universities delegate their 
sponsor responsibilities through their own Clinical Research Facilities/Centre 
(CRF/C)(64). The five CRF/Cs in Ireland, actively collaborate between Universities and 
industry and manage all aspects of a clinical trial from clinical trial documentation, to 
participant recruitment, study monitoring and data analysis (64). They are facilitated 
by the Health Research Board-Clinical Research Coordination Ireland (HRB-CRCI), 
established in 2014 to provide independent, centralized support in the conduct of 
multi-center clinical trials across Ireland(64). To date, the  CRF/Cs have sponsored 
numerous clinical trials (64). These trials are primarily financed by public funding such 
as EU’s Seventh Framework Programme (FP7), the Irish Health Research Board (HRB) 
or the Science Foundation Ireland (SFI)(64, 65).  
It is widely noted that Irish academic sponsored clinical trials have the potential to 
improve patient care and save lives(66). A strong academic clinical research 
infrastructure gives Irish people access to lifesaving trials and in 2018 the Irish Health 
Research Board committed €11.6 million to ensure that this continues to happen(67).  
In May 2018, the Irish clinical trials infrastructure network was showing growth at a 
steady pace with 237 trial sites opened across the Irish network, up from 134 in 2014 
when HRB-CRCI was first established (67).  There trials are led by a team of over 330 
clinical investigators(68).  
 
Although many clinical trials are still performed in a single country, over the years 
there has been a trend to perform large-scale, multi-site international clinical 
trials(10, 32). These international, collaborative trials facilitate the fast recruitment 
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of large sample sizes by recruiting participants from multiple geographical locations 
and ethnicity, which also enhances the external validity of a trial(69).  However, 
despite its many advantages, the rise in international multi-site clinical trials has also 
increased the complexity of conducting clinical research(10, 69). These issues are not 
as inhibiting for larger pharmaceutical companies, who have the resources to 
manage this complexity (66, 70). Such resources are not normally available to 
academic sponsors who often run a clinical trial under a small, restrictive public 
funding grant(70).  
Furthermore, pharmaceutical companies often have divisions in the different 
countries where a multi-centre trial is being performed, giving them access to local 
expertise and native language speakers(71). In addition, many pharmaceutical 
companies employ multinational Contract Research Organisations (CROs) to conduct 
their clinical trials (63). Such arrangements are often extremely expensive. Whereas 
academic sponsors, who in most cases are performing trials on small public funding 
grants, cannot afford outsourcing their trial to a CRO(71). Thus, academic sponsors 
of clinical trials in many instances, due to lack of funding, infrastructure and 
experienced permanent staff; have great difficulties dealing with the requirements 
of performing large, multi-centre international trial(32, 70). 
1.3 Clinical trial ethics   
The goal of a clinical trial is to develop new knowledge and insight that will hopefully 
improve human health(1). This knowledge is generated by determining if new drugs 
and treatments are safe and effective by testing them on volunteer human 
participants(2, 40). However, before a clinical trial can begin, the researchers must 
first decide if the benefits of the new drug or therapy under investigation outweigh 
its risks to participant safety(23). For example, a new therapy may be associated with 
greater efficacy for patients but also an unacceptable level of adverse medical 
outcomes for study participants(40, 72). Moreover, once a trial begins it should be 
terminated early if the risk-benefit relationship changes and the risks to study 
participants outweigh the benefits (73).  
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Nevertheless, by placing some people at risk of harm for the good of others, clinical 
research has the potential to exploit study participants(72). The Hippocratic Oath, 
historically taken by all physicians, states that doctors must first ‘do no harm’ to their 
patients(74).  Moreover, this principle forms the basis for clinical trial ethics, by which 
clinical researchers must endeavour by all reasonable means to ensure that no harm 
comes  to study participants and to preserve the integrity of the science of the 
trial(72, 74).  However a clinical researcher who is motivated by scientific discoveries 
may be tempted to jeopardize their participant’s safety by enrolling them in a clinical 
trial where its risks outweigh the benefit for that participant (75, 76). Thus human 
subjects could potentially be put at risk for the benefit of others which make 
exploitation inherently possible in all stages of a clinical trial (77-81).    
The ethical concerns of clinical trials have been debated for as long as clinical trials 
have been conducted and unfortunately research involving human subjects has a 
corrupt past(82, 83). Historical evidence has documented many examples of ethical 
misconduct in clinical trials(76, 84). For example, the term ‘human experimentation’ 
will forever be linked to the unprincipled clinical trials conducted by the Nazis on war 
prisoners in early 1940, during World War II and the Holocaust(85).  These trials were 
a series of medical experiments performed on large numbers of prisoners, including 
children, in Nazi concentration camps. Nazi physicians forced prisoners to participate 
in trial that typically resulted in death, trauma, disfigurement or 
permanent disability(85). These experiments are now considered examples 
of medical torture and have greatly influenced the development of ethical standards 
for clinical trials.(85). 
The Tuskegee Syphilis Study is another example of an unethical clinical trial(76, 84). 
This study was conducted by the United States Public Health Service in collaboration 
with Tuskegee University, between 1932 and 1972(76, 84).  The study aimed to track 
the natural progression of untreated syphilis  and to determine the best treatment 
options(84). The researchers recruited over six hundred thousand impoverished 
African-American farmers from Alabama(84). Most participants had syphilis before 
they were recruited to the trial(84). The 40-year study was entirely unethical, as 
researchers knowingly failed to treat patients with penicillin when it was found to be 
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an effective cure for the disease in the 1940s(76). This trial is citied as the most 
scandalous biomedical research projects in US history (84). 
Arising out of such clinical trial abuses were the development of ethical guidelines; 
created to assist clinical researchers to conduct ethical research(85, 86) (see Figure 
1). The Nuremberg Code, published in 1947, was the first major international 
document to provide guidance on research ethics(85). It made voluntary participant 
consent mandatory for all clinical trials. It required researchers to use appropriate 
study methods and not to conduct a trial if its risks outweighed its potential benefits. 
It also states that a clinical trial should be based on previous knowledge (e.g., data 
derived from animal experiments) that justifies the  trial to be performed on human 
subjects (82). 
 Unfortunately, despite the introduction of the Nuremberg Code in 1942, in the 1960s 
new medicines were still licenced for patient use without supporting clinical trial 
evidence(85). The thalidomide disaster in 1962 is one such example. Without clinical 
trial evidence, thalidomide became an over the counter drug for the treatment of 
morning sickness in pregnant women(87). Shortly after the drug was sold, thousands 
of infants worldwide were born with limb malformation(87). In response to the 
thalidomide disaster, the U.S Congress enacted the Kefauver-Harris Amendment to 
the Food and Drug Cosmetic Act in 1962. This amendment required new drugs be 
proven efficacious in ‘adequate and well -controlled investigations’(33, 88). By 1970, 
the Food and Drug Administration (FDA) interpreted the amendment as requiring 
randomised controlled, double blind clinical trials for the approval of new 
pharmaceuticals(88, 89). The Council of the European Economic Community (EEC) 
soon implemented similar regulations(90).  
By the end of the 1970s most countries had their own regulations and guidelines for 
conducting, reporting and evaluating clinical trial data(90)To overcome global 
inconsistencies, in clinical trial guideline for trial conduct, in 1996 the International 
Conference for Harmonization of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) published the guideline for Good Clinical Practice E6 (R1)(11). This 
guideline is more commonly known as the ICH GCP guideline(11, 91).    
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Figure 1: Evolution of Clinical Trial ethics  
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1.4 ICH GCP guideline 
The ICH GCP guideline published in 1996, is a consolidated document setting out a 
tripartite standard for the conduct of clinical trials across the European Union (EU), 
Japan and the United States (US)(11). The guideline were developed by drug 
regulators and the pharmaceutical industry in the early 1990s, with little input from 
academic researchers (92, 93). The aim of the guideline was to facilitate the 
standardization of clinical trial processes; so that clinical trial results would be 
accepted by regulatory authorities in these jurisdictions (11, 92). This means, for 
example that the results of a US based clinical trial conducted in accordance ICH GCP, 
can be accepted by the European Medicines Agency (EMA), the body responsible for 
drug licensing in Europe(94).    
ICH GCP was finalised in 1996 and became effective in 1997 but was not enforced 
into law at this time (94, 95).  The guideline quickly became an international ethical 
and scientific quality standard for the design, implementation, monitoring, recording, 
analyses and reporting of clinical trials that involve the participation of human 
subjects(11). It includes fourteen principles, that if followed should provide 
assurance that the data and reported results of a clinical trial are credible and 
accurate while still protecting the rights and safety of trial participants (Table 3)(23). 
Table 3: ICH GCP principles 
  
1 Clinical trials should be conducted in accordance with the ethical principles 
that have their origin in the Declaration of Helsinki, and that are consistent 
with GCP and the applicable regulatory requirement(s). 
2 Before a trial is initiated, foreseeable risks and inconveniences should be 
weighed against the anticipated benefit for the individual trial subject and 
society. A trial should be initiated and continued only if the anticipated 
benefits justify the risks.  
3 The rights, safety, and well-being of the trial subjects are the most important 
considerations and should prevail over interests of science and society. 
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4 The available nonclinical and clinical information on an investigational 
product should be adequate to support the proposed clinical trial. 
5 Clinical trials should be scientifically sound, and described in a clear, detailed 
protocol. 
6 A trial should be conducted in compliance with the protocol that has received 
prior institutional review board (IRB)/independent ethics committee (IEC) 
approval/favourable opinion. 
7 The medical care given to, and medical decisions made on behalf of, subjects 
should always be the responsibility of a qualified physician or, when 
appropriate, of a qualified dentist. 
8 Everyone involved in conducting a trial should be qualified by education, 
training, and experience to perform his or her respective task(s).  
9 Freely given informed consent should be obtained from every subject prior to 
clinical trial participation. 
10 All clinical trial information should be recorded, handled, and stored in a way 
that allows its accurate reporting, interpretation and verification. 
11 The confidentiality of records that could identify subjects should be protected, 
respecting the privacy and confidentiality rules in accordance with the 
applicable regulatory requirement(s). 
12 Investigational products should be manufactured, handled, and stored in 
accordance with applicable good manufacturing practice (GMP). They should 
be used in accordance with the approved protocol 
13 Systems with procedures that assure the quality of every aspect of the trial 
should be implemented. 
14 Aspects of the trial that are essential to ensure human subject protection and 
reliability of trial results should be the focus of such systems. 
 
The 2004 European Clinical Trials Directive (CTD) 2001/20/EC as S.I. 190(2004) 
changed the process of clinical trials. This Directive made compliance with the GCP 
guideline a legal requirement for all Clinical Trial of an Investigational Medicinal 
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Product (CTIMPs), conducted in Europe. CTIMPs examine the safety or efficacy of a 
medicine/foodstuff/placebo in humans (57).  
The Directive aimed to regulate clinical research in a uniform way across Europe. It 
sought to speed up the research and development of new medicines by cutting the 
bureaucracy that was caused by differing regulatory requirements in different EU 
countries(57, 95, 96). To transpose the Directive into national law, each EU member 
including Ireland had to change its established legal framework for clinical drug 
research to meet the requirements of the Directive(95).  Accordingly, in Ireland the 
new Directive superseded the Control of Clinical Trials Acts 1987 and 1990(97). Under 
the Directive clinical trials in Ireland, like in all EU countries, could  only commence 
once the sponsor has received ethical and regulatory approval(98). In Ireland, 
approval to conduct a CTIMP must be granted by the Health Products Regulatory 
Authority (HPRA) and by an Ethics Committee which is supervised by the Department 
of Health and independent of pharmaceutical industry involvement(99). The HPRA 
and an Ethics Committee individually review a clinical trial application, containing 
supporting medical and scientific data primarily of laboratory and animal testing for 
toxicity(99). Once approval has been received from the HPRA and an Ethics 
Committee, a clinical trial must then be carried out in accordance with the EU Clinical 
Trial Directive and the ICH GCP guideline (97, 99). 
1.4.1 Clinical Trial Monitoring 
In accordance with the GCP guideline, enforced by legislation such as the EU Clinical 
Trial Directive, the clinical trial sponsor whether pharmaceutical, academic or a 
government agency, must set up appropriate measures to monitor their clinical 
trial(11, 57). Accordingly, monitoring should ensure the participants’ wellbeing and 
safety is protected, that the trial complies with the approved protocol and regulatory 
requirements and that trial data are accurate and complete(11).  GCP states that the 
sponsor must decide the appropriate type and frequency of monitoring required to 
adequately monitor their clinical trial(11). This decision should be based on the 
characteristics of the clinical trial such as its objective, phase, complexity, blinding, 
size, and endpoints under investigation(11). However regardless of the characterises 
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of a trial, the original ICH GCP guideline recommended on-site monitoring to be 
performed, before, during, and after the trial(11).  
Traditionally, sponsors interpreted GCP’s monitoring directive as a requirement for 
all clinical trials to  be monitored through extensive on-site monitoring  during which 
100% source data verification (SDV) had to be performed on trial documents(100). 
This meant that all clinical trials regardless of the phase of the study, the 
investigational medicinal product under investigation, the study population or the 
experience of the individuals conducting the study; were monitored using the same 
traditional approach(100, 101). Even though, traditional monitoring can be time 
consuming and expensive to perform (100, 102). 
 
On-site monitoring involves an in-person evaluation carried out by a study monitor 
at the clinical trial site location (Figure 1) (103, 104). During an on-site visit, source 
data verification is the process by which data, within a participant’s case report form 
(CRF) or other data collection system, are compared to the original source of 
information(100).Normally, during an on-site visits, all the information documented 
in a participant’s  case report form is verified against source data such as hospital 
records, clinical and office charts, laboratory notes and pharmacy dispensing 
records(102, 105). This process, known as on-site SDV monitoring, aims to identify 
errors in case report forms, review essential documentation, assess protocol 
compliance and evaluate investigators supervision. The frequency of on-site visits in 
a clinical trial generally follows a pre-specified schedule that can be influenced by 
participant recruitment rates(106). 
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Figure 1: Traditional monitoring 
 
A report published in 2014, estimated the cost of developing a prescription drug that 
gains market approval was $2.6 billion, a 145% increase since 2003 estimates(107), 
with the top three cost drivers of clinical trial expenditures being procedure costs, 
staff costs, and site monitoring costs (15%)(18, 108). Traditional monitoring has been 
criticized as being reactive, expensive and limited in its ability to quickly identify 
issues and prevent them from recurring(18, 100). Since monitoring a clinical trial by 
a monitor being physically being present, is expensive both in terms of money spent 
on logistics as well as time spent by a monitor attending each site(109). It is reported 
that almost 46% of on-site monitoring effort goes into SDV, which translates to about 
34% of a total phase III study budget(110).  
Although monitoring can consumed almost 15% of a clinical trial budget, evidence to 
support the effectiveness of on-site monitoring or SDV is lacking(111). In 2013, a 
systematic review of on-site monitoring, found methods differed worldwide with 
little evidence to suggest it guarantees participants’ safety or prevents data quality 
issues(100). This may be due to SDV’s  limited ability to quickly identify issues such 
as incorrect participant consent procedures and prevent them from recurring in a 
clinical trial(18). Therefore, traditional on-site 100% SDV monitoring may be over 
cautious at best, and, at worst, might be a complete waste of resources(18, 100).  
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It must also be noted that the GCP guideline and consequently the EU Clinical Trial 
Directive does not stipulate upper and lower limits of on-site monitoring and source 
date verification(57). It has been suggested that the use of  on-site visits and 100% 
source data verification was driven partly by concerns over the expectations of 
competent authorities such as the HPRA and in part by Contract Research 
Organization, who had a strong financial incentive to push 100% on-site source data 
verification(110).  
Several reports recommend reducing on-site monitoring and replacing it with 
centralized monitoring (18, 20, 21). Centralized monitoring is the remote evaluation 
of the study data, carried out by monitors and clinical trial staff at a location other 
than the sites at which the clinical investigation is being conducted(112).  A study 
conducted in 2012 found that more than 90% of the problems identified during on-
site monitoring of a 9385 participant, 6-site trial performed in Africa,  could have 
been identified by central monitoring practices(20). Furthermore, it is estimated that 
implementing a modified monitoring plan that largely replaces on-site monitoring 
with centralized monitoring could reduce clinical trial costs by more than 20%(18). 
1.4.1.1 Centralized monitoring 
Centralised monitoring allows monitoring activities which were previously conducted 
on-site to be conducted remotely(20). In centralized monitoring, the monitor is still 
very much involved, but he/she does not spend time onsite. Instead the monitor 
performs all the study monitoring processes remotely, using a secure online platform 
(20, 113). For example, in trial that perform centralized monitoring, the research 
team enter study and patient data into a database or paper forms(113). Once this is 
done, the research team have additional step of uploading all or some of the source 
documents, labs, medical histories, informed consent forms, and other such 
documents to the secured online platform which will then become available to the 
monitor instantaneously.  This step may involve scanning documents to the online 
platform. Once the documents for a particular visit or referring to a specific clinical 
trial requirement (i.e. insurance certification) are on the online platform, the monitor 
can examine the documents for errors. The monitor then communicates the results 
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back to the clinical trial team via the online platform, email or telephone 
conversation(113). 
However, for the purpose of this study, centralised monitoring will be defined as the 
remote monitoring of clinical trial data that is held on an Electronic Data Capture 
(EDC) system and not just the review of data from a remote location distant to the 
clinical trial investigation site (106, 107).  This type of centralized monitoring has been 
described as a requirement for RBM(26). It has emerged from the need to speed up 
the progress of clinical trials to shorten research cycle and reduce the rate of data 
errors (20, 114). It involves a review of centralized data held on an Electronic Data 
Capture (EDC) system and not just the review of data from a remote location distant 
to the clinical trial investigation  site(115, 116).   
Conventional data collection for clinical trials involved collecting data on paper-based 
case report forms (CRF) followed by double data entry into an interactive data 
base(100). Although well established, this method was time consuming, resource 
heavy and prone to errors (92).  It created substantial administration and cost 
implications as paper CRFs had to be couriered to a central data entry location, which 
introduced the risks of losing data, breaching data protection laws and damaging 
paper CRFs making them illegible(117). Moreover, this process slowed down the 
reporting and analyses of clinical trial results as a database could only be locked once 
all the paper-based data was validated and entered into the database(118).  
In 1990, clinical researchers acted to alleviate the problems associated with paper 
based CRFs by changing to a remote data entry system(118). This system facilitated 
the submission of paper-based CRFs to the data center by fax. Then once received by 
the central data center, a data manager would manually type the information 
contained on the paper CRF into the central database(118). The development of 
modern technology networks, web based clinical data collection systems such as EDC 
systems, enabled clinical researchers to input data directly into the computer system 
(116, 117). This process also improved clinical trial monitoring as it allowed the 
monitor to log into the computer system and perform source data verification(119). 
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In addition, the EDC system had inbuilt programme edit checks that validated data 
entry in real time(118). 
The increased use of EDC systems over the past decade have facilitated the use of 
centralized monitoring in clinical trials(119). These systems provide researchers with 
the capabilities to enter, review, analyses and edit data in real time and to implement 
online data validation checks to ensure improved data quality at the point of data 
entry(120, 121). In May 1997, the FDA issued the regulation 21 CRF Part 11, which 
provided guideline on EDCs and the use of electronic signatures(122).  Under this 
regulation, EDCs are not classified as  a computer system in clinical trial data 
management which is fully compliant with CRF 11(122). In 2018, it was estimated 
that more than 50% of clinical trials in the United States use an EDC system(116). The 
increased use of EDC systems has facilitated the use of centralised monitoring(116). 
1.4.2 Problems with ICH GCP 
By the early 2000s, despite the extensive global use of the ICH GCP guideline, 
researchers still questioned its value(123). Some researchers believed the ICH GCP 
guideline made clinical trials more expensive and complex to conduct(124). They 
believed the one-size fits all approach to the design and conduct of a clinical trial, 
taken by the ICH GCP guideline, was not appropriate(123). This is true as all clinical 
trials are not comparable; they vary greatly in terms of study populations, IMPs and 
research teams(40, 123). Many critics believe the ICH GCP guideline was developed 
for pharmaceutical companies conducting large, heavily resourced clinical trials and 
that ICH GCP was not tailored towards small clinical trials sponsored by academic 
institutions and individuals(123). 
Members of the global clinical trial community thought the GCP guideline included 
an over emphasis on less important aspects of a clinical trial such as source data 
verification, at the expense of other important aspects of the clinical trial such a 
randomisation(124). Moreover, they believed that a lack of flexibility on the GCP 
guideline and its interpretation for low risk academic trials has resulted in clinical trial 
processes that are unnecessarily complex and expensive for low risk academic 
trials(92). This shortcoming is thought to have hindered the development and 
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adoption of innovative clinical trial methodologies in areas such as participant 
recruitment and the participant consent process(17, 92). 
Since the GCP guideline was transposed into law with the introduction of the EU 
Clinical trial Directive in 2004, academic researchers have called for the guideline to 
be revised (123). Unlike other countries such as the USA and Japan, the EU Clinical 
Trial Directive did not differentiate between commercial and non-commercial 
academic trials(37). This means that the same level of regulation applies to all types 
of CTIMPs regardless of their risk profile. This results in making some trials such as 
Phase III trials of licenced drugs, excessively resource and time consuming without 
any benefit for the safety of the participants or the quality of the data(124). 
 In 2016, the More Trials initiative was established, by over 230 trialists from 35 
countries, to instigate change to ICH GCP(124). The initiative called for aspects of 
clinical trials such as monitoring to be proportionate to the risks of the trial, which 
they believe is mostly dependent on the study drug under investigation(124). They 
state that a new drug in development would require much more intensive monitoring 
and safety review compared to a vitamin or over-the-counter product which has 
been in use for many years(124). One of More Trials suggestions, particularly in the 
context of academic sponsored, noncommercial trials is that monitoring should be 
tailored to the risk profile of each trial(124). A proportional approach to the ICH GCP 
guideline should be adapted to participant safety risks as well as to the risks related 
to the reliability of the trial results(25).   
More Trial’s request for a review of the ICH GCP guideline was answered in 2017 
when ICH publicly recognised the failings of the ICH GCP guideline ;“Although ICH E6 
generally can be interpreted as providing sponsors flexibility to implement innovative 
approaches, it has been misinterpreted and implemented in ways that impede 
innovation by, for example, emphasizing less important aspects of trials (e.g., 
focusing on the completeness and accuracy of every piece of data) at the expense of 
critical aspects (e.g., carefully managing risks to the integrity of key outcome 
data)(125).” 
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The ICH have recognised that when they first published ICH GCP guideline in 1996, 
the process of conducting a clinical trial, including risk assessment and monitoring, 
was largely paper-based(126). Since then clinical trials have advanced and they are 
now more complex, costly, large global projects. At the same time, major advances 
in technology and data analytics are making it possible for clinical trials to be more 
effective and efficient at certain aspects of monitoring such as centralised 
monitoring(127). To keep up with these advances, in 2017 the ICH published the 
International Council for Harmonisation (ICH) E6 – good clinical practice (GCP) 
(R2)(126).  The aim of the revised ICH GPC guideline is to encourage the 
implementation of improved approaches for the management of clinical trials (127). 
The change to ICH GCP comes from the clear recognition to have an open dialogue 
with all clinical trial stakeholders not just the pharmaceutical industry(125). By far 
the most substantial change to ICH E6 relates to clinical trial monitoring(23). Each 
study is now required to have a study-specific monitoring plan which was not a 
requirement in the original 1996 ICH GCP guideline(23).  The monitoring plan should 
clearly state how and why the trial is to be monitored, taking consideration for the 
participant’s safety and data integrity. In addition, the revised ICH GCP guideline, per 
section 5.18 requires the sponsor to develop ‘monitoring reports’, including both 
centralised reports and on-site monitoring visit reports and now these reports must 
be provided to the sponsors by the monitor in a timely manner and with enough 
detail to allow sponsors to follow up, if needed(23). Finally, the addendum 
incorporates elements from the FDA’s (2013) risk-based monitoring guidance, which 
supports alternative monitoring approaches such as risk-based monitoring to 
traditional extensive on-site monitoring with 100% SDV(12, 23).  
1.5 Transition to Risk based monitoring – ICH GCP E6 R2 
Globally, clinical researchers are looking for ways to reduce the cost and increase the 
quality of clinical trial monitoring(23). Risk based monitoring (RBM) has been 
proposed as one such solution (23, 128, 129). The RBM approach as endorsed by the 
new ICH GCP guideline has several main objectives. First, it is intended to enable 
more real-time identification of emerging trends and potential risks that impact 
patient safety and data integrity(10). Secondly this risk-proportionate approach is 
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intended to enable monitors, when on-site, to focus more on the activities that best 
support the site and drive data quality and patient safety(10). The new ICH GCP 
guideline echoes FDA’s endorsement of RBM which recommends that sponsors 
develop a systematic, prioritized, risk-based approach to monitoring clinical trials(12, 
23).  This approach should include a combination of on-site and centralised 
monitoring, or, where justified just centralised monitoring alone(23). The sponsor 
should document the rationale for the chosen monitoring strategy in the monitoring 
plan(23).  
To achieve these objectives, RBM should incorporate both on-site and centralised 
monitoring that are proportional to the risks associated with the clinical trial(10). 
These risks relate to the IMP, study population and the robustness of the study 
design(26). RBM should enable clinical researchers to focus on all aspects of a clinical 
trial from protocol development to data analysis (127). It should allow researchers to 
be flexible and adjustable to unexpected risks that emerge along the duration of a 
clinical trial.  Ideally, the RBM process should start at the time of protocol design, so 
mitigation can be built into the protocol and other trial related documents (e.g. 
monitoring plan) (26). Moreover once a trial starts, RBM should become a pre-
emptive process and so the risk profile of a trial should be continuously reviewed and 
monitoring practices modified accordingly (26). By focusing on clinical trial risks, it is 
thought the implementation of RBM should improve clinical trial data quality while 
ensuring subjects’ rights protection and regulatory compliance(128). 
1.5.1 RBM process 
The new ICH GCP guideline sets a target for RBM, but does not describe a path 
towards implementation(130). Indeed, RBM cannot be served by a “one size fits all” 
approach and ICH’s acknowledgement is welcomed regarding the sponsor’s 
responsibility to determine the optimal approach to study oversight and not 
mandate any given strategy(28). However, as stated above, the new ICH GCP 
guideline suggests RBM should involve a combination of onsite and centralized 
monitoring activities(23). Unfortunately, the guideline fails to provide more detail or 
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instruction related to how a sponsor can determine to what extent this combination 
of on-site and centralised monitoring is right for their clinical trial (25). 
However, several more specific recommendations for RBM do exist(10, 26). For 
example in 2012 a group of biopharmaceutical companies called TransCelerate 
developed a four stage RBM approach outlined in Figure 2 (26).  .This approach first 
involves a risk assessment to identify clinical trial risks that could affect participants’ 
safety or clinical trial data(26). Such risks relate to the complexity of the study design, 
the study population, study team’s experience, the safety profile of the IMP and the 
quantity of data been collected(26). The identified risks should then be assessed and 
prioritized by considering the likelihood of errors occurring, impact of such errors on 
participants protection and trial integrity and the extent to which such errors would 
be detectable(26). Secondly, the results of the risk assessment should guide the 
development of a monitoring plan(26). The type (e.g., on-site or centralized), 
frequency (e.g., early versus throughout the study), and extent (100% SDV versus 
targeted or random review of certain data), of monitoring activities should depend 
on the frequency and types of risks identified during the risk assessment(26). Finally, 
once a trial starts, RBM should become a pre-emptive process(26). Sponsors must 
continuously review the risk profile of a trial while it is ongoing and modify 
monitoring practices accordingly(26).  When done correctly, it is suggested that RBM 
can allow for the proactive mitigation of likely sources of error, rather than the 
reactive correction of errors that have already happened(131).   
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Figure 2: RBM process 
 
Furthermore in 2012, the Organisation for Economic Co-operation and Development 
(OECD) published recommendations for clinical trial governance which advised 
clinical researchers to use a RBM tool when developing their RBM plan(10). Such 
tools have two functions, first they must support the assessment of risk in a clinical 
trial protocol and secondly that should provide guidance for subsequent monitoring 
activity that can mitigate the risks identified(10, 27).  For example, TransCelerate’s 
Risk Assessment and Categorization Tool (RACT) is a RBM tool that helps determine 
risks that could affect subject safety, data quality and regulatory compliance, and 
provides guidance on how and by which function the risks may be managed(112). A 
variety of paper based and electronic RBM tools have been developed but, to date, 
research comparing them has not been conducted(132). 
For RBM to be efficient, it is imperative that the initial risk assessment phase is simple 
and does not create additional burden for a clinical trial team (27). However despite 
the availability of RBM guidance, the question remains around how clinical trial risk 
should be measured(32).Various RBM strategies for clinical trials have been 
developed across the world, particularly with the objective of defining clinical trial 
risk(32). These include: 
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1. Stratified approach -based on the definition of discrete risk categories.  
This approach involves determining the risk profile of a clinical trial based on the 
market authorization of the Investigational Medicinal Product under investigation 
(28). This process will lead a discrete single dimension of risk based solely on the 
hazards to participants related to the study drug(28). This approach has inspired a 
UK initiative  that created three risk categories based on the IMP(28): 
o Category A: Clinical trials using already marketed medicine under the 
licensed indication 
o Category B: Clinical trials using already marketed medicinal products, 
exploring their use in new indications, new populations 
o Categories C: Clinical trials exploring safety and efficacy of never 
marketed medicinal products  
This process is limited as it does not take account of other risk factors in a trial such 
as study population and experience of the study team(28, 133). It is suggested that a 
stratified approach to risk assessment will result in a monitoring strategy that will 
only mitigate the risks imposed by the marketing status of the Investigational 
Medicinal Product(28). 
2. Personalized approach -based on a case per case assessment of each individual 
clinical trial protocol using guidance and decision trees. 
The personalized approach involves an individual unique risk assessment and risk 
mitigation strategy for every clinical trial(32). This risk assessment process is 
conducted on a case by case basis, to assess all the risks associated with an individual 
trial prior to the trial starting and the monitor’s green light visit(134). This approach 
is supported by decision trees and taxonomy such as the Risk indicator taxonomy for 
supervision of clinical trials on medicinal products(133). 
The personalized risk assessment approach considers the various dimensions of 
predefined clinical trial risks such as: hazards to the participants (rights, safety) and 
hazards to the results data design and analysis). It also considers the experience and 
training of the trial team, as well as the robustness of trial procedures such as 
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randomization and determinants of data credibility(32).   The personalized approach 
aligns to the quality by design concept which states that a clinical trial monitoring 
plan should focus on critical points of the trial protocol(32). 
1.6 RBM evidence gap 
The new ICH GCP guideline has truly brought RBM to the forefront of clinical trial 
monitoring(25). However, for monitoring to become truly risk-based there needs to 
be cultural shift in many clinical trial teams(29). The concept of RBM implies that the 
chosen monitoring strategy is adapted to the local and trial-specific context(135). 
This means that a one-size-fits-all model is not possible(130). However, despite the 
availability of RBM guidelines, challenges still exist with respect to clinical researchers 
establishing a local RBM process and implementing it in the desired way(29, 135). A 
survey of Clinical Research Organizations found the biggest challenges with 
implementing RBM are a lack of internal knowledge/expertise, perceived inability to 
maintain sufficient quality through RBM and lack of capacity to rapidly adapt to 
changing RBM needs(129). Similarly, a US based report found sponsors were 
reluctant to try new quality control methods such as RBM because they felt they 
would increase their risk of failing an FDA audit(18). These concerns are not without 
merit, and, to date,  no gold standard RBM approach has been developed (129). 
In anticipation of the ICH GCP Addendum industry sponsors, such as CROs and 
pharmaceutical companies that conduct commercial clinical trials, published opinion 
pieces and white papers describing how RBM should be implemented and barriers to 
its implementation(136). Many of these papers view RBM as the same process as 
centralised monitoring, meaning that RBM must be conducted without using 
centralised monitoring activity(137). Furthermore it appears centralised monitoring 
is the biggest driver for RBM by industry sponsors.  Many of the papers claim that 
RBM which is performed through centralised monitoring is cheaper, less resource-
intensive and, more efficient than traditional on-site monitoring(137, 138).  
The industry sponsors (CROs and pharmaceutical companies) like academic sponsors 
claim that the successful implementation of RBM from pilot studies to full-scale 
rollout requires a foundation of quality, appropriate processes, and analytics(139). 
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Industry is acknowledging the realignment of processes and roles, and adoption of 
software technologies that require serious consideration when organizations 
consider implementing RBM(136, 139).  Industry sponsors are looking for electronic 
software providers and tools to support them to perform RBM through centralised 
monitoring, through the provision  of services that can predict key risk indicators in 
their clinical trials that will subsequently  inform their RBM plan (138, 139).  
The implementation of RBM, with the consequent adjustment or reduction of onsite 
monitoring visits and source data verification (SDV), can only succeed after 
establishing an appropriate RBM approach(10, 140). The way that risks are identified, 
evaluated and mitigated commands a change in the mind-set of those who have 
applied ICH GCP and traditional 100% on-site monitoring since 1996(110, 141). Given 
the complexity of risk assessment in clinical trials, appropriate training for clinical 
researchers are yet to be developed to ensure both the reliability of the assessment 
and the development of effective RBM plans(10). Considering that the rationale of 
the chosen monitoring strategy should be documented, the ICH assumes that every 
sponsor would know the advantages of one monitoring method (on-site or 
centralised ) over the other and will be able to choose the right levels of application 
of these methods in their clinical trial (141). Thus to develop an effective RBM plan, 
a clinical trial team should know and understand the rationale for use of the chosen 
RBM method(110).  
The assumption that RBM reduces waste of valuable clinical trial resources, such as 
study budget and staff time and improves participant safety or data quality has yet 
to be proven(31, 129). For example, studies such as the Risk ADApted MONitoring 
(ADAMON) and the OPTimisation of MONitoring for clinical research studies 
(OPTIMON) projects  evaluating the effectiveness and cost efficiency of RBM are still 
ongoing or have produced little evidence to suggest RBM is more effective that 100% 
on-site monitoring (Table 4)(129, 142). Therefore it is imperative with RBM, that the 
monitoring approach should not exempt the sponsor or investigator from their 
responsibilities, and that even if the trial is considered ‘low risk’ participant safety 
must not be neglected(141). 
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Table 4: RBM research 
Study Aim  Results  
Risk ADApted 
MONitoring 
(ADAMON) 
project 
Investigate whether a RBM strategy 
developed by a RBM tool was 
equivalent to an extensive full 
monitoring approach 
Published 2017: RBM 
offers potential 
benefit over 
extensive on-site 
monitoring(142) 
OPTimisation of 
MONitoring for 
clinical research 
studies 
(OPTIMON) 
Compare the efficacy of two 
monitoring strategies: one based on 
the classic standards of quality 
assurance, and the other one being a 
priori optimised strategy guided by an 
RBM tool 
Released in 2015: 
OPTIMON lacked 
sufficient statistical 
power to 
demonstrate non-
inferiority of the RBM 
approach at detecting 
severe errors(143) 
START 
Monitoring Sub 
study (or SMS) 
Evaluate and compare data 
monitoring with two vs three 
components: (central +local 
monitoring) compared to (central + 
local + on-site monitoring) 
Not published(144) 
Targeted 
Monitoring, 
Prospective 
Evaluation and 
Refine Study 
(TEMPER) 
Evaluate targeted monitoring within 
several multicenter cancer trials 
being conducted by the MRC Clinical 
Trials Unit. Using a pre-specified 
trigger for each trial, sites prioritized 
for a site visit will be matched (on 
number of patients recruited and 
time since trial site opened) with one 
that would not be visited based on 
the normal monitoring strategy 
Published in 2018: 
Triggered monitoring 
approaches, as used 
in these trials, were 
not sufficiently 
discriminatory(113) 
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1.7 RBM – implementation in Irish academic-led clinical trials  
Since 2011, health regulators such as the FDA, EMA, the Medicines and Healthcare 
Products Regulatory Agency (MHRA), the Japan Ministry of Health and Swiss Federal 
Constitution have driven initiatives to transition clinical trial monitoring to RBM in 
their local clinical trial organisations (12, 24, 28, 145). For example in 2013, the FDA 
released a clinical trial guidance document that approved RBM as the preferred 
method for trial monitoring (12). In 2014, Switzerland became the first European 
country to introduce a a regulation adopting risk-based categorization into their 
clinical trial methodology(146).   
In contrast, Ireland’s Health Products Regulatory Authority (HPRA) have not 
published RBM guidance. Similarly, the Health Research Board-Clinical Research 
Coordination Ireland (HRB-CRCI) does not have a national strategy to support the 
introduction of RBM into its publicly funded, academic run clinical trial units. In the 
absence of a gold standard RBM approach and national RBM guidelines it remains 
unclear how Irish sponsors will translate ICH GCP’s RBM directive into practice in 
their clinical trials. This is a cause for concern, as clinical trials in Ireland are legally 
obliged to operate in accordance with GCP guideline and in doing so they must 
perform RBM(99). 
1.8 Thesis Aim  
This thesis aims to develop, implement and evaluate a quality improvement (QI) 
intervention to support the implementation of RBM into academic-led clinical trials 
in Ireland.  To date QI interventions have led to changes that have produced better 
patient outcomes, better system performance and better professional 
development(147). However, there is a paucity of evidence documenting the value 
of QI in the conduct of clinical trials to promote high quality and efficient clinical 
trials(148). This thesis supports the global initiative aimed at increasing QI use in 
clinical trials to improve clinical trial methodology (148-150). 
The thesis follows the Knowledge to Action framework which is a conceptual 
framework intended to help deliver sustainable, evidence-based knowledge 
translation interventions(151). Knowledge Translation encompasses all steps 
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between the creation of new knowledge and its application to yield beneficial 
outcomes for the knowledge user, who is an individual likely to use research results 
to make informed decisions about health policies, programs and/or practices(152, 
153). For the purposes of this thesis, the knowledge users are clinical researchers 
working in the CRF/Cs affiliated with the HRB-CRCI in Ireland(64). They include 
principle investigators (PIs), pharmacists, study physicians, nurses, project and 
quality managers, study monitors and statisticians(64). 
The Knowledge to Action Framework (outlined in Figure 3) has two distinct but 
related components: (I) Knowledge Creation (represented by the funnel) surrounded 
by (ii) the Action Cycle which outlines a process, representing the activities needed 
for knowledge to be applied in practice; knowledge is adapted to the local context, 
and barriers and facilitators to its use are explicitly assessed(151). The Knowledge to 
Action phases can be carried out sequentially or simultaneously and the knowledge 
phases may impact on the action phases(151). However at each stage of the 
Knowledge to Action process, the information generated or action taken must be 
tailored to the knowledge user(151).  
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Figure 3: Knowledge to Action framework 
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1.8.1 Thesis Objectives 
The specific objectives of the thesis are informed by the core components of the 
Knowledge to Action framework which are knowledge creation and the application 
of this knowledge into practice. To fulfil the components of the Knowledge to Action 
framework, this thesis will address the following four objectives: 
1. Identify how RBM should be conducted. 
2. Identify the barriers and facilitators to RBM implementation in academic led 
clinical trials in Ireland. 
3. Investigate the difference between on-site and centralized monitoring. 
4. Design a suitable quality improvement intervention to support the 
introduction and on-going use of RBM in academic-led clinical trials in Ireland. 
1.9 Chapter Outline 
This thesis has seven chapters including the Introduction. Chapter 2 describes the 
overall thesis methodology. Chapters 3, 4, 5 and 6 consist of manuscripts that each 
fulfil one of the four thesis objectives outlined above (Figure 4). Lastly, Chapter 7 
summaries and compares the findings from those four manuscripts, contextualize 
the findings within the existing literature, and identifies contributions and direction 
for future research.  
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Figure 4: Thesis outline 
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Chapter 2.  Methods 
2.1 Introduction 
This thesis aims to develop, implement and evaluate a quality improvement 
intervention to support the implementation of RBM into academic-led clinical trials 
in Ireland.  To achieve this aim, a multi-method research strategy, informed by the 
Knowledge to Action framework was employed. Several Knowledge Translation 
frameworks exist(154). To select a suitable Knowledge Translation framework for this 
thesis, a search of PubMed and Google Scholar was conducted in 2014 and ten 
potential Knowledge Translation frameworks were identified (Appendix A). The 
Knowledge to Action framework was identified as the most appropriate for this 
research project because it best supported the aim of this thesis. 
This chapter outlines the phased implementation of the Knowledge to Action 
framework which was executed through a multi-method research strategy over four 
years from October 2014. Multi-method research involves the combination of 
individual research elements to provide an answer to one research question (1).  It is 
not the same as mixed methods research, which incorporates various quantitative 
and qualitative strategies in a single research project (1). 
2.1.1 Knowledge to Action framework  
The Knowledge to Action framework has two components (i) Knowledge Creation 
and (ii) the Action Cycle, which has seven subcomponents: 
1. identifying research problems and selecting knowledge  
2. adapting knowledge to local context 
3. accessing barriers to knowledge use 
4. selecting, tailoring and implementing intervention 
5. monitoring knowledge use 
6. evaluating outcome  
7. sustaining on-going knowledge use (2).   
 
51 
 
Accordingly, this thesis included four individual pieces of research that were guided 
by the components of the knowledge to Action framework (Table 5). For example, 
this meant that at least one of the research elements had to create RBM knowledge, 
as knowledge creation is a core component of the Knowledge to Action 
framework(151).   
Table 5: Application of the Knowledge to Action framework 
Study Knowledge to Action 
component 
Objective Study design 
1 Knowledge creation Examine how should 
RBM be implemented 
Systematic 
review 
2 Action Cycle 
• Identify problems and select 
knowledge 
• Adapt knowledge to local 
context 
• Assess barriers to 
knowledge use 
Identify the barriers and 
facilitator to RBM 
implementation in 
academic-led clinical 
trials in Ireland? 
Mixed 
methods- 
quantitative & 
qualitative 
3 Knowledge creation Investigate the difference 
between on-site and 
centralised monitoring 
Document 
analysis 
4 Action cycle  
• Select, tailor and implement 
intervention 
• Monitor knowledge use 
• Evaluate outcome 
• Sustain on-going knowledge 
use 
Identify a suitable 
knowledge translation 
strategy to support the 
introduction and on-
going use of RBM in 
academic-led clinical 
trials in Ireland 
Quality 
Improvement 
(QI) study  
 
2.2 Data collection process 
The research for this thesis was done in four phases. The aim and methodology of 
each of the separate four research phases were developed using an emergent 
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approach such that the results of one study informed the development of the 
subsequent study. Each phase is summarized below and described in detail in the 
following chapters. 
2.2.1 Phase 1:  Knowledge creation  
Phase one involved the creation of RBM knowledge through a systematic review of 
RBM tools. The full title of the systematic review is ‘Risk based monitoring (RBM) 
tools for clinical trials: A systematic review’ (3). It is described in detail in Chapter 3.  
When the thesis began in 2014, regulatory documents produced by the FDA and the 
EMA did not provide clear RBM guidance (12). At that time, RBM tools had been 
developed which provided structured, clear RBM guidance (3). As defined by the 
OECD, RBM tools provide instruction on how clinical researchers should assess the 
risks in their clinical trial protocol and recommend monitoring activity that could 
mitigate the risks identified (4). However, despite the availability of RBM tools, a gold 
standard approach did not exist and literature comparing the methodology used in 
each tool was lacking (3).  
A systematic review was the most appropriate research method to identify and 
compare RBM tools as such a review facilitates the collection and comparison of all 
empirical evidence relating to a research question (5). For this reason, I conducted a 
systematic review to identify, characterize and compare RBM tools. (4, 6).  
2.2.2 Phase 2 - Action cycle 
Phase two of my thesis was based on the action cycle of the Knowledge to Action 
(Table 5). The aim of this phase was to complete the first, three subcomponents of 
the action cycle; which are to identify problems and select knowledge, adapt 
knowledge to local context and access barriers to knowledge use (2). To fulfill these 
criteria, I conducted a mixed methods study titled ‘Perceived barriers and facilitators 
to Risk Based Monitoring in academic-led clinical trials: a mixed methods study’ (7). 
This phase is described in detail in Chapter 4. 
In 2015, Ireland, unlike countries such as Switzerland and the UK, did not have a 
national strategy to support the introduction of RBM into its publicly funded, 
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academic-led clinical trial units (8, 9). The absence of a national strategy and gold 
standard RBM approach meant it was not clear how RBM would be implemented into 
their clinical trial units (7). Given this context, the aim of the mixed methods study 
was to establish how prepared academic trialists were to perform RBM (7). To 
achieve this aim, I explored the experience of, attitudes to, and perceived barriers 
and facilitators associated with the implementation of RBM in academic clinical trial 
units in Ireland (7). I decided to use a mixed methods approach as it allowed for the 
triangulation of quantitative and qualitative data that enabled an in-depth 
examination of my findings (10).  
2.2.3 Phase 3 – Knowledge creation  
The results of the Phase 2, mixed methods study, showed that academic clinical 
researchers in Ireland had limited experience of conducting centralised monitoring 
and felt less equipped to perform this type of monitoring compared to on-site 
monitoring. This primarily due to a lack of centralised monitoring guidelines and 
knowledge (7).  This finding was consistent with literature in the area, which showed 
the limited nature of research describing and comparing the implementation of on-
site and centralised monitoring in a clinical trial (12) To overcome this evidence gap 
and to create RBM knowledge, I conducted a Study Within a Trial (SWAT) to provide 
the first document analysis of on-site and centralised monitoring reports collected 
prospectively in a recent international multi-centre clinical trial: The TRUST Thyroid 
Trial (14, 15).  This study, ‘On-site versus centralised monitoring – the TRUST Thyroid 
Trial experience’, is described in detail in Chapter 5. 
2.2.4 Phase 4 – Action cycle 
The aim of Phase 4 was to complete the last, four subcomponents of the Action cycle. 
These are select, tailor and implement a Knowledge Translation intervention, 
monitor its use, evaluate its outcome and sustain on-going knowledge use (2). To 
fulfill these criteria, I conducted a quality improvement intervention study titled 
‘Introducing risk-based monitoring tools into academic-led clinical trial units in 
Ireland: a quality improvement intervention’. This phase is described in detail in 
Chapter 6. 
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Phase 4 was informed by the results of my mixed methods study (Phase 2) and 
systematic review (Phase 1).  The mixed method study had shown that a lack of RBM 
tool usage was one of the main barriers to RBM implementation in academic-led 
clinical trials in Ireland (7). This barrier was intensified by a lack of regulatory 
endorsed RBM guideline (7). To overcome this barrier, I decided to develop a quality 
improvement (QI) intervention that would support the use of RBM tools in academic 
CRF/Cs. Participants were clinical researchers recruited from academic-led CRF/Cs in 
Ireland. 
2.3 Ethical considerations  
Ethics approval was required for Phase 2 because it involved primary data collection 
from study participants. Accordingly, ethical approval was obtained from the 
Research Ethics Committee of the Cork Teaching Hospitals (CREC). Ethical approval 
was not required for Phase 1, 3 and 4 because Phase 1 and 3 involved secondary data 
analysis and Phase 4 was a Quality Improvement intervention which is exempt from 
the requirement for ethical approval (17).  Ethical considerations are described in 
detail in Chapters 3, 4, 5 and 6.  
2.4 Participants 
Phase 2 and Phase 4 involved data collection from study participants which included 
principle investigators (PIs), pharmacists, study physicians, nurses, project and 
quality managers, study monitors and biostatisticians working in one of the five 
university led CRF/Cs in Ireland.  Participants and the recruitment process are 
described in detail in Chapter 4 and Chapter 6. 
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3.1 Abstract  
Introduction: In November 2016, the Integrated Addendum to ICH-GCP E6 (R2) will 
advise trial sponsors to develop a risk-based approach to clinical trial monitoring. This 
new process is commonly known as risk-based monitoring (RBM). To date, a variety 
of tools have been developed to guide RBM. However, a gold standard approach does 
not exist. This review aims to identify and examine RBM tools. 
Methods: Review of published and grey literature using a detailed search-strategy 
and cross-checking of reference lists. This review included academic and commercial 
instruments that met the Organisation for Economic Co-operation and 
Development’s (OECD) classiﬁcation of RBM tools. 
Results: Ninety-one potential RBM tools were identiﬁed and 24 were eligible for 
inclusion. These tools were published between 2000 and 2015. Eight tools were 
paper based or electronic questionnaires and 16 operated as Service as a System 
(SaaS). Risk associated with the investigational medicinal product (IMP), phase of the 
clinical trial and study population were examined by all tools and suitable mitigation 
guidance through on-site and centralised monitoring was provided. 
Conclusion: RBM tools for clinical trials are relatively new, their features and use vary 
widely, and they continue to evolve. This makes it difﬁcult to identify the “best” RBM 
technique or tool. For example, equivalence testing is required to determine if RBM 
strategies directed by paper based and SaaS based RBM tools are comparable. Such 
research could be embedded within multi-centre clinical trials and conducted as a 
SWAT (Study within a Trial). 
3.2 Introduction  
The ICH-GCP guideline list clinical trial monitoring as a primary quality standard. 
Accordingly, trial sponsors must monitor their trial to ensure it complies with 
regulatory obligations, safeguards its participants and produces reliable data (11). 
More traditional monitoring approaches rely on intensive on-site visits and 100% 
source data veriﬁcation (SDV) irrespective of the risk levels in the study(11, 22). SDV 
can be a laborious task because it involves the validation of data presented in case 
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report forms (CRFs) against original source data such as laboratory notes, pharmacy 
dispensing records and consent forms(11, 104). In recent years, SDV and on-site 
monitoring have been associated with high cost and limited contribution to clinical 
trial data quality (105, 155, 156). Consequently, those responsible for the ICH-GCP 
wish to reform clinical trial monitoring(12, 24). In June 2015, the ICH published a draft 
version of the integrated addendum to ICH-GCP, advising Sponsors to develop a 
systematic, prioritised, risk-based approach to monitoring clinical trials(157). This 
process is more commonly known as risk-based monitoring (RBM). It will also be 
prioritised in the forthcoming European Union (EU) Clinical Trial Regulation when 
reduced monitoring will be permitted for low-risk intervention trials(128). It is 
hypothesised that RBM will prevent valuable clinical trial resources, such as study 
budget and staff time, being wasted on unnecessary monitoring activity that does 
not improve participant safety or data quality (130, 156). 
RBM incorporates both centralised monitoring conducted off-site through an 
examination of electronic trial data and on-site monitoring practices that are 
proportional to the risks associated with the clinical trial(12, 24). These risks relate to 
the Investigational Medicinal Product (IMP), the study population, research team and 
the robustness of the study design(133). For example, in high-risk trials RBM may 
involve 100% SDV onsite monitoring while for low-risk trials it may include 80% SDV 
through centralised and on-site monitoring practices(12, 24). Moreover, once a trial 
starts, RBM becomes a reactive process. Sponsors must continuously review the risk 
proﬁle of a trial while it is ongoing and modify monitoring practices accordingly. The 
Organisation for Economic Co-operation and Development (OECD) advise clinical 
researchers to use a RBM tool when developing their RBM plan(10). Such tools 
should have two functions, ﬁrstly they must support the assessment of risk in a 
clinical trial protocol and secondly they should provide guidance for subsequent 
monitoring activity that can mitigate the risk identiﬁed(10). A variety of paper based 
and electronic RBM tools have been developed (129, 158). To date, research 
comparing them has not been conducted(10). The purpose of this review is to 
systematically identify and summarize RBM tools for clinical trial monitoring. 
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3.3 Methods  
A descriptive narrative synthesis method was chosen for this review. This allows the 
ﬁndings of literature derived from qualitative and quantitative methods to be 
synthesised by identifying gaps, extracting data and grouping common ideas or 
arguments(159). 
3.3.1 Ethical consideration 
Ethical approval was not required for this study as no human subjects were involved 
and all data used in the review are available in the public domain. 
3.3.2 Search strategy 
PubMed and EMBASE were systematically searched for relevant published literature 
in August 2016 using a detailed search strategy (see Appendix B). No language or 
publication date restrictions were applied in the search or in the selection process. 
In August 2016, the Google search engine was searched to identify eligible grey 
literature which was deﬁned according to the Twelfth International Conference on 
Grey Literature's deﬁnition as follows: 
‘Grey literature stands for manifold document types produced on all levels of 
government, academics, business and industry in print and electronic formats 
that are protected by intellectual trial property rights, of sufﬁcient quality to 
be collected and preserved by library holdings or institutional repositories, 
but not controlled by commercial publishers i.e., where publishing is not the 
primary activity of the producing body’(160). 
The following search terms were used: Clinical trial AND risk assessment tool OR risk 
analysis AND Risk based monitoring. The Google search was restricted to the ﬁrst 25 
pages of results as no eligible papers were identiﬁed after the 16th page of results. 
No other restrictions were applied through the Google advanced search function. 
European experts, working on academic and commercially led clinical trials, were 
contacted by email and asked to name computer aided commercial RBM tools not 
identiﬁed during the search of published and grey literature. Publicly available 
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databases, ClinicalTrial.gov and Cochrane Central Register of Controlled Trials 
(CENTRAL) were searched for supplementary documents(161, 162). In addition, the 
references in all eligible literature were checked for RBM tools that had not been 
identiﬁed by other means(163). 
In total, 443 titles or abstracts of papers and documents describing RBM tools were 
retrieved from published and grey literature. Two independent reviewers, Caroline 
Hurley (CH) and Jessica Power (JP) assessed these documents for eligibility using the 
eligibility criteria listed below. 
3.3.3 Inclusion criteria 
• Peer-reviewed publications and grey literature as deﬁned by the Twelfth 
International Conference on Grey Literature. 
• RBM tools meeting the OECD criteria for such tools. 
• RBM tools that were developed by academic, regulatory and commercial 
organisations such as Contract Research Organisations (CROs) that outsource 
clinical trial management for pharmaceutical, biotechnology and medical 
device industries and Independent Software Vendors (ISVs) that specialize in 
making or selling software designed for mass or niche markets(164). 
• RBM tools for which information was available in the public domain or was 
provided to us to allow sufﬁcient details about the tool to be included in this 
review. 
3.3.4. Exclusion criteria 
• Literature that only provided general narrative guidance for RBM in clinical 
trials and did not discuss RBM tools. 
• RBM tools from commercial organisations (CROs and ISVs) that did not 
consent for their RBM tool to be included in this review (see Figure 6). 
3.3.5. Quality assessment 
CH assessed the methodological quality of included literature using the authority, 
accuracy, coverage, objectivity, date and signiﬁcance (AACODS) checklist for grey 
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literature(165), which has been used in other research assessing the quality of grey 
literature(166-168). The AACODS checklist grades papers on a scale from of 0–6 
(165). A paper was awarded a high-quality score if it fulﬁlled ﬁve or six of the 
following quality criteria; authority, accuracy, coverage, objectivity, date and 
signiﬁcance (see Appendix B). 
3.3.6 Data extraction 
Two reviewers (CH and JP) extracted data from the eligible papers that described a 
tool speciﬁcally designed to guide RBM. The extracted data covered: 
• Characteristics of the RBM tools – authors, geographical location, the tool's 
language and mode of administration etc. 
• Risk indicators used by each tool to identify and classify risks in a clinical trial. 
• Monitoring guidelines recommended by each tool to mitigate the risk 
identified. 
3.4 Results 
3.4.1 Search strategy 
After initial screening of titles and abstracts, 91 papers or documents were eligible 
for further examination. Both reviewers (CH and JP) obtained the full text of these 
papers or documents and supplemental information on their corresponding RBM 
tools, through consultation with associated authors and commercial organisations 
(CROs and ISV). Twenty-four of these papers or documents and their corresponding 
RBM tools met the inclusion criteria and were included in the review. An overview of 
the literature review process is displayed in Figure 6, using the Preferred Reporting 
Items for Systematic Reviews and Meta Analyses (PRISMA) ﬂow diagram. 
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Figure 5: PRISMA flowchart 
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3.4.2.     Risk assessment tools – characteristics 
3.4.2.1     Afﬁliated clinical trial organisation; year of publication/release and 
country of origin 
This review identiﬁed 24 eligible RBM tools and their characteristics are outlined in 
Table 6. Nineteen tools were sourced from grey literature and the other ﬁve tools 
were obtained from published papers. All the identiﬁed tools were published or 
released between 2000 and 2015 in Europe, the USA or Russia. All tools can be 
applied to all clinical trial phases (Phase I to Phase IV) and clinical trials of medical 
devices apart from the Risk classiﬁcation method, Risk Assessment Tool (RAT) and 
the TORPEDO-CF: Risk analysis form(27, 169). Five RBM tools were developed by 
academic clinical trial researchers (Table 6: items1&4–7). Two RBM tools were 
developed by academic and regulatory organisations (Table 6: items 2–3). 
TransCelerate's Risk Assessment Categorization Tool (RACT) was the only tool in this 
review to be developed by a non-proﬁt biopharmaceutical organisation (Table 6: 
item 8). The remaining 16 RBM tools were developed by commercial organisations, 
CROs and ISVs. 
3.4.2.2 Mode of administration 
Six of the RBM tools are paper based checklists (Table 6: items 1–5 and 7). Two tools, 
the Risk Assessment Categorization Tool (RACT) (26)and the SCTO risk 
assessment(170), function via Microsoft Excel. The other 16 RBM tools operate as 
commercial computer aided Service as a Systems (SaaS) that can be accessed through 
a web browser (Table 6: items 9–24). Three SaaS RBM tools; the Quality Risk Radar, 
DATATRAK Uniﬁed Experience and ERT Insights Cloud operate as a component of the 
trial's Electronic Data Capture (EDC) system (Table 6). Six SaaS RBM tools can operate 
independently or as an integrated function of the trial's EDC system (Table 6: items 
14, 15, 18, 19 & 21). Six SaaS RBM tools operate independently to the trial's EDC 
system (Table 6: items 9, 16, 17, 20, 22–24). 
3.4.2.3 Language of administration 
All 24 RBM tools included in this review operate in the English language. Seven SaaS 
RBM tools are available in multiple languages (Table 6: items 9–15). The Risk 
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Assessment Tool (RAT) was developed by German academic clinical researchers and 
is available in both English and German formats(171). The Risk-Assessment Form 
(RAS) and accompanying tool is available in English and French formats(129). 
3.4.2.4 Cost 
The six-paper based RBM tools developed by academic and regulatory clinical 
researchers are available free of charge and can be downloaded from each 
organisation's webpage (Table 6: items 1, and 4–7). The Microsoft Excel version 2 of 
the Risk Assessment Categorization Tool (RACT) is also available free of charge and 
can be downloaded from the TransCelerate website(26). The risk assessment 
questionnaire used as part of the Early Bird RBM tool is provided free of charge on 
the Cyntegrity website(172). The 16 RBM tools included in this review that operate 
as SaaS must be purchased (Table 6: items 9–24). The costs of these SaaS are based 
on licence and hosting fees and trial speciﬁcation, such as the number of study sites 
in the trial, the phase of the trial and the number of study participants. 
3.4.2.5 Quality check process 
The Risk Assessment Form (RAS) is the only tool to provide data demonstrating how 
its RBM strategy was tested for non-inferiority against 100% on-site SDV monitoring 
(see Table 6). The RBM approach in the RAS was less effective than 100% on-site SDV 
monitoring at detecting errors in the participant consent process, late notiﬁcation of 
serious adverse events (SAEs) and incorrect application of participant's eligibility 
criteria and inaccurate reporting of the main study outcome  (143). Similarly the 
ADAMON project is comparing the effectiveness of the RBM strategy directed by its 
risk assessment form against traditional intensive monitoring with frequent visits and 
100% source data veriﬁcation(171). ADAMOM is a cluster randomised study involving 
twelve different clinical trials that are randomised to either RBM or a traditional 
monitoring approach. The results of this study are expected in late 2016 (171). 
Currently Cyntegrity, the developers and providers of the Early Bird RBM tool are also 
conducting the PUEKS project – Process Optimisation in Clinical Trial Monitoring 
which aims to develop and validate a Risk- based Monitoring process using robust 
data-driven indicators(134). 
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Table 6: Characteristics of RBM tools 
Author Affiliated 
clinical trial 
organisation 
Risk 
assessment 
tool 
Publication/
Marketing  
Year 
Country of 
Origin 
Applicable 
clinical 
trial phase  
Applicable 
to medical 
devices  
Mode of 
administration 
Language Cost Quality check 
process 
1. Brosteanu et al  
(171) 
Academic  Risk analysis 
form 
2009 Germany All Yes  Paper based English & German None Ongoing: Non-
inferiority 
testing with 
traditional on-
site SDV 
monitoring 
2. Journot et 
al(129) 
 
Academic & 
Regulatory 
Risk-
assessment 
scale (RAS) 
2011 France All Yes Paper based English & French None  RBM strategy 
tested for non-
inferiority 
against 
traditional 
monitoring 
3. MRC/DH/MRH
A(28) 
Academic & 
Regulatory  
Risk 
classification 
method   
2011 UK All No Paper based English None  No 
4. Nordic 
Monitoring 
Network 
(NORM) (27) 
Academic  Risk 
Assessment 
Tool (RAT) 
2015 Norway 
Denmark 
Sweden 
Finland 
All No  Paper based English None  No 
5. Smith et al (169) Academic  TORPEDO-CF: 
Risk analysis 
form 
2014 UK All No  Paper based  English None  No 
6. Swiss Clinical 
Trial  
Organisation 
(SCTO) (170) 
Academic  Risk 
assessment 
for risk-
adapted 
monitoring  
2015 Switzerlan
d 
All Yes  Electronically 
via Microsoft 
Excel 
English None  No 
7. Yee et al(173) Academic  Masonic 
Cancer Centre 
(MCC) Risk 
2012 USA  All Yes  Paper based  English None  No 
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Assessment 
Checklist 
8. TransCelerate 
BioPharama 
Inc(26) 
Biopharmac
eutical -
nonprofit 
organisation 
Risk 
Assessment 
Categorization 
Tool (RACT) 
2014 USA All Yes  Electronically 
via Microsoft 
Excel 
English None  No  
9. Bioclinica(174) Independent 
Software 
Vendor (ISV) 
Bioclinica 
Compass RBM 
2014 USA All Yes Software as a 
service (SaaS): 
operates 
independent to 
EDC system 
English-primary 
language but 
language can be 
changed to match 
trial specifications 
Cost based 
on licence 
&hosting 
fees, trial 
duration & 
study sites, 
consultatio
n services 
 In-house 
validation  
10. DATATRAK 
International 
Inc(175) 
ISV DATATRAK 
Unified 
Experience 
2000 USA All  Yes SaaS- it is a 
component of 
the EDC 
Multiple 
languages 
including English, 
Kanji & Chinese 
Hosting 
fees 
In-house 
validation 
11. ICON (176) Contract 
Research 
Organization 
(CRO)  
ICONIK 2011 Ireland  All Yes SaaS Multiple 
languages 
including English 
Hosting 
fees 
In-house 
validation 
12. JMP(177) ISV JMP® Clinical 2010 USA All Yes SaaS English & Chinese Hosting 
fees 
In-house 
validation 
13. Medidata(178) ISV Targeted 
Source Data 
Verification 
(TSDV) 
2014 USA All Yes  SaaS All languages  Hosting 
fees 
In-house 
validation 
14. xClinical (179) ISV Marvin 2002 Germany All Yes SaaS: can 
operate 
independently 
or can integrate 
with trial’s 
Electronic Data 
Capture (EDC) 
system 
Multiple 
languages 
Cost based 
on no. of 
data items 
In-house 
validation 
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15. Flex 
Databases(180) 
ISV Clinical Trial 
Management 
System 
2005 Russia All Yes SaaS: can 
operate 
independently 
or can integrate 
with EDC 
English & multiple 
languages 
Hosting 
fees, 
helpdesk, 
data 
storage & 
backup & 
training 
In-house 
validation 
16. Triumph 
Research 
Intelligence 
(TRI)(181) 
ISV OPRA 2013 USA All Yes SaaS: typically 
operates as an 
independently 
to the EDC but 
uses EDC as a 
source of data 
to analyze 
English Hosting 
fees on a 
monthly 
basis  
Fully validated 
17. Cyntegrity(172) ISV Early Bird 2014 Germany All Yes SaaS: operates 
independent to 
system 
English Cost 
depends 
on study 
size 
&phase. 
But free 
version of 
risk 
assessmen
t 
questionna
ire -RACT 
available 
on 
Cyntegrity 
website 
In -house 
validation and 
as part of a 
scientific 
collaboration 
project- 
‘Process 
Innovation in 
Clinical 
Monitoring 
(PUEKS) 
18. CluePoints(182) ISV Central 
Monitoring 
Platform 
2014 Belgium & 
USA 
All Yes SaaS: operates 
independent or 
can integrate 
with EDC 
system 
English Cost 
depends 
on no. of 
sites & 
participant
s, hosting 
Technical & in-
house validation 
via customer 
and in-house 
validation 
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& 
consultatio
n fees 
19. Remarque 
Systems(183) 
ISV Remarque 2016 USA All Yes SaaS: can 
operate 
independently 
or integrated 
with EDC 
systems  
English Cost based 
on the 
number of 
participant
s, sites, 
duration 
and type 
of trial 
(e.g. phase 
of trial) 
In-house 
validation 
20. Algorics(184) ISV Acuity 2016 USA All Yes SaaS: operates 
independent to 
EDC 
English Cost 
depends 
on no. of 
sites & 
participant
s, hosting 
& 
consultatio
n fees 
In-house 
validation 
21. Kestrel 
Biologic(185) 
ISV iQROS 2011 Canada & 
USA 
All Yes SaaS: can 
operate 
independently 
or integrated 
with EDC 
Mainly English Based on 
the trial’s 
level of 
complicati
on, 
enrolment 
and 
frequency 
of 
monitoring 
In-house 
validation and 
system quality 
checks in trials  
22. Clindata(186) ISV Clindate Cloud 2014 USA All Yes SaaS: operates 
independent to 
ECD system 
English Based on 
system 
customizat
ion for a 
In-house 
validation 
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given 
study and 
subsequen
t 
monitoring 
fee 
23. Clinerion(187) ISV Quality Risk 
Radar 
2011 Switzerlan
d 
All Yes SaaS: integrated 
with EDC 
system 
English Hosting 
fee 
determine
d by 
number of 
studies 
In-house: 
computer 
software 
validation and 
vendor 
validation 
24. ERT(188) ISV ERT Insights 
Cloud 
2014 USA All Yes SaaS: integrated 
with EDC 
system 
English Based on 
number of 
studies, 
users and 
the 
number of 
source 
systems to 
be 
connected 
In-house and 
customer 
validation 
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3.4.3 RBM strategy informed by RBM tools  
3.4.3.1 Baseline risk assessment process 
Table 7 describes the process used by each of the 24 RBM tools to assess baseline 
risks in a clinical trial. All 24 RBM tools identiﬁed risks in the clinical trial protocol 
using a checklist of pre-determined risk categories. The six-paper based, and the two 
Excel powered RBM tools used a pre-determined risk assessment questionnaire to 
identify risks in a clinical trial (Table 7: items 1–8). Sixteen RBM tools, that operate as 
SaaS, applied a more ﬂexible approach to risk assessment which allows for the 
identiﬁcation of ad-hoc trial speciﬁc risks that are not pre-deﬁned in the risk 
assessment questionnaire (Table 7: items 9–24). All RBM tools examined several 
similar risk categories that would negatively affect patient safety and the credibility 
of trial data. These categories included the safety proﬁle of the IMP, the phase of the 
clinical trial under investigation, clinical trial medical procedures, pharmacovigilance 
reporting, proﬁle of the study population and data collection procedures. Seven RBM 
tools based their risk assessment process on TransCelerate's RACT tool (Table 7: 
items 8, 12,13, 17, 19–21). 
The risk indicators used by the 24 RBM tools were mapped onto an established risk 
indicator taxonomy for supervision of clinical trials of medicinal products (see Table 
8). The taxonomy includes risk indicators that relate to ‘What IMP’ is under 
investigation, ‘Who is conducting the clinical trial’ and ‘How’ the trial is being 
conducted(133). Only 12 of the 24 RBM tools included in this review examined all 12 
risk indicators listed in the taxonomy (Table 8 : items 4:, 5, 8, 9, 12, 13, 15, 17    –19, 
21& 22). 
3.4.3.2 Classiﬁcation of clinical trial risk 
The RBM tools included in this review used two methods to grade the risks identiﬁed 
during the risk assessment process (see Table 7). One method involved the 
assignment of an overall risk category to the clinical trial based on the types of risks 
identiﬁed during the risk assessment phase (Table 7: items 1–3, 5–7, 9 & 23). The risk 
categories most commonly used by the RBM tools were low, medium or high risk. 
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The Risk analysis form developed by Brosteanu et al. in 2009, used this method(171). 
This RBM tool recommends that a high risk score should be assigned to a trial that is 
either a Phase I trial or is using an IMP for an unlicensed indication (Table 7: item 
1)(171). The subsequent risk mitigation strategy should focuse on controlling the 
overall risk of the clinical trial.  
Nine RBM tools used a different method to classify risks which involved ranking each 
risk category individually (Table 7: items 4, 8,10,12,13,15,16,17 & 18). These RBM 
tools assigned an independent risk classiﬁcation (e.g. low, medium or high) to each 
risk category identiﬁed during the risk assessment process. TransCelerate's RACT 
used this method and ranked each independent risk category based on its probability 
of occurring, how detectable the risk is and its impact (26). The overall risk score for 
each of the 13(+1) risk categories is calculated and the value determines whether the 
risk category is low, medium or high (Table 7: item 8)(26). The subsequent risk 
mitigation strategies focus on controlling individual risk categories. 
Three SaaS operated RBM tools were able to rank risks using two systems. The ﬁrst 
graded risks based on individual risk indicators and the second system applied an 
overall risk category to the clinical trial level (Table 7: items 19, 21 & 22). xClinical's 
RBM tool, does not assign risk classiﬁcation because the company believes it is 
inappropriate for the software to assign a risk category and, instead, this needs to be 
completed manually by the study team (Table 7: item 14)(179). 
3.4.3.3 On-site monitoring guideline 
ICONIK was the only RBM tool that did not support on-site monitoring to mitigate 
clinical trial risk (Table 7: item 11)(176). Instead, another ICON software called the 
Error Capture and Action Tool (ECAT) can be used in partnership with ICONIK to guide 
on-site monitoring(189). The 23 other RBM tools recommend on-site monitoring 
strategies to mitigate risks identiﬁed during the risk assessment (see Table 7). The 
Risk Assessment Tool (RAT)(27) and the Risk Assessment Categorization Tool 
(RACT)(26) advised what types of risk categories should be controlled using on-site 
monitoring(Table 7: items 4 & 8). These risks include patient safety risks, data 
accuracy risks, staff training and internal site risks. 
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Six RBM tools provided explicit guidance for on-site monitoring based on a trial's risk 
classiﬁcation and the stage of the trial (Table 7: items 1–3 & 5–7). For example, the 
Risk classiﬁcation tool advised scheduled on-site visits were not required for low risk 
trials (Table 7: item 3).  
Risks identiﬁed during on-site monitoring could be manually entered into seven of 
the SaaS based RBM tools (Table 7: items 10, 17–22). Cyntegrity's RBM tool, Early 
Bird, allows the clinical trial team to create an issue management system (IMS) ticket 
and assign it to the site and risk (Table 7: item 17)(172). 
3.4.3.4 Centralised monitoring guideline 
The MCC Risk Assessment Checklist was the only RBM tool included in this review 
that did not provide guidance for risks mitigation through centralised monitoring 
(Table 6: item 7)(173). Seven tools, ﬁve paper based and two Excel RBM provided 
information on how and what risks should be controlled through centralised 
monitoring activity (Table 7: items 1–6 & 8). These risks include patient safety risks, 
data ac- curacy risks, staff training and internal site risks (see Table 7). For example, 
the RBM tool developed by the Swiss Clinical Trial Organisation (SCTO), advised that 
protocol compliance could be monitored centrally for low-risk trials (Table 7: item 
6)(170). These seven RBM tools did not provide guidance on suitable Electronic Data 
Capture (EDC) or clinical trial management system (CTMS) that a clinical trial should 
use to sup- port centralised monitoring(190). In contrast, the main function of the 16 
SaaS RBM tools is to perform centralised monitoring (Table 7: items 9– 24). 
3.4.3.5 Recommended process for systematic review of trial's risk proﬁle 
The paper based Risk Assessment Scale (RAS) was the only RBM tool included in this 
review that did not recommend a process for systematic review of the trial's risk 
proﬁle (Table 7: item 2)(129). The other seven non-SaaS RBM tools provided varying 
level and types of advice for how a clinical trial team should manually reassess the 
trial's risk proﬁle as   the trial   progresses (Table 7:   items   1, 2–8).   For example, 
TransCelerates's RACT suggests that the risk proﬁle of a trial should be reassessed 
whenever the protocol is amended (Table 7: item 8)(26). 
72 
 
The SaaS based RBM tools included in this review provided functions that allowed for 
their software to reassess the risk in a trial automatically by systematically analysing 
electronic trial data (Table 7: items 9–19 & 21–24). For example, the Clinical Trial 
Management System from Flex Databases, performs real time risk analysis on both 
sub-sample and total sample analysis in accordance with predeﬁned 
milestones/time- lines(180). If a risk indicator is notiﬁed, the trial team is alerted via 
email and system alert (Table 7: item 15).  
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Table 7: RBM strategy informed by RBM tools: risk assessment, risk classification and risk mitigation strategy (on-site & centralised 
monitoring). 
Author Categories of baseline risks 
assessed before the trial 
begins 
Risk Classification of a clinical 
trial (CT) 
Recommended 
On- site monitoring activity 
Recommended 
Centralised monitoring 
activity 
Recommended process for 
systematic review of a 
trial’s risk profile  
1. Brosteanu et al  
(171) 
1. Potential risk associated 
with therapeutic 
intervention 
2. Trial specific risk analysis -
Patient related indicators  
3. Trial specific analysis - 
Indicators of robustness 
Trial specific analysis - Site 
related indicators  
The CT is assigned an overall 
risk category based on the 
results of the risk assessment 
as follows: 
K3 – low/comparable risk:  
Phase IV or IIIb trial, IMP 
relates to its licenced range of 
indicators. Trial has patient 
related critical indicator that 
can be controlled by on-site 
monitoring & at least one 
indicator of robustness 
K2- intermediate risk: Phase II 
or IIIb trial, IMP used for a new 
unlicensed indication. Trial has 
no patient related critical 
indicator that can be 
controlled by on-site 
monitoring & at least one 
indicator of robustness 
K1- high risk:  Phase I trial. IMP 
is used for unlicensed 
indication. Trial has no patient 
related critical indicator that 
can be controlled by on-site 
monitoring 
Schedule of on-site visits for: 
K3 – low/comparable risk:  
one annual on-site visit. 
Triggered on-site visits 
recommended if concerns 
emerge through centralised 
monitoring 
K2- intermediate risk: pre-
study visit; initiation visits; first 
visit after 1-2 patients 
recruited; at least 3 routine on-
site visits annually. Close out 
visits only if required. 
K1- high risk:  pre-study visits; 
initiation visits; first visit after 
1st patient enrolment; at least 
6 routine on-site visits annually 
and close out visit.  
Categories of risks to be 
monitored centrally:  
K3 – low/comparable risk: 
trial-specific documentation 
such as high level of 
inconsistencies or implausible 
data  
K2- intermediate risk: close 
central monitoring – no 
further guideline. 
K1- high risk:  close central 
monitoring – no further 
guideline. 
For-cause monitoring is 
recommended to deal with 
risks that emerge 
throughout the trials when 
irregularities that exceed a 
pre-defined tolerance limit 
are detected e.g. Serious 
Adverse Events (SAEs) are 
regularly reported late or 
incomplete 
2. Journot et al(129) 
 
1. Stage 1 – identifying the 
focus of the study and its 
characteristics i.e. IMP, 
study phase & 
The CT is assigned an overall 
risk category based on the 
results of the risk analysis as 
follows: 
Schedule of on-site visits for 
Risk level A: initiation visit if 
site is not known; routine on-
site visits to check SAE 
Categories of risks to be 
monitored centrally:  
Risk level A: verification of 
resources adequacy at 
Not specified 
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physiopathology 
techniques 
2. Stage 2- Identifying one or 
more parameter 
increasing risk i.e. 
vulnerable study 
population  
A -Low risk: Trial of low risk 
certified medical device; or an 
IMP outside it’s licensed 
indications along with simple 
study questionnaires and 
minimally invasive medical 
intervention 
B-normal risk: Trial of 
low/moderate risk certified or 
uncertified medical device; or 
an IMP outside it’s licensed 
indications along with 
technique or biopsy 
performed on an internal 
organ & use of questionnaire 
for severe medical condition 
C-high risk: Trial of 
moderate/high certified 
medical device; or an IMP 
outside its licensed indications 
involving the generalisation of 
a new surgical technique 
D- very high risk: Trial of 
moderate/high risk certified or 
uncertified medical device; or 
an IMP outside its licensed 
indications involving the 
development of a new surgical 
technique  
management- number of 
routine visits not specified  
Risk level B: initiation visit if 
site is not known; 1st routine 
on-site visits when 10% of 
patients are recruited; 
additional triggered visits if 
issues identified 
Risk level C: initiation visit if 
site is not known; at least 1 
annual visit to study sites and 
another visit when pre-
determined recruitment levels 
are achieved; additional 
triggered visits if issues 
identified and site close-out 
visit 
Risk level D: not specified  
investigator site; study 
initiation; verification of CRF, 
consent process, detection of 
unreported SAEs; 
administrative closure of 
study site 
Risk level B: verification of 
resources adequacy at 
investigator site; study 
initiation; administrative 
closure of study site; 
detection of unreported SAEs 
Risk level C: verification of 
resources adequacy at 
investigator site; study 
initiation; detection of 
unreported SAEs and CRF 
verification  
Risk level D: not specified 
3.MRC/DH/MRHA(28) 1. Risks to participant’s 
safety in relation to the 
IMP 
2. Phase of trial  
3. IMP safety profile 
The CT is assigned an overall 
risk category primarily based 
on the risk associated with the 
IMP:  
Type A: No higher than the risk 
of standard medical care 
Schedule of on-site visits for: 
Type A: no requirement for 
scheduled on-site visits. 
Triggered on-site visits 
recommended if concerns 
emerge through centralised 
monitoring 
Categories of risks to be 
monitored centrally:  
Type A: protocol adherence 
& data quality 
Type B: safety data quality & 
timeliness; protocol 
Risk assessment and 
associated monitoring 
plans should be kept under 
review during the trial and 
modified as necessary if 
unanticipated risks emerge 
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4. Risks to participants from 
clinical procedure 
specified by the protocol 
5. Data protection risks 
6. Risks to the reliability of 
study results  
Type B:  Somewhat higher 
than the risk of standard 
medical care 
Type C: Markedly higher than 
the risk of standard medical 
care 
Type B: triggered visits for 
poor data return or protocol 
adherence concerns & unusual 
level of Serious Adverse Events 
(SAE) 
Type C: intense scheduled on-
site monitoring (amount not 
specified) 
adherence and trial data 
quality 
Type C: safety data quality & 
timeliness; protocol 
adherence and trial data 
quality 
4.Nordic Monitoring 
Network (NORM) 
(27) 
1. Study Organisation and 
governance 
2. Training (staff) 
3. Trial subjects’ rights and 
safety 
4. Data 
(protection/validation) 
5. Protocol procedures 
6. Study Drug/IMP 
7. Safety Reporting 
(Pharmacovigilance) 
8. Impact (study results) 
9. Other  
Each risk category is 
independently ranked based 
on the severity (1-3 scale) and 
probability (1-3 scale) of the 
risks within each category. 
 
For example, when assessing 
risk Category 6- Study 
Drug/IMP: the risks associated 
with handling the study drug 
are classified on the 
probability of negative 
outcome emerging and their 
severity 
Categories of risks to be 
mitigated by on-site 
monitoring: 
• Study Organisation and 
governance 
• Training (Staff) 
• Trial subject’s rights and 
general safety 
• Protocol Procedure  
• Study drug/IMP 
• Impact of study results  
Categories of risks to be 
monitored centrally:  
• Data – data protection 
• Protocol Procedure 
through the electronic 
clinical report form 
(eCRF) 
• Safety Management  
To be considered based on 
the findings of each routine 
on-site visit 
5.Smith et al (169) 1. Patients Hazards/Research 
Staff Hazards (right and 
safety) 
2. Study Hazards 
(Completion and 
Reliability) 
3. Organisational Hazards 
The CT is assigned an overall 
risk category based on the 
results of the risk analysis as 
follows: 
Low risk: CT has a risk score of 
≤ 33% 
Moderate risk: CT has a risk 
score of ≥ 34 to ≤ 67% 
High risk: CT has a risk score of 
≥68 to ≤ 100% 
Example given for low risk 
TORPEDO-CF trial. 
Schedule of on-site visits for: 
• Green light visit 
• Triggered visits 
• Study close-out visit  
Example given for low risk 
TORPEDO-CF trial. 
Ongoing schedule of central 
monitoring: 
• Consent forms 
• Patient recruitment 
• Protocol deviations  
• Missing primary outcome 
data 
• Adverse Events (AE) 
• Case report forms 
• Data entry process 
Frequency and review of 
trial monitoring should be 
amended during the trial if 
issues that require 
immediate action are 
identified 
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6.Swiss Clinical Trial  
Organisation (SCTO) 
(170) 
1. Potential risk of 
therapeutic intervention in 
comparison to standard of 
medical care 
2. Potential trial participant-
related critical indicator 
3. Robustness related 
indicators – “hard primary 
endpoints” and/or simple 
clinical trial procedure 
The CT is assigned an overall 
risk category based on the 
results of the risk analysis as 
follows:  
• Low risk: IMP is 
authorised in Switzerland 
& trial has at least one 
indicator of robustness 
• Intermediate risk: IMP is 
authorised in Switzerland 
& trial has no indicator of 
robustness 
• High risk: IMP not 
authorised in Switzerland 
and trial has no indicator 
of robustness 
Schedule of on-site visits for: 
• Low risk trial: pre-trial 
visit; annual monitoring 
visit to review Trial Master 
File(TMF) and Sites Files 
(SF) and close out visit 
• Intermediate risk trial: 
pre-trial visit; 1-3 
monitoring site visits 
annually to review TMF & 
SF and close out visit 
• High risk trial: pre-trial 
visit; site-initiation visits; 
2-8 monitoring site visits 
annually to review TMF & 
SF and close out visit 
Categories of risks to be 
monitored centrally:  
• Low risk trial: site 
initiation and consistency 
checks (protocol 
compliance; Case Report 
Forms (CRFs) and clinical 
research participant 
information) 
• Intermediate risk trial: 
site initiation and 
consistency checks 
• High risk trial: 
Consistency checks 
An additional risk 
assessment is required if 
the trial undergoes 
substantial amendments  
7.Yee et al(173) 1. Phase of trial (phase I or II, 
or pilot study) 
2. Known toxicity of IMP 
3. Unknown toxicity of IMP 
4. Origin of trial agents, 
devices or processes 
5. Does trial involve an 
Investigational New Drug 
Application (IND) or an 
Investigational Device 
Exemption (IDE) 
6. Complexity of processes 
involved in the trial i.e. 
IMP administration  
7. Experience of Principle 
Investigator 
The CT is assigned an overall 
risk category based on the 
results of the risk analysis as 
follows:  
• Low risk: no risks 
identified during risk 
assessment  
• Moderate risk: one of the 
following risks are present 
- Pilot or phase II trial 
- PI has ˂2 completed 
trials 
- the trial procures are 
complex 
• High risk: one of the 
following risks are present 
- Phase I trial 
- Unknown IMP toxicity 
- High known IMP 
toxicity 
Schedule of on-site visits for: 
• Low risk trial: annually 
review from Data Safety 
Monitoring Committee 
(DSMC) 
• Moderate risk trial: Twice 
yearly monitoring by both 
trial monitor and DSMC 
• High risk trial: Twice 
yearly monitoring by trial 
monitoring and queerly 
DSMC visits 
Not discussed  For high enrolling studies 
(recruitment goal >100 
subjects)-100% SDV is 
advised for first 50 subjects 
recruited. If no issues 
emerge the Data Safety 
Monitoring Committee 
(DSMC) may subsequently 
allow SDV monitoring 
activity to only be 
performed on 10% of 
subject data during the 
remaining recruitment 
period  
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- New Drug Application 
(IND) or an 
Investigational Device 
Exemption (IDE) 
8.TransCelerate 
BioPharama Inc(26) 
1. Safety related to IMP 
2. Study phase 
3. Complexity of study i.e. 
no. of study sites 
4. Study population  
5. Technology 
6. Data collection/CRF source 
7. Endpoints 
8. Organisational experience 
9. Investigational 
product/study medication 
10. IMP logistics/supply chain 
11. Blinding 
12. Operational complexity 
13. Geography of study sites 
Other risks  
Each risk category is 
independently ranked based 
on its probability of occurring 
(1-3), how detectable the risk 
is (1-3) and its impact (1-.3)  
 
The overall risk score for each 
the 13(+1) risk categories is 
calculated and depending on 
the value, the risk categories 
are classified as:  
• Low risk 
• Medium risk 
• High risk  
 
 
Categories of risks to be 
mitigated by on-site 
monitoring: 
• Safety risks 
• Study phase 
• Complexity 
• Subject population  
• Data collection- CRF 
source 
• Endpoints 
• Organisational experience 
• IMP logistic/supply chain 
• Blinding 
• Operational complexity 
• Geography of study sites 
Categories of risks to be 
monitored centrally:  
• Safety risks 
• Complexity 
• Technology 
• Subject population  
• Data collection- CRF 
source 
 
The risk profile of the trial 
should be reassessed 
whenever the protocol is 
amended  
9.Bioclinica(174) The tool has 46 standard risk 
assessment (KRIs) questions 
which are quantitative and 
qualitative in nature  
Additionally, KRIs can be added 
to the system of required by 
the trial.  
An overall site quality score is 
calculated by Compass based 
on the assignment and 
weighting of KRI’s 
 
 
Tool supports routine and 
triggered on-site monitoring- 
process is unique to each trial 
and is determined by the trials 
KRIs, study SOPS and study 
team’s business plan 
It is not possible to manually 
enter issues captured during 
on-site into the Compass 
software 
Tool supports centralised 
monitoring – process is 
unique to each trial and is 
determined by the trials KRIs, 
study SOPS and study team’s 
business plan 
Compass performs monthly 
risk assessments on 
centrally stored electronic 
trial data using inbuilt 
algorithm assessing the 
study sites performance 
against KRIs. Subsequent 
risk concerns are flagged, 
and appropriate action is 
requested via on-screen or 
email notification 
10.DATATRAK 
International Inc(175) 
Risk can be pre-determined in 
the study design by selecting 
forms that require or do not 
Each risk category is 
independently ranked. The 
DATATRAK Unified Experience 
evaluates risk based on the 
information provided by the 
No -but DATATRAK Unified 
Experience has a data 
management function which 
provide the ability to enter and 
track manual events that ate 
Tool supports centralised 
Monitoring by evaluating 
incoming data attributes and 
to determine future risk 
profiles. 
The software provides real-
time analysis to evaluate 
risk and determine the 
appropriate risk-based 
approach. Risks include site 
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require SDV, Data Review or 
eSignature.  Risk can also be 
calculated based on a patent-
pending User Score which 
evaluates the site user’s 
quality of data entry to 
determine how much review is 
required.  The system also 
supports dynamic percentage 
risk  
trial data such as participant 
case form and the activity of 
the monitoring team to 
determine the risk factors for 
each individual trial that must 
be mitigated during 
monitoring. 
identify during on-site 
monitoring 
and clinical trial team 
activity.  
However, the system does 
not currently support 
proactive signalling based 
on changes in the risk 
profile. 
11.ICON (176) Risks are identified using 
various analytics and 
visualization for identifying 
trends & signals  
Not disclosed - information 
protected under 
 Confidentiality Data 
Agreement (CDA) 
Tool does not support on-site 
monitoring – on-site 
monitoring is supported by 
complimentary ICON software 
called the Error Capture and 
Action Tool (ECAT) 
Tool supports centralised 
monitoring 
Not disclosed 
12.JMP(177) Risks are measured using 
TransCelerate’s risk 
indicators(26) and organise by 
different Clinical Data 
Interchange Standards 
Consortium(CDISC)(191) 
domains and custom criteria 
Each risk category is 
independently ranked. Risk is 
not assessed at the clinical trial 
level. Goal is to identify sites 
within a clinical trial that are 
underperforming 
Tool supports routine and 
triggered on-site monitoring 
Tool supports centralised 
monitoring 
Not disclosed 
13.Medidata(178) Risks are measured using an 
edited version of 
TransCelerate’s risk indicators 
as follows: 
• Study design complexity 
• Patient population 
• Investigational Medicinal 
Product (IMP) 
Each risk category is ranked 
independently as either:  
• Low risk 
• Medium risk 
• High risk  
 
Tool supports routine and 
triggered on-site monitoring 
Tool supports centralised 
monitoring 
Not disclosed 
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14.xClinical (179) Risk is evaluated at each trial 
center by the data manager 
according to set risk then 
Marvin (RBM tool) applies a 
predefined SDV pattern  
No – Marvin does not assign 
risk classification as company 
believe it is too risky for 
software to assign a risk 
category – this is instead 
completed manually by study 
team  
Marvin applies a predefined 
SDV pattern for on-site 
monitoring 
Tool supports centralised 
monitoring 
Risks are reassessed via a 
manual report and risk 
concerns are notified by 
report/email 
15.Flex 
Databases(180) 
Flex Databases measure risk 
using a risk assessment 
questionnaire customized to 
track risk indicators in each 
trial  
Each risk category is 
independently ranked. Trial 
sites are assigned an individual 
risk level which is determined 
by the number of risk factors 
in each trial site 
Supports triggered on-site 
monitoring to mitigate risks 
Tool supports centralised 
monitoring through real time 
analysis of trial data collected 
electronically 
 
 
The system performs real 
time risk analysis on both 
sub-sample and total 
sample analysis in 
accordance with 
predefined 
milestones/timelines. If a 
risk indicator is notified the 
trial team is alerted via 
email and system alert 
16.Triumph 
Research 
Intelligence (TRI)(181) 
The OPRA system measures 
risks using statistical 
algorithms and adaptable KRIs 
Each risk category is 
independently ranked. Risk 
category assigned to each KRI 
and each study site 
Yes- software will guide 
activities that should be 
performed during on-site 
monitoring 
Tool supports centralised 
monitoring, software will 
guide activities that should be 
performed through 
centralised monitoring 
The OPRA system reassess 
the trial’s risk profile each 
time data is entered into 
the system 
17.Cyntegrity(172) EarlyBird ‘s risk assessment 
based on TransCelerate’s RACT 
and Metric Champion 
Consortium (MCC) and 
retrospective assessment of 
already finished trials. 
Each risk category is 
independently ranked. Risk 
classification based 
TransCelerate’s RACT and 
Metric Champion Consortium 
(MCC) 
Yes – the clinical trial team can 
create an issue management 
system (IMS) ticket and assign 
it to the site and risk 
Tool supports centralised 
monitoring. Real time 
analysis for operational & site 
level risks. Risk profiles are 
adjusted every night. Study 
level risks are assessed 
quarterly or every 6 months.  
Risk concerns are flagged 
via a built-in (IMS) with 
escalation logic, issue 
priorization, internal 
communication, root cause 
analysis and mitigation 
plan. 
18.CluePoints(182) The Central Monitoring 
Platform assesses baseline risk 
using pre-determined KRIs, risk 
algorithm, risk assessment 
questionnaire 
Each risk category is 
independently ranked. Risk 
category is assigned to each 
individual risk and an overall 
risk score is assigned to a trial 
Yes- it informs on-site 
monitoring by identifying those 
sites most at risk and why 
those sites need priority 
monitoring attention. Issues 
that are identifying during on-
site monitoring can be 
Tool supports centralised 
monitoring. Key risk 
indicators are assessed using 
real time analysis or every 1-2 
weeks depending on the 
client’s preference. Overall 
data quality assessment is 
Risk concerns are flagged 
via an in-built Action 
Tracking Management 
System  
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manually entered into the 
software 
performed monthly or every 
2-4 months 
19.Remarque 
Systems(183) 
Remarque RBM assesses 
baseline risk using 
TransCelerate’s RACT  
Risk categories can be 
assigned to either individual 
risk indicator or overall risk by 
categories, by patient or site, 
Yes- if a risk concern is flagged, 
Remarque RBM can create an 
action item that requires onsite 
monitoring 
Tool supports centralised 
monitoring, identified risks 
are continuously monitored 
using central data 
The system supports 
continuous risk assessment 
and If a risk concern is 
flagged Remarque alerts 
the user through machine 
learning algorithms and 
through programmed 
triggers 
20.Algorics(184) Risks are measured using 
TransCelerate’s RACT, but 
Acuity can include additional 
risks as per client’s request  
Not disclosed Yes- system can capture data 
collected during on-site 
monitoring 
Acuity uses subject and site-
specific dashboards and 
alerts to monitor critical data 
points in real time for 
scheduled and ad-hoc 
reviews 
The system uses algorithms 
to reassess site risk profiles 
and predictive trending 
drive focused site 
monitoring and provide 
traceability from 
assessment to action 
21.Kestrel 
Biologic(185) 
iQROS assesses risk using 
Failure Mode Effect Analysis 
(FMEA) and can incorporate 
TransCelerate’s RACT tool 
Risk categories are assigned to 
individual risk indicators and 
can be aggregated to the trial 
level 
Yes – system creates a to list of 
monitoring activates that can 
be completing via on-site 
monitoring. Data that is 
collected via on-site 
monitoring can be manually 
entered into the system  
Tool supports centralised 
monitoring – software stored 
all data collected from 
monitoring activity 
The system does not 
reassess the risk level, 
instead the status of each 
individual risk mitigation is 
shown, and the risk level 
cab be updated at any 
time. Subsequently iQROS 
will create a to-list if 
monitoring activities the 
clinical trial team must 
action 
22.Clindata(186) Clinidata Cloud assesses risk 
using a risk assessment 
questionnaire, KRIs,machine 
learning risk predictive 
algorithm 
Risk categories are assigned to 
individual risk indicators or to 
trial level 
Yes- onsite monitors can use 
specifically designed risk 
monitoring screens to enter 
their observations and the 
system then triggers 
remediation actions if risk 
concerns are flagged 
Tool supports centralised 
monitoring; the system runs 
100% real time reassessment 
of entire clinical trial data 
using Machine learning and 
mining algorithm 
If risk concerns are flagged, 
the system sends real time 
mobile alerts such as 
emails to the trial team and 
this activity in documented 
in pre-defined scheduled 
reports 
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23.Clinerion(187) Quality Risk Radar (IQR) covers 
a holistic risk assessment 
starting with the study 
protocol at concept stage, 
followed by regular trial site 
assessments which enable 
targeted monitoring 
Overall risk classification. QRA 
calculates risk per patient 
safety as well as the data 
integrity per trial site and per 
study protocol.  Additional risk 
levels per trial sites are: 
structural risk, procedural risk 
and risk details (KRI level) 
System can signal risk concerns 
that require mitigation through 
onsite monitoring. Presently, 
manual addition of risk 
information cannot be entered 
into the system 
Tool supports centralised 
monitoring – system 
monitors central data at 
regular intervals to reassess 
the risk profile of the trial 
Risk signals are refreshed 
after arch re-assessment of 
risk and displayed in real 
time throughout the 
system dashboards. In 
addition, email 
notifications can be 
configured as required 
24.ERT(188) ERT Insights Cloud allows 
Customers to configure/ 
weight pre-determined KRIs. 
Protocol assessments 
performed by the customer, 
and study-specific algorithms 
and analytics are developed 
using protocol or endpoint- 
related risk criteria. 
Risk categories are limited to 
the KRI (key risk indicator) 
Yes, the tool includes 
electronic monitoring visit 
report, scheduling, and alerts. 
CRAs can be notified of the 
need for a monitoring visit. The 
system can track that the visit 
has taken place, as well as 
integrate information from the 
monitoring report back into 
the system. 
Yes, the tool provides real 
time analysis of risk through 
centralised monitoring 
Risk indicators can be 
weighted with temporal 
parameters for each site 
depending on investigator 
experience or other 
contextual information. 
Composite scores are 
generated by weighting 
sites against each other. 
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Table 8: RBM tools mapped to the Risk indicator taxonomy for supervision of 
clinical trials on medicinal products 
Author A. What: IMP 
A1. Knowledge 
and IMPs in 
human 
A2. Treatment 
aspects 
A3. Potential 
large patient 
population 
A4. High- risk 
IMP 
B. By whom: 
investigator, 
clinical trial 
site, and 
sponsor 
B1. 
Professionalism 
B2. Reputation 
B3. Level of 
experience 
 
C. How: trial 
design 
C1. Participant 
characteristics 
C2. High burden 
for participants 
related to study 
procedures 
C3. Duration of 
treatment 
(>1month) 
C4. Design 
(protocol) 
C5. Conduct 
1. Brosteanu et al (171) All (A1-A4) None All (C1-C5) 
2. Journot et al(129) 
 
All (A1-A4) None All (C1-C5) 
3. MRC/DH/MRHA(28) All (A1-A4) None All (C1-C5) 
4. .Nordic Monitoring 
Network (NORM) (27) 
All (A1-A4) All (B1-B3) All (C1-C5) 
5. Smith et al (169) All (A1-A4) All (B1-B3) All (C1-C5) 
6. Swiss Clinical Trial  
Organisation (SCTO) (170) 
All (A1-A4) Only B3 All (C1-C5) 
7. Yee et al(173) All (A1- A4) Only B3 All (C1-C5) 
8. TransCelerate 
BioPharama Inc(26) 
All (A1-A4) All (B1-B3) All (C1-C5) 
9. Bioclinica(174) All (A1-A4) All (B1-B3) All (C1-C5) 
10. DATATRAK International 
Inc(175) 
Some (A1 & 
A2) 
Some (B1 &B2) Some (C1-C4) 
11. ICON (176) Not disclosed Not disclosed Not disclosed 
12. JMP(177) All (A1-A4) All (B1-B3) All (C1-C5) 
13. Medidata(178) All (A1-A4) All (B1-B3) All (C1-C5) 
14. .xClinical (179) None None None 
15. Flex Databases(180) All (A1-A4) All (B1-B3) All (C1-C5) 
16. Triumph Research 
Intelligence (TRI)(181) 
Some (A1-A3) Some (B1 &B2) Some (C1, C3-C5) 
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17. Cyntegrity(172) All (A1-A4) All (B1-B3) All (C1-C5) 
18. CluePoints(182) All (A1-A4) All (B1-B3) All (C1-C5) 
19. Remarque Systems(183) All (A1-A4) All (B1-B3) All (C1-C5) 
20. Algorics(184) Some (A2-A3) Some (B3) All (C1-C5) 
21. Kestrel Biologic(185) All (A1-A4) All (B1-B3) All (C1-C5) 
22. Clindata(186) All (A1-A4) All (B1-B3) All (C1-C5) 
23. Clinerion(187) Some (A2- A4) Some (B1 & B3) Some (C2 – C5) 
24. ERT(188) None None Some (C3 & C4) 
 
3.5 Discussion  
3.5.1 Main ﬁndings 
This systematic review identiﬁed 24 RBM tools that fulﬁlled the OECD classiﬁcation. 
Accordingly, these tools can identify and assess clinical trial risks and recommend 
appropriate procedures and strategies to mitigate the risks identiﬁed(10). Our review 
did not ﬁnd a standardized approach for examining the baseline risks in a clinical trial 
protocol. The risk assessment process developed by TransCelerate BioPharma Inc. 
appears to be the most operational as it has been replicated by six other RBM tools 
(see Table 7). We only identiﬁed 12 of RBM tools that assessed the 12 fundamental 
risk indicators listed in a recently published risk indicator taxonomy for supervision 
of clinical trials on medicinal products (see Table 8)(133). This ﬁnding strongly 
suggests that a gold standard approach to risk assessment has not yet been 
determined. However, despite the difference in the composition of the risk 
categories, most of the RBM tools evaluated risks associated with the safety proﬁle 
of the IMP, the phase of the clinical trial and the data collection process. These risks 
correspond with ICH-GCP's monitoring demands to ensure the rights and well-being 
of human subjects are protected and the reported trial data are accurate, complete 
and veriﬁable from the source document(11). 
The majority of RBM tools included in our review provided comprehensive guideline 
or functions for risk mitigation through on-site and centralised monitoring. This is 
important because the new ICH-GCP guideline states that RBM should be a mix of 
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centralised and on-site monitoring practices implemented speciﬁcally to control the 
risk identiﬁed during the risk assessment(12, 128).  
Unlike on-site monitoring, which was introduced with ICH-CGP in 1996, centralised 
monitoring is still relatively new to clinical trials(130). This process involves checking 
electronic clinical trial data for errors and is performed primarily on a trial's Electronic 
Data Capture (EDC) systems(192). The paper-based tools included in this review did 
provide guidance for centralised monitoring, but they did not give examples of EDC 
systems to support their recommendations (see Table 6). In comparison, the 16 RBM 
tools that operate as Service as a System (SaaS) could function either independently 
or as an integrated component of a trial's EDC system (see Table 6). However, it 
should be noted that some of the SaaS RBM tools did not allow for manual events to 
be entered into their systems. Consequently, if an on-site monitor identiﬁes risks, for 
example, relating to how study medication is stored, this information cannot be 
added to the SaaS system and so a link between on-site and centralised monitoring 
activity cannot be formed. 
The ICH-GCP addendum states that RBM is a continuous process(157). Therefore, it 
is not sufﬁcient for a RBM tool to simply assess baseline clinical trial risks. Instead a 
risk assessment should be carried out systematically throughout the life cycle of the 
study which involves a concurrent review of trial data collected from on-site and 
centralised monitoring(157, 192). Several of the SaaS RBM tools offered real time 
analysis for operational and site level risks. Concerns are then ﬂagged by the system 
via a built-in Issue Management System (IMS) that issues internal communication 
alerts to the trial team(172). This computer aided function is not provided by the 
paper based RBM tools. 
The 24 RBM tools included in this review can be divided into three categories based 
on their mode of administration: paper-based, powered by Microsoft Excel or 
operated as a Service as a System (see Table 6). It is not clear which mode of 
administration provides the most effective and efﬁcient RBM strategy. They all had 
different merits in terms of cost, administration and function. The paper based Risk 
Assessment Scale (RAS) was the only tool to prospectively test it's RBM strategy for 
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non-inferiority compared to more traditional monitoring methods, such as 100% on-
site SDV(143). However the RAS was shown to be less effective at detecting errors in 
the consent process, SAE reporting, application of participant's eligibility criteria and 
reporting of main study outcomes than traditional monitoring(143). Thus, a superior 
RBM tool or RBM approach was not identiﬁed in this review. Despite the availability 
of a range of paper based and computer aided RBM tools, the comparative 
effectiveness of these tools needs to be examined. This might be done through, for 
example, the embedding of methodology study in a large multi-centre clinical trial. 
This type of research would operate as a SWAT (Study Within A Trial) to provide a 
practical cost efﬁcient approach to prospectively compare the validity of the two 
types of RBM tools(193, 194). 
In the coming months and years, the new ICH-GCP addendum and EU Clinical Trial 
Regulation are poised to make RBM the preferred method for clinical trial 
monitoring(23, 128). The lack of a uniform approach may make it difﬁcult for 
sponsors to decide which RBM tool they should use when developing a RBM plan. To 
help overcome this challenge, we applied the ﬁndings of our review to the ICH-GCP 
and OECD RBM guidelines and developed four criteria to considered when choosing 
a RBM tool(10, 23). These are: 
1. Ensure the RBM tool's baseline risk assessment process examines the risk 
indicators set out in the Risk indicator taxonomy for supervision of clinical 
trials on medicinal products(133). 
2. Ensure the RBM tool can support both on-site and centralised monitoring. 
For SaaS tools ensure that on-site monitoring data can be entered 
manually into the system(192). 
3. Ensure the RBM tool provides a process for systematic review of the trial's 
risk proﬁle(23). 
4. Ensure the RBM tool is cost efﬁcient i.e. the paper-based tools are 
available free of charge however they need the support of an EDC system 
to perform centralised monitoring. 
 
3.5.2. Strengths and limitations 
Our review is the ﬁrst to systematically identify and compare academic and 
commercial RBM tools for clinical trial monitoring. It will make a major contribution 
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to the literature on RBM and provide RBM guidance to the global clinical trial 
community. Our ﬁndings will support the OECD's goal of ensuring appropriate and 
harmonised understanding of risk assessment(32). 
Despite the comprehensiveness of this review it was not possible to capture all 
relevant material, such as unpublished in-house Standard Operating Procedures 
(SOPs) for RBM. Information on the commercially developed tools was in some cases 
limited as these organisations are protected under conﬁdential data agreements. It 
must also be noted that our review was conducted before the ICH-GCP Addendum 
was published, and the release of the new ICH-GCP guideline in late 2017 may lead 
to an increase in the number of RBM tools. The European Clinical Research 
Infrastructure Network (ECRIN) webpage operates a RBM toolbox which contains a 
regularly updated list of primarily free paper- based RBM tools which may be useful 
to anyone wishing to stay updated on advancements in RBM tool development(195). 
3.5.3 Conclusion 
There is increasing recognition of the need to improve the quality and efﬁciency of 
clinical trials so that they can provide reliable and robust evidence needed by 
decision makers in health care who are faced by increasing demands and greater 
pressure on resources(150). This includes work to reduce waste in research, improve 
the selection of outcomes to measure and ensure that patients are more involved in 
all aspects of the trial(196-198). Alongside this, the resources put into the monitoring 
of a trial need to be proportionate to the risks associated with that trial(199). The 
Sensible Guideline Conference, held in Washington in 2007, ﬁrst recommended that 
each new trial should conduct a risk assessment before developing a monitoring 
plan(156). Since 2007, risk assessment and, accordingly, RBM has gained acceptance 
among the global clinical trial community. In 2012, the UK registered Clinical Trial 
Units (Clinical trial units) stated that 53% of all their registered trials conducted a risk 
assessment to determine the level of monitoring(200). Similarly, a global survey 
conducted by the Metrics Champion Consortium (MCC) in 2013 identiﬁed a growing 
appetite for RBM among academic and commercial clinical trialists(25). However, 
despite its international recognition, best practice guidelines for RBM do not 
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exist(10). This review was conducted in anticipation of the forthcoming ICH-GCP 
Addendum that will elevate RBM to the forefront of clinical trial monitoring(23).  
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4.1 Abstract  
Background: In November 2016, the ICH published a requirement for sponsors to 
develop a systematic, prioritised, risk-based approach to monitoring clinical trials. 
This approach is more commonly known as risk-based monitoring (RBM). However, 
recent evidence suggests that a ‘gold standard’, validated approach to RBM does not 
exist and it is unclear how sponsors will introduce RBM into their organisations. A 
first step needed to inform the implementation of RBM is to explore academic 
trialists’ readiness and ability to perform RBM. The aim of this paper is to identify the 
attitudes, and perceived barriers and facilitators to the implementation of RBM in 
academic-led clinical trials in Ireland. 
Methods: A mixed-methods, explanatory sequential design, with quantitative survey 
followed by semi-structured interviews. Academic clinical researchers (N=132) 
working in Ireland were surveyed to examine their use and perception of RBM. A 
purposive sample of survey participants (n=22) were then interviewed to gain a 
greater insight into the quantitative findings. The survey and interview data were 
merged to generate a list of perceived barriers and facilitators to RBM 
implementation, with suggestions for, and solutions to, these issues. 
Results: Survey response rate was 49% (132/273). Thirteen percent (n=18) of 
responders were not familiar with the term risk-based monitoring and less than a 
quarter of respondents (21%, n=28) had performed RBM in a clinical trial. Barriers to 
RBM implementation included lack of RBM knowledge/training, increased costs 
caused by greater IT demands, increased workload for trial staff and lack of evidence 
to support RBM as an effective monitoring approach. Facilitators included 
participants’ legal obligation to perform RBM under the new ICH-GCP guideline, 
availability of RBM guidance and perception of cost savings by performing RBM in 
future trials.  
Conclusion: The results of this study demonstrate a need for training and regulatory- 
endorsed guideline to support the implementation of RBM in academic led clinical 
trials.  The study provides valuable insights to inform interventions and strategies by 
policy makers, and clinical trial regulators to improve RBM uptake. 
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4.2 Introduction  
In 1996, the International Conference on Harmonisation (ICH) published the first 
Good Clinical Practice guideline (GCP) for clinical trial conduct(11). Under ICH-GCP, 
sponsors in America, China and the European Union are legally obliged to monitor 
their trial activity(11). Monitoring aims to protect the rights and well-being of trial 
participants, support accurate data collection and ensure compliance with regulatory 
requirements(11). Traditionally, trials were monitored through intensive on-site 
monitoring visits with 100% source data verification (SDV)(105). SDV can be a 
laborious task because it involves the validation of data presented in Case Report 
Forms (CRFs) against original source data such as consent forms, irrespective of the 
trial’s risk profile(105). Risks associated with the Investigational Medicinal Product 
(IMP), the vulnerability of the study population and the robustness of the study 
design are not considered when developing a traditional trial monitoring plan (105, 
164).    
In recent years the scale, complexity, and cost of clinical trials have increased beyond 
the scope of the original ICH-GCP(23). In November 2016, the ICH published the 
Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2) to 
respond to the changing clinical trial landscape(23).  Under the revised ICH-GCP 
guideline, risk based monitoring (RBM) was recommended as an alternative to 100% 
SDV on-site monitoring(23). RBM incorporates both centralised monitoring 
conducted off-site through an examination of data captured on an electronic data 
capture system (EDC) and on-site monitoring practices that are proportional to the 
risks associated with the clinical trial(28). These risks relate to the Investigational 
Medicinal Product (IMP), the study population, research team expertise and the 
robustness of the study design(101, 129). When developing a RBM plan, the trial’s 
protocol must be formally assessed to identify risks within the trial that can be 
mitigated through either on-site and/or centralised monitoring(170). Accordingly, 
risk assessment is the cornerstone of RBM(26). The emphasis on RBM is due to the 
assumption that it prevents waste of valuable clinical trial resources, such as study 
budget and staff time, on unnecessary monitoring activity that does not improve 
participant safety or data quality(30, 156).  
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The Organisation for Economic Co-operation and Development (OECD) recommends 
that clinical researchers use a RBM tool when developing a RBM plan(10). Such tools 
have two functions: first they support the assessment of risk in a clinical trial protocol 
and second they provide guidance for subsequent monitoring activity (on-
site/centralised) that can mitigate the risk identified(10). We recently published a 
systematic review that identified 24 RBM tools that met the OECD’s criteria(132). 
However there were many differences between the tools in terms of mode of 
administration (paper based versus software as a system), the baseline risk 
assessment process and guidance for on-site and centralised monitoring (132). For 
example, the Medicines and Healthcare Regulatory Agency (MHRA) advise 100% 
centralised monitoring for low risk phase III trials, while the Swiss Clinical Trial 
Organisation (SCTO) advise both on-site and centralised monitoring for similar low 
risk trials(28, 170). 
In the absence of a ‘gold standard’ approach to RBM, it remains unclear how 
sponsors will implement it into their clinical trial units(201). Given this context, it is 
important to establish how prepared academic trialists are to perform RBM(170). 
Presently, Ireland does not have a national strategy to support the introduction of 
RBM into its publicly funded, academic run clinical trial units. A first step in the 
development of such a strategy involves the identification of academic trialists’ 
readiness and ability to perform RBM(201). In this study we explore the experience 
of, attitudes to, and perceived barriers and facilitators associated with, the 
implementation of RBM in academic led clinical trial units in Ireland. 
4.3 Methods  
4.3.1 Design  
We used a mixed methods explanatory sequential design. This design occurs in two 
distinct but interactive phases (202). It begins with the collection and analysis of 
quantitative data, followed by qualitative data collection and analysis to further 
explore the quantitative results (see Figure 7)(202).  In this first study, methods were 
combined for complementarity, where each method addressed a different aspect of 
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the research question. The quantitative phase collected numerical data on the 
uptake of RBM in Ireland and its associated uses. The quantitative results facilitated 
sampling and development of the subsequent qualitative phase which further 
examined the barriers and facilitated associated with RBM. 
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Figure 6: Study design- mixed methods sequential explanatory design 
procedure(202) 
 
Phase    Procedure     Product 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Quantitative 
Data Collection 
• Cross-sectional web-based 
survey (n= 134) 
• Numeric data 
Quantitative 
Data Analysis 
• Frequencies 
• SPSS Software v.11 
• Descriptive 
statistics, 
missing data 
Connecting 
Quantitative and 
Qualitative Phases 
• Purposive samples from RBM 
survey 
• Developing interview questions to 
probe results of survey 
• Cases (n=24) 
• Interview 
protocol and 
topic guide 
QUALITATIVE 
Data Collection 
• Individual semi-structured face 
to face or telephone interviews 
with 22participants  
• Text date 
(interview 
transcripts) 
QUALITATIVE 
Data Analysis 
• Coding and thematic analysis • Codes and 
themes 
Integration of the 
Quantitative and 
Qualitative Results 
• Interpretation and explanation of 
the quantitative and qualitative 
results  
• Discussion 
• Implications 
• Future 
research  
94 
 
4.3.2 Phase 1— Quantitative Surveys 
Survey development: The study survey was adapted from the Clinical Trials 
Transformation Initiative (CTTI) monitoring questionnaire(203). The CTTI 
questionnaire contained 55 questions, collecting information on institutional 
demographics, overall study oversight methods, the use of risk- based monitoring, 
factors that influence risk assessment processes, and details of on-site and 
centralised monitoring practices(203).  
Our survey is a shortened and modified version of the CTTI questionnaire. Questions 
pertaining to a trial’s governance and verifications performed during on-site 
monitoring visits were excluded from our survey as they were not relevant to the 
current study. Our study also included additional questions on RBM tools which were 
not explored in the CTTI survey. In total our survey contained 20 questions. These 
include question regarding the participants’ demographics and their experience and 
understanding of the three primary components of RBM which are 1) risk assessment 
2) on-site monitoring and 3) centralised monitoring. A number of questions focused 
on respondent’s clinical trial experience since the introduction of the European 
Communities-Clinical Trials on Medicinal Products for Human Use Regulations to 
Ireland  in 2004(37). The full survey can be found in Appendix C. 
The survey questions required responses that were either yes/no, multiple choice or 
open ended. Before distribution, the survey was pilot tested with a sample of 10 
clinical researchers. The purpose of the pilot test was to make sure participants could 
understand and complete the survey. Further survey modification was not required 
after the pilot test. 
Recruitment:  The Health Research Board-Clinical Research Coordination Ireland 
(HRB-CRCI) is an independent, integrated, national clinical research network(64). It 
was established in 2014 to provide centralized support in the conduct of multicenter 
clinical trials across Ireland(64). Currently the HRB-CRCI operates as a collaborative 
partnership with five Clinical Research Facilities/Centers (CRF/C) based in five 
universities across Ireland(64). Researchers working in the CRF/Cs were eligible to 
participate in the survey. Participants included principle investigators (PI), 
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pharmacists, study doctors, nurses, project and quality managers, study monitors 
and biostatisticians. 
Data Collection: The survey was administered via Survey Monkey, an online cloud-
based survey development software(204). Participants received the survey invitation 
via an email sent from the Director of the Clinical Research Facility, Cork. This email 
was sent to participants between February and April 2016. It contained an online link 
to the survey. One reminder email was sent to all non-responders, three to six weeks 
after the initial email. The online survey was open for ten months from February to 
November 2016. However, 70% of survey responses were collected between 
February and June 2016. 
Data analysis: Data captured in Survey Monkey were downloaded into Excel and 
then exported into SPSS version 11 for analysis.   
4.3.3 Phase 2 — Qualitative Interviews 
Methodology: Thematic analysis was used to identify barriers and facilitators to the 
implementation of RBM in participants’ past, present and future clinical trials(205).  
Recruitment: Recruitment took place over four weeks from 26th September to the 
24th October 2016. Eligible participants were identified from respondents to the 
online survey, who had answered survey question 8.4, 9,3 or 10.2; ‘Since 2004, have 
you implemented a risk-based monitoring plan in a clinical trial’. Responders of this 
question (n=107) were grouped into three categories (A, B or C) based on their 
response; Group A answered ‘Yes’; Group B answered ‘No’; and Group C answered, 
‘I am not familiar with the term 'Risk-based monitoring’.  
Sampling: A purposive sample (n=24) of different clinical researchers (PIs, nurses, 
doctors, monitors, pharmacists, managers, biostatisticians) were selected from 
Groups A (n=8), Group B (n=8) and Group C (n=8) and invited to participate in the 
interviews via an email invitation. Two participants declined the invitation due to 
work commitments.  
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Setting: Face to face or telephone interviews (if participant was not available for a 
face to face interview) were conducted by an independent researcher (CH) from 7th 
October to the 29th November 2016. Face-to-face interviews were conducted in a 
private room in each participant’s work place.  
Data Collection: A semi-structured topic guide was developed to guide data 
collection. The topic guide was based on the results from Phase 1. The topic guide 
included open-ended questions including: the participant’s most recent clinical trial 
experience including how this trial was monitored; their understanding and attitudes 
towards RBM; foreseen benefits and limitations of RBM; and factors that would 
facilitate or hinder them from implementing RBM in future trials. The topic guide was 
piloted on three clinical researchers based in the Clinical Research Facility, Cork and 
minor revisions were made. Revisions involved the inclusion of three questions 
pertaining to participants past clinical trial monitoring experience. These questions 
were included to gain a greater insight into the participant’s clinical trial experience. 
The full topic guide can be viewed in Appendix C. 
All participants received a Patient Information Leaflet and consent was obtained 
from all participants for their interview to be audio-taped and content to be used for 
research purposes. Interviews lasted between 20-35minutes. Data saturation was 
reached when additional information relating to barriers and facilitators to RBM 
implementation was no longer obtained from interview participants(206). Data 
saturation was assessed independently for Group A, B and C. Data saturation was 
reached for Group A after interview 4, Group B after interview 5 and Group C after 
interview 3. However, all scheduled interviews were conducted, transcribed and 
analyzed.  
Data analysis: Interviews were audio recorded and transcribed verbatim. 
Transcribed interviews were coded and analyzed by two coders CH (epidemiologist 
and clinical trial methodologist) and ER (social policy researcher) using the qualitative 
data analysis software NVivo(207). The analysis followed the six phases of thematic 
analysis outlined by Braun and Clarke which include familiarization with the data, 
97 
 
generating initial codes, searching for, naming, defining and reviewing themes and 
producing a report(205).  
The main themes were found after repeated reading of the interview transcripts, 
paying careful attention to barriers and facilitators associated with the 
implementation of RBM in past, present and future clinical trials. Barriers were 
defined as perceived obstacles that would prevent or impact clinical researchers’ 
implementation of RBM(208). Facilitators were defined as processes that would 
support RBM implementation(208). Emerging themes were organised hierarchically 
in three levels of analysis. At the first level are text relating to the barriers and 
facilitators associated with RBM implementation that that were identified across the 
data set. At the second level are the subthemes, where different codes were 
combined because they shared an underlying meaning. At the third level, are the 
main barriers and facilitators associated with the implementation of RBM.  
4.3.4 Data Integration  
The Good Reporting of a Mixed Methods Study (GRAMMS) framework was used to 
inform reporting of the findings(209). The survey and interview data were integrated 
at the data interpretation phase using the method of merging data(210). Merging 
occurs when researchers bring two data bases together for analysis and 
comparison(210). In this study, the research team conducted separate analyses of 
the quantitative survey data and the qualitative interview data in parallel. Qualitative 
information was used to explore quantitative information collected in Phase 1, as 
dictated by the explanatory sequential design(211).    
4.3.5 Ethics 
The study received ethical approval from the Research Ethics Committee of the Cork 
Teaching Hospitals (CREC). Informed consent was received from all study 
participants.  
4.4 Results 
4.4.1 Participant Characteristics and RBM uptake  
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The survey response rate was 49% (132/273). Characteristics of the survey 
participants are described in Table 9. Forty per cent of respondents were Principle 
Investigators (n=53). Most respondents had over 6 years’ experience of working in 
clinical trials (57%, n=76) and over half had completed multi-centre and regulated 
trials (n=93, 70%).  
Survey findings showed that 37% (n=49) of responders had conducted RBM since 
2004. However, regardless of prior RBM experience, all survey participants said the 
Investigational Medicinal Product (IMP) under investigation, the phase of the clinical 
trial and the experience of the study team were the main factors they would use to 
determine how often a study monitor needed to visit a trial site to perform on-site 
monitoring.  Survey responders reported several protocol deviations, or a high drop-
out rate would warrant additional/triggered on-site monitoring. 
In total, 24 survey respondents from four of the five CRF/Cs were invited to 
participate in the semi-structured interviews. Twenty-two interviews were 
conducted (RR=92%). Interview participants included PIs (n=6), nurses (n=5), 
monitors (n=3), study doctors (n=3), data managers (n=3), biostatistician (n=1) and 
trial pharmacist (n=1). 
Table 9: Online survey participants' characteristics and use of clinical trial 
monitoring 
 Variable  Total 
(n=132) 
% 
Participants – clinical trial role  
 Principle Investigator (PI) 
 Clinical trial nurse 
 Project Manager 
 Quality Manager 
 Study doctor 
 Monitor 
 Biostatistics 
 Pharmacists 
 
55 
35 
21 
4 
5 
5 
2 
6 
 
41% 
26% 
16% 
3% 
4% 
4% 
1% 
5% 
Types of clinical trials conducted by participants 
 Industry 
 Academic 
 Non-regulatory 
 
60 
60 
32 
 
45% 
45% 
24% 
Clinical trial experience (years) 
 <1 
 
5 
 
4% 
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 1 – 3 
 4- 6 
 >6 
37 
14 
76 
28%% 
11% 
51% 
Conducted multi-centre clinical trial 
 Yes 
 No 
 
86 
34 
 
64% 
25% 
 
 
 
 
4.4.2 Barriers associated with the implementation of RBM 
4.4.2.1 Lack of knowledge /training  
The survey results showed that 14% (n = 18) of responders were not familiar with the 
term RBM. Of the participants who did not conduct a risk assessment in the most 
recent clinical trial that they worked on (n = 35), 17% felt that they did not have the 
expertise to perform a risk assessment (Table 10). Over 80% (n = 114) of survey 
responders categorised barriers to implementing centralised monitoring. Almost two 
thirds of these participants (62%, n = 71) identified lack of education as a very 
important barrier (Table 11). The interview data confirmed that several participants 
had not used RBM in past trials because they were not familiar with this type of 
monitoring and many did not know that RBM would be introduced in the new ICH-
GCP guideline: 
‘Well, just from talking to yourself, I have to admit, prior to that I hadn’t heard 
about this, so I wasn’t aware that the GCP was going to be changing’ (Study 
physician-1). 
Several interviewees, who had not conducted RBM in past trials, felt that they did 
not have enough RBM training to confidently perform RBM in future trials: 
‘It would come down to the practical aspects on how is risk defined …what 
information are people using to make that judgement. How is it a clinical trial 
implemented? But ultimately I’d have to understand that before I could say I 
was happy to do it’ (PI-1). 
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They did not feel able to classify clinical trial risks and to translate these risks into 
monitoring activity. Similarly, some interviewees who had conducted RBM in past 
trials still felt ill-equipped to perform RBM in their future trials: 
‘We would say we have conducted a type of risk-based monitoring, but it’s 
getting to the nitty-gritty of exactly what fields you’re going to look at and 
exactly what parameters are in those fields. I would say that I’d be still a bit 
unsure of that’ (Nurse-1). 
Survey responders reported having limited experience of using centralized 
monitoring for essential monitoring activity such as assessing protocol compliance, 
inspecting informed consent and recording pharmacovigilance information. Lack of 
education was the main reason that survey participants did not perform centralized 
monitoring (Table 11). A small number of participants from the five CRF/Cs (n = 17) 
reported having a Standard Operating Procedure (SOP) for centralized monitoring in 
their CRF/C. However, over a third of participants (n = 48) were unsure if such a SOP 
existed in their CRF/C. Analysis of the qualitative interviews showed that some study 
nurses and monitors did not know how centralized monitoring could replace on-site 
monitoring. One participant felt that on-site monitoring offered better governance 
of junior clinical trial staff. This participant also felt that centralized monitoring would 
result in monitors having less oversight of clinical trial activity: 
‘As sponsor, all of the monitoring is on-site, and that’s for two reasons…, 
because it’s our first time working with a lot of these investigators and we’re 
not sure of their experience in running regulated trials, we want to make sure 
that they understand what’s required and what they need to do in terms of 
quality’ (Monitor-2). 
4.4.2.2 Increased cost caused by greater Information Technology (IT) demands 
Almost half the survey responders identified IT demands (46%, n = 53) and cost (40%, 
n = 45) as problems associated with the implementation of centralized monitoring in 
past and future clinical trials (Table 11). The interview data revealed that this 
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perception was related to higher costs associated with EDC systems. Some 
interviewees felt that centralized monitoring would be costly to run as they would 
have to store trial data on an EDC system: 
‘As sponsor, all of the monitoring is on-site…, because we don’t have 
electronic data capture in any of these studies because they’re not 
commercial studies – they’re usually grant funded, or just the PI – so there’s 
very little money, you’re using paper CRF’. (Monitor-1).  
This was a particular concern for trialists working on smaller trials. They felt that their 
organizations would not have sufficient budget to support an EDC system and were 
only resourced to conduct on-site monitoring: 
‘Some of the eCRFs, let’s say that company that we had, you could be talking 
nearly half a million, a million to get it up and running, and what small study 
has that if you’re talking about an oncology study which has maybe 10 
patients coming into it? An eCRF is not going to be worth the set-up costs. So 
they’ll stick to the paper’ (Monitor-3). 
4.4.2.3 Increased work load 
Survey findings showed that perceived work load was the main reason why 
responders did not conduct a risk assessment prior to developing the monitoring plan 
for their most recent trial (Table 10). Forty-one percent of survey responders 
(n = 114) thought that increased workload was a barrier associated with the 
implementation of centralized monitoring (Table 11). Interviewees, who had 
previously conducted centralized monitoring, felt that it resulted in more 
administration work for trial sites as they had to support trial monitors by scanning 
and uploading site documents to EDC systems: 
‘I noticed one of the girls downstairs was saying in the last couple of weeks… 
this company kept saying, “We still don’t have the CV,” and she’d sent it three 
times to them. So you need to have good people at the other side doing the 
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monitoring and stuff like that. It’s just if it’s maybe stuff from the trial master 
file that they’re not here checking and consent forms and that. That probably 
might add some work’ (Nurse-3). 
Some interview participants felt that sponsors would use RBM as an excuse to 
perform less on-site monitoring and more remote monitoring. These participants felt 
that a reduction in on-site visits would results in a trial monitors spending less time 
on site checking trial documentation such as patient Consent Forms. These 
participants felt that study nurses may be expected to do extra administration tasks 
to support trial monitors perform remote monitoring: 
‘They have these centralized systems now where everything is stored 
centrally and it’s, like, “Logon and you’ll find the latest version of your 
protocol”. So you have to complete training for that system, you have to 
logon every time the new protocol is available or whatever. The onus is on 
the site to print it off. The onus is on the site to do everything and it’s just 
more and more it’s on the site, and we are not paid adequately for everything 
that we are being requested to do. It’s our admin staff as well. It’s like they’re 
just working for the pharma companies. There’s just a huge amount of 
resources, and it’s not accounted for’ (Nurse-4). 
4.4.2.4 Lack of verification 
The survey found that 27% (n = 35) of responders did not conduct a risk assessment 
prior to developing the monitoring plan for their most recent clinical trial. Some 
participants did not conduct a risk assessment because they felt that it was not a GCP 
requirement and would not improve patient safety (Table 10). However, these 
participants did use an informal process to determine what level of on-site 
monitoring was required for their clinical trial. Also, 21% of survey responders 
(n = 28) reported previous RBM experience. 
Interview analysis showed that participants perceived a lack of scientific evidence 
supporting RBM and saw this as a potential barrier to its implementation in their 
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future clinical trials. Many felt that enough proof did not exist to confirm that RBM 
was at least as effective and efficient as the 100% SDV on-site monitoring process 
that they currently used: 
‘So it’s just our experience that the more frequent the monitoring the better. 
I have a negative attitude towards already a negative perception of the risk-
based monitoring because 100% source data verification is what I would 
prefer’ (Nurse-1). 
Some interviewees believed that RBM would lead to a greater reliance on centralized 
monitoring and a move away from on-site monitoring: 
‘I know the new ICH-GCP guideline are more into the technology, and I know 
that’s the way we’re going and things like that. At the end of the day, I don’t 
think it fully replaces the on-site’ (Nurse-2). 
Many felt that the merits of centralized monitoring had yet to be proven and so were 
not comfortable conducting RBM in future trials if it meant fewer on-site visits: 
‘I suppose the fact that things are going more electronic and it is more EDC-
based. It’s the management of stuff that cannot be converted into EDC and 
how that’s going to be verified and how that’s going to be monitored’ 
(Monitor-1). 
Table 10: Reasons why survey responders did or did not conduct a risk assessment 
prior to developing the monitoring plan 
Facilitators % Barriers % 
To improve patient safety 43 (88%) Question not relevant, 
developing monitoring 
plan is a Sponsor duty 
15 (47%) 
To improve data accuracy 32 (65%) Not sure 9 (28%) 
To fulfil GCP requirements 29 (59%) It is not a GCP 
requirement 
7 (22%) 
To determine a schedule 
for on-site monitoring 
visits 
21 (43%) Do not have the expertise 
to perform a risk 
assessment 
6 (19%) 
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To fulfil HPRA/IMB 
requirements 
20 (41%) It is too time consuming 6 (19%) 
To reduce monitoring costs 8 (16%) It will not improve patient 
safety 
2 (6%) 
Not sure 3 (6%) It is too expensive  1 (3%) 
 
 
 
 
Table 11: Perceived problems associated with the implementation of centralised 
Monitoring (n=114) 
 
 
 
4.4.3 Facilitators 
4.4.3.1 Necessary requirement/mandate 
Compliance with GCP was the main criterion participants considered when selecting 
a RBM tool. Of the 35 survey responders who did not conduct a risk assessment of 
their most recent monitoring, 20% (n = 7) of these participants attributed this to the 
absence of a GCP requirement to do so (Table 10). Correspondingly, the interview 
data confirmed that fulfilling GCP requirements would now motivate them to 
conduct RBM in future trials: 
‘Yes, we will because it will be ICH-GCP will require us to do so’ (Monitor-3). 
Several interview participants said that adapting monitoring to the level of risk was a 
justified addition to ICH-GCP: 
Factor Yes  No Not 
sure 
Lack of education and training in centralised 
monitoring 
71 
(62%) 
36 
(31%) 
8 (7%) 
Cost associated with centralised monitoring 45 
(40%) 
54 
(48%) 
13 
(12%) 
IT demands of centralised monitoring 53 
(46%) 
53 
(46%) 
9 (8%) 
Workload associated with centralised monitoring 47 
(42%) 
48 
(16%) 
18 
(16%) 
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‘It does make sense that there’s some degree difference of risk, and therefore 
that the regulator environment would recognise that’ (PI-2). 
They viewed the new requirements positively because they felt that RBM was a more 
sustainable approach to monitoring than existing approaches: 
‘The landscape of clinical research has been changing, and is always changing, 
and just changes, changes… It is inevitable because the days of 100% source 
data verification is just not sustainable, really. But yeah, no, we’re definitely 
going to go down that route, so we are, when we get ourselves together. You 
know, we get more experienced, and get a bit of training’ (PI-4). 
Similarly, several participants said that they would implement RBM if it became a 
funding or publication requirement: 
‘People will put it into practice if it helps them to get funded or it helps them 
to publish their work’ (Biostatistician-1). 
4.4.3.2 Availability of, and need for, guidance 
Survey results suggest that more regulatory guidance would have facilitated the use 
of RBM in past trials (Table 10). Similarly, most interview participants believed that 
the introduction of regulatory-endorsed guideline would facilitate the 
implementation of RBM. In Ireland, clinical trials are regulated by the Health 
Protection Regulatory Authorities (HPRA) and some participants suggested that this 
organisation should lead the way in RBM implementation: 
‘I think it would be very important to have the HPRA involved, because, as you know, 
they come and monitor our studies’ (Monitor-3). 
‘Well, somebody from the HPRA. There need to be quality and regulatory affairs. 
Managers involved and stuff like that. HPRA maybe’ (Nurse-5). 
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Some participants thought that RBM would result in more efficient monitoring 
because monitoring activity would be based solely on the risk classification of each 
individual trial: 
‘I think it would be useful in making sure that wastage saved, that there was 
proper scrutiny of patients in the study. It’s a robust means of recording data, 
and probably having expert, external review of any adverse events’ (PI-5). 
4.4.3.3 Economic benefits 
Perceived financial benefit of RBM served as another facilitator encouraging 
interview participants to perform RBM in their future trials. Participants felt that RBM 
could reduce trial expenditure because monitoring activity would only be done as 
required: 
‘But I think it is more cost-effective as well and I think that is an advantage’ 
(Quality manager-1). 
Some interviewees believed that RBM would lead to a reduction in the number of 
on-site visits that would be performed by a monitor in each trial. These participants 
thought that reduced on-site monitoring visits would lead to an overall reduction in 
trial expenditure on monitoring: 
‘So there clearly are benefits. The first one is to the extent that you’re able to 
replace on-site monitoring with risk-based monitoring. You have achieved a 
cost saving for the sponsor of the study’ (Nurse-5). 
4.5 Discussion  
As far as we are aware, this is the first mixed methods study to investigate the 
perceived barriers and facilitators to RBM in academic-led clinical trials. Our survey 
showed that over one-third of respondents had previously performed RBM. The ICH-
GCP Integrated Addendum will come into effect on the 14th of June 2017 so the 
proportion of clinical researchers performing RBM is likely to rise in the future. 
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However, the survey results show that currently the majority of staff in academic 
CRF/Cs have no experience of performing RBM. Our qualitative analysis found a lack 
of RBM verification as one of the main barriers preventing interview participants 
from performing RBM. Most interviewees said that they would feel uncomfortable 
conducting RBM as they believed its effectiveness had yet to be proven. Some 
participants felt that RBM may reduce the quality of clinical trial monitoring by 
offering a less intensive monitoring approach compared to traditional 100% on-site 
SDV. These concerns are well founded as scientific evidence confirming the 
effectiveness and efficiency of RBM is sparse (29). To date, results from the OPTIMON 
trial are the only ones that compare RBM to traditional 100% on-site SDV monitoring. 
Of note, this study lacked sufficient statistical power to demonstrate non-inferiority 
of the RBM approach at detecting errors in the participant consent process, 
notification of serious adverse events (SAEs) and incorrect application of participant’s 
eligibility criteria(143). Thus, data supporting the safety and effectiveness of RBM are 
much needed(146). However, irrespective of this evidence gap, to be ICH-GCP 
compliant clinical researchers must implement RBM in their future trials (146, 212). 
 
Our study highlighted three additional barriers that may inhibit the introduction of 
RBM into academic-led clinical trial units. These included lack of RBM 
knowledge/training, perceived risk of increased costs caused by greater IT demands 
and perceived risk of increased workload for trial staff. Lack of RBM 
knowledge/training was identified as a major obstacle to RBM implementation 
among interview participants. Many felt ill-equipped to perform the initial risk 
assessment phase of the RBM process. This finding was reflected in the survey 
results, which revealed that less than one third of responders had performed a risk 
assessment prior to developing the monitoring plan for their most recent clinical trial. 
Also, the use of risk assessment among our study population was much lower than 
the 87% uptake recorded among American academic clinical trialists in 2011 (203). 
The low uptake of risk assessment among our study participants is a cause for 
concern. Under the new ICH-GCP guideline, sponsors must base their monitoring 
plans on the results of a risk assessment of their trial protocol (23). Therefore, in 
Ireland, the knowledge gap surrounding risk assessment must be addressed if 
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academic trialists are to become proficient RBM practitioners (146). Interviewees 
believed that the availability of regulatory-endorsed guideline would facilitate the 
introduction of RBM into their academic-led clinical trial organizations. To increase 
the use of risk assessments, Irish clinical trial regulators should develop or select an 
approved RBM tool at a national level (170). A RBM tool would provide formal 
instruction on how to perform a risk assessment of a clinical trial protocol (10). 
Clinical trial regulators in the United Kingdom and France have already developed 
their own RBM tools (28, 31). Additionally, in 2014, Switzerland became the first 
European country to introduce a regulation adopting risk-based categorization into 
their clinical trial methodology(146). Consequently, a new article added to the Swiss 
Federal Constitution, provided the legal framework to regulate human research 
according to the risk to which participants are exposed(146). However, it must be 
noted that in Switzerland the structured risk categorization approach was not better 
than an ad-hoc risk assessment approach (146). Therefore, a RBM tool should only 
be used to guide risk assessment and not as a one-size-fits-all approach. 
Survey findings suggest that participants are not yet equipped to perform centralised 
monitoring. Participants had limited experience of performing essential monitoring 
activity, such as inspecting informed consent and protocol compliance, through 
centralized monitoring. This is worrying as centralized monitoring is a primary 
component of RBM. As outlined in the new ICH-GCP guideline, sponsors should use 
centralized monitoring, it should be used to complement and reduce the extent 
and/or frequency of on-site monitoring (23). The perception of centralized 
monitoring was explored further in the qualitative phase of this study. Interview 
analysis showed that some participants believed that centralized monitoring would 
be costly to run as they would have to store trial data on an EDC system. Participants 
who worked on small academic trials thought that they would have insufficient 
budgets to support an EDC system and so they could only conduct on-site monitoring. 
The practical challenges associated with centralized monitoring will impact the 
implementation of RBM in Ireland because centralized monitoring is a major 
component of RBM(26, 134). If researchers do not have the resources to perform 
centralized monitoring, then in turn they will not be able to perform RBM as their 
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only option is to mitigate every clinical trial risk through on-site monitoring. Research 
is needed to develop pragmatic solutions to the challenges surrounding the use of 
centralized monitoring (20). In 2016, the Food and Drug Administration (FDA) signed 
an Agreement with CluePoints to explore and develop a data-driven centralized 
monitoring approach in clinical trials(213). CluePoints is an IT company that offers 
cloud-based RBM software. Following the FDA lead, it may be useful for other 
countries to develop a national SOP for centralized monitoring(213). This may involve 
collaboration between academic clinical researchers and computer programmers 
who specialize in RBM systems. 
Conclusion 
The results of this study confirm the absence of, and the need for, training and the 
availability of regulatory-endorsed guidelines to support the implementation of RBM 
in academic-led clinical trials. The results of this study should be used to inform 
interventions and strategies by policy-makers and clinical trial regulators to improve 
RBM uptake. 
Strengths/limitations 
To our knowledge, this is the first mixed-methods study to focus specifically on the 
barriers and facilitators associated with clinical researcher’s implementation of RBM 
in academic-led clinical trials. The triangulation of the data enabled the in-depth 
examination of our findings, providing a deeper understanding of the influences at 
work and corroborating the interpretation of the data. This approach improves the 
validity of the data and increases its comprehensiveness (211). In addition our study 
was reported in accordance with Good Reporting of a Mixed Methods Study 
(GRAMMS) framework (209). 
We believe that the results of this study are generalizable to the global academic 
clinical trial community that operates under ICH-GCP guideline. Our study included a 
sample of all researchers who would typically work on a clinical trial in an academic 
setting. These include PIs, nurses, physicians, monitors, pharmacists, managers and 
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biostatisticians (23). Our diverse study population allowed for the collection of data 
from all types of clinical trial staff and this increased our understanding of how RBM 
will be implemented into a real clinical trial setting (29). 
However, our study does have some limitations. The study was  cross-sectional which 
meant that estimates of RBM implementation could only be assessed at the present 
time point(214). The study used a mixed-methods, explanatory sequential design, 
with a quantitative and qualitative component. This type of study is inherently more 
challenging than a single-method study design as it involves the design, conduct and 
data integration of two different sources (215). Achieving true integration in a mixed-
methods study can be difficult(215). To overcome this barrier, our study used the 
process of ‘merging’ to accurately link and analyze the quantitative and qualitative 
data(216). Integration through merging of data occurs when researchers bring the 
two databases together for analysis and for comparison(216). In the design phase, a 
plan was developed for collecting the quantitative and qualitative data that was 
conducive to merging the databases(216). Accordingly, the quantitative survey 
contained a series of questions pertaining to RBM that were like the questions 
included in the semi- structured interviews.  
It should also be noted that our study was conducted before the new ICH-GCP 
guideline come into effect on 14 June 2017(212). A longitudinal study would allow us 
to track RBM uptake over time and explore its impact on clinical trial conduct and 
monitoring outcomes. Such a study could use the quantitative results of this study as 
baseline data. The response rate for the survey was 49% and, therefore, responses 
may represent a biased sample and may not be fully representative of all academic 
clinical researchers working in Irish CRF/Cs. Furthermore, the response rate for the 
qualitative phase of our study was 92%. The high response rate may be due to 
sampling bias(217). Finally, the qualitative phase of our study used two forms of data 
collection, face-to-face interviews and telephone interviews. We are confident that 
this did not impact the qualitative findings as there were no differences apparent in 
the data generated by both collection methods. This observation is in line with other 
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research which found no significant differences in the data generated by face-to-face 
and telephone interviews(218). 
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Chapter 5. On-site and centralised monitoring – the TRUST study experience 
5.1 Abstract  
The second version of the International Conference on Harmonisation (ICH) Good 
Clinical Practice guidelines (GCP) recommends risk-based monitoring (RBM) for 
clinical trials of an Investigational Medicinal Product.  RBM requires a combination of 
on-site and centralized monitoring. GCP does not specify which clinical trial activity 
should be performed on-site or centrally. In the absence of a gold standard approach, 
it is challenging for researchers to develop monitoring plans for their clinical trials 
that incorporate on-site and centralized monitoring and fulfill GCP’s seventeen 
recommended monitoring activities. This document analysis is the first such study of 
on-site and centralised monitoring reports collected prospectively in an international 
multi-centre clinical trial, the TRUST study. It provides support for the use of RBM 
through a combination of on-site and centralised monitoring practices. 
5.2 Introduction  
In June 2017, the ICH published the revised ICH GCP guideline for clinical trial conduct 
(11). Under ICH GCP, sponsors in America, China and Europe are legally obliged to 
monitor clinical trial activity(11). ICH GCP recommends seventeen recommended 
monitoring activities (Table 14) for all Clinical Trials of an Investigational Medicinal 
Product (CTIMP). These monitoring activities include verifying protocol compliance, 
confirming IMP is correctly managed, ensuring trial staff are adequately trained, 
reporting participant recruitment rates and checking that participants have given 
informed consent (11). ICH GCP recommends that risk-based monitoring (RBM) 
should be used to complete these monitoring activities (126).  
RBM has two sequential phases (10). First, the trial team must assess the risks in their 
study (10). Such risks relate to the IMP, study population and research team’s 
experience (26, 133). Secondly, when the risks have been identified, the trial team 
must decide whether to monitor these risks through on-site (at the trial site) or 
centralised (remote evaluation of electronically captured trial data) monitoring; or 
both (10, 26). Centralized monitoring is the remote evaluation of the study data, 
carried out by a team including central monitors, medical reviewers at a location 
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other than the sites at which the clinical trial is being conducted (26). It is claimed 
that centralized monitoring can provide many of the capabilities of on-site 
monitoring as well as additional capabilities such as providing a cost efficient and 
data driven monitoring strategy(21, 46). Despite these claims, many trialists are 
reluctant to use centralised monitoring as they fear it may not be as good as on-site 
monitoring at detected errors and some believe they do not have the expertise or 
knowledge needed to perform centralised monitoring (29, 219) 
However, the new ICH GCP guideline does not specify what monitoring activities 
should be performed on site or centrally (132, 219). Furthermore, there is no 
published research comparing the effectiveness of on-site and centralised 
monitoring in a trial (20). In the absence of evidence-based guidelines for clinical trial 
monitoring, trialists are unsure how to develop RBM plans that incorporate both on-
site and centralised monitoring and fulfill ICH GCP’s seventeen recommended 
monitoring activities (219).Until now, other studies in this area have only 
retrospectively compared monitoring practices by testing if findings from on-site 
monitoring could have been identified through centralized monitoring (119, 213). The 
findings of these studies suggest that in theory centralized monitoring could have 
detected the same findings as on-site monitoring (20). However, no study has 
compared on-site, and centralized monitoring activity conducted prospectively in a 
clinical trial. 
We recently conducted a Study Within a Trial (SWAT) to provide the first document 
analysis of on-site and centralised monitoring reports collected prospectively in an 
international multi-centre clinical trial – the Thyroid Hormone Replacement for 
Subclinical Hypo-Thyroidism Trial (TRUST study) (149, 220).The TRUST study, was a 
randomised, multi-centre, phase III clinical trial, that compared thyroxin replacement 
to placebo (65). The study recruited participants from four European sites. Each site 
had the same frequency of centralised monitoring, but individual on-site monitoring 
plans were developed to manage local trial activity. The aim of the SWAT was to 
review the monitoring reports generated for the TRUST study to determine if on-site 
and centralised monitoring used simultaneously in a clinical trial, perform the same 
monitoring activities. This chapter reports the findings. 
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5.3 Methods  
5.3.1 SWAT context 
A Study within a Trial (SWAT) is a self-contained research study that has been 
embedded within a host trial with the aim of evaluating or exploring alternative ways 
of delivering or organising a trial process. SWATs evaluate alternative ways of doing 
a trial process (e.g. recruiting patients, helping them to stay in the study, or reporting 
the findings) to provide evidence about how to improve the process.This SWAT was 
embedded within the TRUST study, a randomised, multi-centre, phase III clinical trial 
(149, 221), that compared thyroxin replacement to placebo in 738 community 
dwelling adults aged ≥65 years with subclinical hypothyroidism (SCH). The trial was 
conducted over three-and-a-half years from 2013-2017 (221).  It had recruiting sites 
in four EU countries (UK, Netherlands, Ireland and Switzerland) (221). 
   
The SWAT protocol (SWAT number 38) is registered on the  SWAT Repository 
Store managed by the Northern Ireland Hub for Trials Methodology Research(222). 
 
5.3.2 Study -Design  
This SWAT used a deductive qualitative document analysis approach to compare on-
site and centralised monitoring reports from the TRUST study.  
5.3.3 Study - Sample and data collection 
5.3.3.1 Data source 
All on-site and centralised monitoring reports generated by the trial’s four recruiting 
sites. TRUST participants had four in-person visits and one telephone contact over a 
minimum 1-year follow-up period(221).  Data generated from these visits or 
telephone call were entered into an electronic case report form (eCRF)(220). The 
eCRF data were managed, monitored and analysed centrally by the Robertson Centre 
for Biostatistics in Glasgow. Each site had the same frequency of centralised 
monitoring. In addition, research staff at each site devised their individual on-site 
monitoring plan to manage local trial activity. 
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5.3.3.2 On-site monitoring  
In total, 29 on-site monitoring reports were analysed (Table 12). On-site monitoring 
reports included:  
1) pre-trial monitoring reports (n=3) that verified the sites suitability to 
conduct the trial 
2) trial initiation monitoring reports (n=2), confirming trial procedures were 
adequate for the trial to start  
3) trial monitoring reports (n=20), documenting routine monitoring visits 
during the trial and  
4) final close out monitoring reports (n=4), checking all close out activities 
(such as data archiving )were completed before the trial ended (126). 
5.3.3.3 Centralised monitoring  
We have defined centralised monitoring as the generation of eCRF data queries. 
These data queries were either automatic or manual. Automatic data queries were 
raised if data entered into the eCRF did not comply with pre-specified validation rules 
such as participant inclusion criteria (Appendix D). A manual data query was raised 
when random eCRF checks identified data errors (Appendix D). Identification of an 
automatic or manual data query resulted in the Robertson Centre sending an email 
to the relevant trial site requesting correction or clarification of the data entry (Figure 
8). In total 1,825 data queries were raised, and all queries were analyzed for this 
report (Table 12).  
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Figure 7: Data query process 
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Table 12: Summary of on-site monitoring reports and centralised monitoring (data 
queries) 
 
 
5.3.4 Data Analysis  
Two researchers (CH and MZ) independently analyzed all monitoring reports using 
deductive document analysis. The data analysis consisted of four phases: 
decontextualisation; recontextualisation; categorisation; and compilation (223). 
These are described in Table 13. 
Table 13: Four phases of deductive document analysis 
Phase Purpose 
1. Decontextualisation CH and MZ independently read through the monitoring 
reports three times to familiarize themselves with the 
data. The data were then reduced to potential meaning 
units using highlighted text (223). A meaning unit was 
defined as the smallest piece of text from a monitoring 
report data that related to at least one of ICH GCP’s 
seventeen recommended monitoring activity (Table 14). 
2. Recontextualisation CH and MZ compared the potential meaning units to 
identify ‘actual’ meaning units that they agreed fulfilled at 
least one of ICH GCP’s seventeen recommended 
monitoring activities.  Next, CH and MZ re-read the 
On-site monitoring Centralised 
monitoring 
Site Pre-trial 
monitoring 
report visit 
(n=3) 
Trial 
initiation 
monitoring 
report 
 
(n=2) 
Trial 
monitoring 
visits 
reports 
 
(n=20) 
Close-out 
monitoring 
reports 
(n=4) 
Automatic 
data 
queries 
 
(n=1335) 
Manual 
data 
queries 
 
(n=490) 
Site 1 1 1 9 1 503 74 
Site 2 0 1 3 1 267 152 
Site 3 1 0 3 1 206 103 
Site 4 1 0 5 1 359 161 
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monitoring reports alongside the final list of ‘actual’ 
meaning units. After this process was performed, 
unmarked text in each monitoring report that did not 
relate to a meaning unit was excluded. 
3. Categorisation CH and MZ independently condensed meaning units into 
pre-defined categories based on ICH GCP’s seventeen 
recommended monitoring activities. 
4. Compilation CH and MZ compared results and reached consensus on 
all meaning units. Each meaning unit was then 
dichotomized into a yes or no variable (Table 14).  
 
The Yes variable was defined as a meaning unit that showed an ICH GCP monitoring 
activity had been achieved through on-site or centralised monitoring (Table 14).  For 
centralised monitoring, the results were combined for all four recruiting sites 
because each site received the same frequency and types of centralised monitoring 
(see section 5.3.3). The No variable was defined as an ICH GCP monitoring activity 
that was not described in the monitoring report.   
5.3.5 Ethical approval 
This study involves the secondary analysis of data collected for the TRUST study. 
TRUST received full ethical and regulatory approval from the relevant bodies in each 
of the four recruiting countries. The TRUST Thyroid Trial publication committee 
approved this SWAT.  
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5.4. Results  
The Results section is presented in accordance with the two primary components of 
deduction analysis that was discussed in detail in section 5.3.2. These components 
are the identification of meaning units and the application of the meaning units to 
the pre-defined ICH GCP monitoring activity.  
5.4.1. Identification of meaning units 
For this study, a meaning unit was defined as a finding reported in the on-site and 
centralized monitoring reports (automatic and manual queries) that related to at 
least one of the ICH GCP’s seventeen recommended monitoring activity.   
5.4.1.1 Meaning units derived from on-site monitoring reports (n=29). 
Two researchers (CH & MZ) reviewed the on-site monitoring reports for each of the 
four trial sites and identified meaning units that they agreed related at least one of 
GCP’s seventeen recommended monitoring activities (Table 14). The researchers 
identified evidence in the on-site monitoring reports that showed at least one of the 
four sites had used on-site monitoring to implement (completely or partially) sixteen 
of GCP’s recommended monitoring activity. For example, if the on-site monitoring 
report commented on the presence of the trial team’s signed and dated Curriculum 
Vitae in the Investigational Site File, this information was converted into a meaning 
unit that confirmed GCP recommended monitoring activity 2 (verifying the 
investigator has adequate qualifications and resources to complete the trial) was 
fulfilled through on-site monitoring.  A meaning unit for GCP recommended 
monitoring activity 6-Verifying that written informed consent was obtained before 
each subject's participation in the trial’ was identified from findings included in the 
monitoring report that confirmed the monitor had checked that informed consent 
was provided by all participants that were enrolled into the trial. However, the 
researchers did not identify text in the on-site monitoring reports, for the four sites, 
that provided evidence to suggest on- site monitoring was a main line of 
communication between the sponsor and the investigator (GCP recommended 
monitoring activity 1).    
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Table 14 : Meaning units identified from on-site monitoring reports 
 
ICH GCP monitoring activity Site A 
(12 monitoring reports) 
Site B 
(5 monitoring reports) 
Site C 
(5 monitoring reports) 
Site D  
(7 monitoring reports) 
1. Acting as the main line of 
communication between the 
sponsor and the investigator. 
No evidence present in 
the on-site monitoring 
reports to confirm this 
activity  
No evidence present in 
the on-site monitoring 
reports to confirm this 
activity 
No evidence present in 
the on-site monitoring 
reports to confirm this 
activity 
No evidence present in 
the on-site monitoring 
reports to confirm this 
activity 
2. Verifying that the investigator 
has adequate qualifications and 
resources and remain adequate 
throughout the trial period, that 
facilities, including laboratories, 
equipment, and staff, are 
adequate to safely and properly 
conduct the trial and remain 
adequate throughout the trial 
period.   
Yes – in the monitoring 
reports the monitor 
repots on the presence 
of the trial team’s 
signed and dated CVs in 
the Investigational Site 
File  
Yes – in the on-site 
monitoring report it 
states that the team’s  
CVs and GCP certificates 
are present in up to 
date.  
No evidence in the 
reports to suggest this 
activity was performed 
through on-site 
monitoring  
 Yes – in the monitoring 
reports the monitor 
repots on the presence 
of the trial team’s 
signed and dated CVs in 
the Investigational Site 
File 
 
3. Verifying, for the investigational 
product(s) 
 (i) That storage times and conditions 
are acceptable, and that supplies are 
sufficient throughout the trial.  
Yes- the monitoring 
report includes findings 
from assessing the 
storage and supply of 
the investigational 
produce which was 
Yes – all the activities (I 
–v) were assessed and 
findings reported in the 
close out monitoring 
visit.  
 Yes – the monitoring 
report states that the 
"complete and accurate 
accountability records 
for study medication 
was kept" and that the 
 Yes – the monitoring 
reports discusses the 
review of the 
‘accountability log’ 
which shows how the 
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(ii) That the investigational product(s) 
are supplied only to subjects who are 
eligible to receive it and at the 
protocol specified dose(s).  
(iii) That subjects are provided with 
necessary instruction on properly 
using, handling, storing, and returning 
the investigational product(s). 
 (iv) That the receipt, use, and return 
of the investigational product(s) at 
the trial sites are controlled and 
documented adequately.  
(v) That the disposition of unused 
investigational product(s) at the trial 
sites complies with applicable 
regulatory requirement(s) and is in 
accordance with the sponsor 
documented in the 
Pharmacy site file. 
 
study medication as 
properly stored.  
 
medication was stored 
and dispensed. 
In the close out 
monitoring visit, the 
monitor included 
findings referring to how 
patients returned 
unused medication to 
the trial site and then 
destroyed by the 
pharmacy. 
  
 
4. Verifying that the investigator 
follows the approved protocol 
and all approved amendment(s), 
if any.   
Yes – in the monitoring 
reports it states that all 
protocol deviations 
were assessed, and 
recommendations 
assigned to ensure 
Yes – in the monitoring 
reports it states that all 
protocol deviations 
were assessed, and 
recommendations 
assigned to ensure 
 Yes – in the monitoring 
reports it states that all 
protocol deviations 
were assessed, and 
recommendations 
assigned to ensure 
 Yes – in the monitoring 
reports it states that all 
protocol deviations 
were assessed, and 
recommendations 
assigned to ensure 
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outstanding deviations 
were completed. 
outstanding deviations 
were completed. 
outstanding deviations 
were completed. 
outstanding deviations 
were completed. 
5. Verifying that written informed 
consent was obtained before 
each subject's participation in the 
trial.  
Yes – the monitoring 
reports checked and 
states that informed 
consent was provided 
by all participants 
enrolled into the trial.  
Yes – the monitoring 
reports checked and 
states that informed 
consent was provided 
by all participants 
enrolled into the trial. 
 Yes – the monitoring 
reports checked and 
states that informed 
consent was provided 
by all participants 
enrolled into the trial. 
 Yes – the monitoring 
reports checked and 
states that informed 
consent was provided 
by all participants 
enrolled into the trial. 
6. Ensuring that the investigator 
receives the current Investigator's 
Brochure, all documents, and all 
trial supplies needed to conduct 
the trial properly and to comply 
with the applicable regulatory 
requirement(s).   
Yes- Trial Master File 
reviewed during on-site 
visit and findings 
included in the 
monitoring report 
Yes- Trial Master File 
reviewed during on-site 
visit and findings 
included in the 
monitoring report 
 Yes- Trial Master File 
reviewed during on-site 
visit and findings 
included in the 
monitoring report 
No – no information 
included in the 
monitoring reports to 
suggest the Trial Master 
File or the Site Master 
File was reviewed during 
the on-site visits 
7. Ensuring that the investigator and 
the investigator's trial staff are 
adequately informed about the 
trial. 
Yes- delegation log 
available and signed by 
all staff  
Yes- delegation log 
available and signed by 
all staff 
 Yes- delegation log 
available and signed by 
all staff 
  Yes- delegation log 
available and signed by 
all staff 
8. Verifying that the investigator 
and the investigator's trial staff 
are performing the specified trial 
functions, in accordance with the 
protocol and any other written 
agreement between the sponsor 
Yes- delegation log 
available and signed by 
all staff  
Yes- delegation log 
available and signed by 
all staff 
 Yes- delegation log 
available and signed by 
all staff 
  Yes- delegation log 
available and signed by 
all staff 
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and the investigator/institution 
and have not delegated these 
functions to unauthorized 
individuals.  
9. Verifying that the investigator is 
enrolling only eligible subjects 
Yes – the monitoring 
report states that the 
eligible of study 
participants was 
assessed during the on-
site visit 
Yes – the monitoring 
report states that the 
eligible of study 
participants was 
assessed during the on-
site visit 
 Yes – the monitoring 
report states that the 
eligible of study 
participants was 
assessed during the on-
site visit 
Yes – the monitoring 
report states that the 
eligible of study 
participants was 
assessed during the on-
site visit 
10. Reporting the subject 
recruitment rate.  
Yes- the number of 
participants enrolled in 
the trial is documented 
in the monitoring report 
No – the recruitment 
rate or even the overall 
number of participants 
enrolled in the trial was 
not documented in the 
monitoring report 
No – the recruitment 
rate or even the overall 
number of participants 
enrolled in the trial was 
not documented in the 
monitoring report 
Yes- the number of 
participants enrolled in 
the trial is documented 
in the monitoring report 
11. Verifying that source documents 
and other trial records are 
accurate, complete, kept up-to-
date and maintained.   
Yes- source documented 
such as laboratory 
reports and participant 
questionnaires were 
reviewed during the on-
site visit 
 Yes- source 
documented such as 
laboratory reports were 
reviewed during the on-
site visit 
 Yes- source 
documented such as 
patient report forms 
were reviewed during 
the on-site visit 
 Yes- source 
documented such as 
laboratory reports and 
participant 
questionnaires were 
reviewed during the on-
site visit 
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12. Verifying that the investigator 
provides all the required 
reports, notifications, 
applications, and submissions, 
and that these documents are 
accurate, complete, timely, 
legible, dated, and identify the 
trial.   
Yes – evidence provided 
in the monitoring report 
that the application and 
approval for protocol 
amendments and ethic 
submissions were 
regularly performed by 
the investigator 
Yes – evidence provided 
in the monitoring report 
that the application and 
approval for protocol 
amendments and ethic 
submissions were 
regularly performed by 
the investigator 
 Yes – evidence 
provided in the 
monitoring report that 
the application and 
approval for protocol 
amendments and ethic 
submissions were 
regularly performed by 
the investigator 
 Yes – evidence 
provided in the 
monitoring report that 
the application and 
approval for protocol 
amendments and ethic 
submissions were 
regularly performed by 
the investigator 
13. Checking the accuracy and 
completeness of the CRF entries, 
source documents and other 
trial-related records against 
each other. The monitor  
specifically should verify that:  
 
 (i) The data required by the protocol 
are reported accurately on the CRFs 
and are consistent with the source 
documents. 
(ii) Any dose and/or therapy 
modifications are well documented 
for each of the trial subjects.   
(iii) Adverse events, concomitant 
medications and intercurrent illnesses 
Yes – patient case 
report forms were 
reviewed during and 
findings included in the 
on-site monitoring 
reports. 
Yes – the on-site report 
includes the number 
and brief description of 
SAEs and resolution 
action performed by the 
trial team 
 Yes – the on-site report 
includes the number 
and brief description of 
SAEs and resolution 
action performed by the 
trial team 
 Yes – the on-site report 
includes the number 
and brief description of 
SAEs and resolution 
action performed by the 
trial team 
Yes – patient case 
report forms were 
reviewed during and 
findings included in the 
on-site monitoring 
reports. 
Yes – the on-site report 
includes the number 
and brief description of 
SAEs and resolution 
action performed by the 
trial team 
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are reported in accordance with the 
protocol on the CRFs.   
(iv) Visits that the subjects fail to 
make, tests that are not conducted, 
and examinations that are not 
performed are clearly reported as 
such on the CRFs.  
 (v) All withdrawals and dropouts of 
enrolled subjects from the trial are 
reported and explained on the CRFs.  
14. Informing the investigator of 
any CRF entry error, omission, 
or illegibility. The monitor 
should ensure that appropriate 
corrections, additions, or 
deletions are made, dated, 
explained (if necessary), and 
initialled by the investigator or 
by a member of the 
investigator's trial staff who is 
authorized to initial CRF changes 
for the investigator. This 
authorization should be 
documented.  
Yes – the monitor report 
includes a 
recommendation for 
action required to 
correct errors in the 
CRF. The 
implementation of the 
recommendation is 
reviewed by the monitor 
at later on-site visits. 
 Yes – the monitor 
report includes a 
recommendation for 
action required to 
correct errors in the 
CRF. However, no 
evidence to suggest the 
implementation of the 
recommendations is 
later assessed. 
Yes – the monitor report 
includes a 
recommendation for 
action required to 
correct errors in the 
CRF. The 
implementation of the 
recommendation is 
reviewed by the monitor 
at later on-site visits. 
 Yes – the monitor 
report includes a 
recommendation for 
action required to 
correct errors in the 
CRF. However, no 
evidence to suggest the 
implementation of the 
recommendations is 
later assessed. 
15. Determining whether all 
adverse events (AEs) are 
appropriately reported within 
Yes – the on-site report 
includes the number 
and brief description of 
Yes – the on-site report 
includes the number 
and brief description of 
 Yes – the on-site report 
includes the number 
and brief description of 
 Yes – the on-site report 
includes the number 
and brief description of 
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the time periods required by 
GCP, the protocol, the IRB/IEC, 
the sponsor, and the applicable 
regulatory requirement(s).  
SAEs and resolution 
action performed by the 
trial team 
SAEs and resolution 
action performed by the 
trial team 
SAEs and resolution 
action performed by the 
trial team 
SAEs and resolution 
action performed by the 
trial team 
16. Determining whether the 
investigator is maintaining the 
essential documents 
Yes- Trial Master File 
reviewed during on-site 
visit and findings 
included in the 
monitoring report 
Yes- Trial Master File 
reviewed during on-site 
visit and findings 
included in the 
monitoring report 
 Yes- Trial Master File 
reviewed during on-site 
visit and findings 
included in the 
monitoring report 
No – no information 
included in the 
monitoring reports to 
suggest the Trial Master 
File or the Site Master 
File was reviewed during 
the on-site visits 
17. Communicating deviations from 
the protocol, SOPs, GCP, and the 
applicable regulatory 
requirements to the investigator 
and taking appropriate action 
designed to prevent recurrence 
of the detected deviations 
Yes- the monitoring 
report shows the 
number and brief 
description of all 
protocol deviations and 
action taken for their 
resolution 
Yes- the monitoring 
report shows the 
number and brief 
description of all 
protocol deviations and 
action taken for their 
resolution 
Yes- the monitoring 
report shows the 
number and brief 
description of all 
protocol deviations and 
action taken for their 
resolution 
Yes- the monitoring 
report shows the 
number and brief 
description of all 
protocol deviations and 
action taken for their 
resolution 
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5.4.1.2 Meaning units identified from centralised monitoring reports (automatic and 
manual queries)  
Table 15 shows the meaning units that were identified in the automatic and manual 
queries raised by the Robertson Centre for the four trial sites. Of the seventeen GCP 
recommended monitoring activities, meaning units could only be identified for 
eleven monitoring activities. For example, a meaning unit for GCP recommended 
monitoring activity 8, ‘Verifying that the investigator and the investigator's trial staff 
are performing the specified trial functions, in accordance with the protocol’, was 
developing from automatic queries that were raised trial site’s that had deviated 
from the approved protocol by not conducting participant’s visits within the allocated 
time frame. 
Table 15: Meaning units derived from centralised monitoring reports (automatic and 
manual queries). 
 GCP monitoring activity automatic and manual queries 
(combined for all four trial sites) 
1. Acting as the main line of 
communication between the sponsor 
and the investigator. 
No evidence in the automatic and manual queries to 
suggest centralized monitoring was used as a line of 
communication 
2. Verifying that the investigator has 
adequate qualifications and 
resources and remain adequate 
throughout the trial period, that 
facilities, including laboratories, 
equipment, and staff, are adequate 
to safely and properly conduct the 
trial and remain adequate 
throughout the trial period.   
No evidence in the automatic and manual queries to 
suggest centralized monitoring was used to verify the 
investigator had adequate qualifications and resources 
to conduct the trial 
3. Verifying, for the investigational 
product(s) that storage times and 
conditions are acceptable, and that 
supplies are sufficient throughout 
the trial.  That the investigational 
product(s) are supplied only to 
subjects who are eligible to receive it 
and at the protocol specified dose(s).  
That subjects are provided with 
necessary instruction on properly 
using, handling, storing, and 
returning the investigational 
product(s). 
• That the receipt, use, and return of 
the investigational product(s) at the 
trial sites are controlled and 
documented adequately.  
Yes - manual queries raised regarding the supply of the 
Investigation Product to ineligible patients. Through 
review of the electronic Case Report Form ( e CRF ) a 
number of manual queries were raised regarded the 
supply of study medication to patients that were on 
‘prohibited medicine’ as listed in the ( e CRF )  
 
128 
 
• That the disposition of unused 
investigational product(s) at the trial 
sites complies with applicable 
regulatory requirement(s) and is in 
accordance with the sponsor 
 
4. Verifying that the investigator 
follows the approved protocol and 
all approved amendment(s), if any.   
Yes - several automatic queries were raised for each site 
regarding protocol deviations 
For example, participants missing scheduled visits as 
outlined in the protocol.  
  
5. Verifying that written informed 
consent was obtained before each 
subject's participation in the trial.  
No - no evidence to suggest informed consent was 
checked through centralised monitoring 
6. Ensuring that the investigator 
receives the current Investigator's 
Brochure, all documents, and all trial 
supplies needed to conduct the trial 
properly and to comply with the 
applicable regulatory 
requirement(s).   
No – no evidence to suggest this activity was performed 
through centralised monitoring 
7. Ensuring that the investigator and 
the investigator's trial staff are 
adequately informed about the trial. 
Yes – the automatic and manual queries are raised in a 
timely manner and keep the investigators informed on 
the trial activity. 
 
For example - delays in entering participants blood test 
results into their e CRF  
 
8. Verifying that the investigator and 
the investigator's trial staff are 
performing the specified trial 
functions, in accordance with the 
protocol and any other written 
agreement between the sponsor and 
the investigator/institution and have 
not delegated these functions to 
unauthorized individuals.  
Yes – several automatic queries were raised for trial 
site’s that had deviated from the approved protocol by 
not conducting participant’s visits within the allocated 
time frame.  
9. Verifying that the investigator is 
enrolling only eligible subjects 
Yes - several manual queries raised for participants that 
reported taking concomitant medications in the e CRF. 
The manual query was raised asking the investigator to 
confirm the participant’s eligibility to participate in the 
trial as this was a protocol deviation. 
10. Reporting the subject recruitment 
rate.  
No – no evidence to suggest this activity was performed 
through centralised monitoring 
11. Verifying that source documents and 
other trial records are accurate, 
complete, kept up-to-date and 
maintained.   
Yes – all participant information was entered into an e 
CRF. Several automatic queries were raised for instances 
when the investigators had omitted participant data 
such as #last time the patient ate’. 
12. Verifying that the investigator 
provides all the required reports, 
notifications, applications, and 
submissions, and that these 
documents are accurate, complete, 
timely, legible, dated, and identify 
the trial.   
Yes – manual queries raised regarding the submission of 
outstanding SAE reports and laboratory reports. 
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13. . Checking the accuracy and 
completeness of the CRF entries, 
source documents and other trial-
related records against each other. 
The monitor specifically should verify 
that: 
(i) The data required by the protocol are 
reported accurately on the CRFs and are 
consistent with the source documents. 
(ii) Any dose and/or therapy modifications 
are well documented for each of the trial 
subjects.   
(iii) Adverse events, concomitant 
medications and illnesses are reported in 
accordance with protocol on the CRFs.   
(iv) Visits that the subjects fail to make, 
tests that are not conducted, and 
examinations that are not performed are 
clearly reported as such on the CRFs.  
(v) All withdrawals and dropouts of 
enrolled subjects from the trial are 
reported and explained on the CRFs. 
Yes – automatic queries were raised when an AE was 
reported for a patient, but no AE specialised interest 
forms was completed on the patients e CRF. The 
automatic queries requested the completion and 
submission of the AE form.  
 
 
14. Informing the investigator of any CRF 
entry error, omission, or illegibility. 
The monitor should ensure that 
appropriate corrections, additions, 
or deletions are made, dated, 
explained (if necessary), and 
initialled by the investigator or by a 
member of the investigator's trial 
staff who is authorized to initial CRF 
changes for the investigator. This 
authorization should be 
documented. 
Yes – all participant information was entered into an e 
CRF. Several automatic queries were raised for instances 
when the investigators had omitted participant data 
such as #last time the patient ate’. 
15. Determining whether all adverse 
events (AEs) are appropriately 
reported within the time periods 
required by GCP, the protocol, the 
IRB/IEC, the sponsor, and the 
applicable regulatory 
requirement(s). 
Yes – automatic queries were raised when an AE was 
reported for a patient, but no AE specialised interest 
forms was completed on the patients e CRF. The 
automatic queries requested the completion and 
submission of the AE form. 
16. Determining whether the 
investigator is maintaining the 
essential documents 
No – findings regarding essential documents such as the 
Site Files and patient informed consent forms were not 
raised through automatic or manual queries   
17. Communicating deviations from the 
protocol, SOPs, GCP, and the 
applicable regulatory requirements 
to the investigator and taking 
appropriate action designed to 
prevent recurrence of the detected 
deviations 
Yes - several manual queries raised for participants that 
reported taking concomitant medications in the e CRF. 
The manual query was raised asking the investigator to 
confirm the participant’s eligibility to participate in the 
trial as this was a protocol deviation. 
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5.4.2 Application of the meaning units to identify of ICH GCP monitoring activity 
performed through on-site and centralised monitoring   
Categorisation and compilation: condensed meaning units into pre-defined 
categories based on ICH GCP’s seventeen recommended monitoring activities. Each 
meaning unit was then dichotomized into a yes or no variable and Results are 
outlined in Table 16. 
5.4.2.1 On-site monitoring  
The results presented in Table 16 show that none of the four recruiting sites achieved 
all of ICH GCP’s seventeen monitoring activities through on-site monitoring. None of 
the sites appeared to have used on-site monitoring to complete GCP monitoring 
activity 1 – which was to confirm the monitor was ‘Acting as the main line of 
communication between the sponsor and the investigator’. 
 
All four sites used on-site monitoring to complete eight of the GCP monitoring 
activities, 2, 3, 4, 5, 8, 9, 15 and 17 (Table 16). Sites B and C did not ‘Report the subject 
recruitment rate’ (GCP monitoring activity 10) in their on-site monitoring reports. Site 
B was the only site that did not indicate completion of GCP monitoring activity 16, 
‘Determining whether the investigator is maintaining the essential documents’ in 
their on-site monitoring report. Site D was the only site that did not indicate that GCP 
monitoring activity 6 had been performed in their monitoring report- ‘Ensuring that 
the investigator receives the current Investigator's Brochure, all documents, and all 
trial supplies needed to conduct the trial properly and to comply with the applicable 
regulatory requirement(s)’. On-site monitoring reports for Site C suggested that six 
GCP monitoring activity (2, 7, 10, 11, 12 and 14) had not been checked during on-site 
visits (Table 16). 
 
5.4.2.2 Centralised monitoring  
The four recruiting sites had the same frequency and type of centralised monitoring 
(Table 16). Ten of GCP’s seventeen monitoring activities were completed through 
centralised monitoring (4, 7, 8, 9, 11, 12, 13, 14, 15 and 17). All ten activities 
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monitored centrally were also monitored through on-site monitoring at each of the 
four recruiting sites (Table 16). Six monitoring activities (1, 2, 5, 6, 10 and 16) were 
not reported in the centralised monitoring reports (Table 16). 
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Table 16: GCP monitoring requirement fulfilled through on site and centralised monitoring (automatic and manual queries) 
ICH GCP monitoring activity Site A Site B Site C Site D 
Onsite Central Onsite Central Onsite Central Onsite Central 
1. Acting as the main line of communication between the 
sponsor and the investigator. 
No No No 
 
No No No No No 
2. Verifying that the investigator has adequate qualifications and 
resources and remain adequate throughout the trial period, 
that facilities, including laboratories, equipment, and staff, are 
adequate to safely and properly conduct the trial and remain 
adequate throughout the trial period.   
Yes No Yes No No No Yes No 
3. Verifying, for the investigational product(s) 
 (i) That storage times and conditions are acceptable, and that 
supplies are sufficient throughout the trial.  
(ii) That the investigational product(s) are supplied only to 
subjects who are eligible to receive it and at the protocol 
specified dose(s).  
(iii) That subjects are provided with necessary instruction on 
properly using, handling, storing, and returning the 
investigational product(s). 
 (iv) That the receipt, use, and return of the investigational 
product(s) at the trial sites are controlled and documented 
adequately.  
(v) That the disposition of unused investigational product(s) at 
the trial sites complies with applicable regulatory 
requirement(s) and is in accordance with the sponsor 
Yes Yes Yes Yes Yes Yes Yes Yes 
4. Verifying that the investigator follows the approved protocol 
and all approved amendment(s), if any.   
Yes Yes Yes Yes Yes Yes Yes Yes 
5. Verifying that written informed consent was obtained before 
each subject's participation in the trial.  
Yes No Yes No Yes No Yes No 
6. Ensuring that the investigator receives the current 
Investigator's Brochure, all documents, and all trial supplies 
Yes No Yes No Yes No No No 
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needed to conduct the trial properly and to comply with the 
applicable regulatory requirement(s).   
7. Ensuring that the investigator and the investigator's trial staff 
are adequately informed about the trial. 
Yes Yes Yes Yes No Yes Yes Yes 
8. Verifying that the investigator and the investigator's trial staff 
are performing the specified trial functions, in accordance with 
the protocol and any other written agreement between the 
sponsor and the investigator/institution and have not 
delegated these functions to unauthorized individuals.  
Yes Yes Yes Yes Yes Yes Yes Yes 
9. Verifying that the investigator is enrolling only eligible subjects Yes Yes Yes Yes Yes Yes Yes Yes 
10. Reporting the subject recruitment rate.  Yes No No No No No Yes No 
11. Verifying that source documents and other trial records are 
accurate, complete, kept up-to-date and maintained.   
Yes Yes Yes Yes No Yes Yes Yes 
12. Verifying that the investigator provides all the required 
reports, notifications, applications, and submissions, and that 
these documents are accurate, complete, timely, legible, 
dated, and identify the trial.   
Yes Yes No Yes No Yes Yes Yes 
13. Checking the accuracy and completeness of the CRF entries, 
source documents and other trial-related records against each 
other. The monitor specifically should verify that:  
 (i) The data required by the protocol are reported 
accurately on the CRFs and are consistent with the source 
documents. 
(ii) Any dose and/or therapy modifications are well 
documented for each of the trial subjects.   
(iii) Adverse events, concomitant medications and 
intercurrent illnesses are reported in accordance with the 
protocol on the CRFs.   
(iv) Visits that the subjects fail to make, tests that are not 
conducted, and examinations that are not performed are 
clearly reported as such on the CRFs.  
 (v) All withdrawals and dropouts of enrolled subjects from 
the trial are reported and explained on the CRFs.  
Yes Yes Yes Yes Yes Yes Yes Yes 
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14. Informing the investigator of any CRF entry error, omission, or 
illegibility. The monitor should ensure that appropriate 
corrections, additions, or deletions are made, dated, explained 
(if necessary), and initialled by the investigator or by a 
member of the investigator's trial staff who is authorized to 
initial CRF changes for the investigator. This authorization 
should be documented.  
Yes Yes Yes Yes No Yes Yes Yes 
15. Determining whether all adverse events (AEs) are 
appropriately reported within the time periods required by 
GCP, the protocol, the IRB/IEC, the sponsor, and the applicable 
regulatory requirement(s).  
Yes Yes Yes Yes Yes Yes Yes Yes 
16. Determining whether the investigator is maintaining the 
essential documents 
Yes No Yes No Yes No No No 
17. Communicating deviations from the protocol, SOPs, GCP, and 
the applicable regulatory requirements to the investigator and 
taking appropriate action designed to prevent recurrence of 
the detected deviations 
Yes Yes Yes Yes Yes Yes Yes Yes 
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5.5 Discussion  
The aim of the SWAT was to review the monitoring reports generated for the TRUST 
study to determine if on-site and centralised monitoring used simultaneously in this 
clinical trial, perform the same monitoring activities. To our knowledge, this is the 
first study to compare on-site activity centralised monitoring activity using data 
collected prospectively in a clinical trial. We found that on-site monitoring was used 
more frequently than centralised monitoring in the TRUST study. Sixteen of the 
seventeen recommended ICH GCP monitoring activities were completed through on-
site visits. In contrast, only eleven of the seventeen recommended monitoring 
activities were completed through centralised monitoring (Table 16). This finding 
supports results from previous our study on the perspective of RBM in academic-led 
clinical trials (chapter 4), which showed that trialists favoured on-site monitoring 
over centralised monitoring (219).  Trialists said they preferred on-site monitoring, 
as they felt they did not have the expertise needed to perform centralised monitoring 
(219). 
The findings of the centralised monitoring activity performed in the TRUST study 
must be considered with caution. In accordance with the deductive document 
analysis methodology, two researchers analysed the automatic and manual queries 
to identify potential meaning units pertaining to GCP monitoring activity performed 
through centralised monitoring. As stated above, for centralized monitoring activity, 
meaning units could only be identified for eleven monitoring activities, from text 
included in the automatic and manual queries. However it must be noted that 
automatic and manual queries were only raised if a data entry error in a participant’s 
eCRF was identified centrally by the Robertson Centre, who managed, monitored and 
analysed data entered into the trials Electronic Data Capture system. Therefore, the 
Robertson Centre may have been performing more centralised monitoring activity 
that was not fully apparent through our review of the automatic and manual queries. 
Furthermore, the on-site monitoring reports included in this study were not 
developed specifically for this SWAT and so they did not have a standardised the 
format. These reports differed in content, detail and length. Despite this limitation, 
the on-site monitoring reports still fulfilled the three quality criteria for documentary 
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evidence which are authenticity, credibility and comprehensiveness(224).  The on-
site monitoring reports were authentic documents from the TRUST Thyroid trial, they 
are credible monitoring reports typical of a clinical trial and all monitoring reports 
generated from the four TRUST sites were analysed in the document analysis.  
 
The results of this research add to the evidence base for clinical trial monitoring and 
will help clinical researchers wishing to implement ICH GCP and move towards a 
system of diverse monitoring practices. Until now, other studies in this area have only 
retrospectively compared monitoring practices by testing if findings from on-site 
monitoring could have been identified centrally by adding specific data queries to the 
trial’s EDC system (127, 225). These studies suggest critical on-site monitoring 
findings such as incorrect participant consent processes and inappropriate IMP 
dispensing, could have been identified through central monitoring techniques. 
However, the results of those studies are limited: both used arbitrary criteria to 
classify monitoring activity and neither reviewed all monitoring findings from a 
completed trial (127, 226). Our study is the first to compare on-site and centralised 
monitoring, during a completed trial, using ICH GCP guidelines.  
This study showed all centralised monitoring activity was being completed through 
on-site monitoring which suggest on-site, and centralised monitoring are being used 
to complete the same recommended monitoring activities which could potentially 
lead to research wastage.  This is an interesting finding as ICH GCP’s emphasis on 
RBM is based on the assumption that on-site and centralised monitoring can be used 
together to  prevent the waste of clinical trial resources (such as study budget and 
staff time) on monitoring activity that does not improve participant safety or data 
quality (24, 30, 131). 
In recent years, many reports have been published claiming that centralised 
monitoring is more cost efficient and accurate than on-site monitoring. However, 
empirical data supporting these claims are lacking. On-site and centralised 
monitoring practices need to be evaluated empirically, including costs, to provide 
robust evidence for their contribution to trial performance and quality. From the four 
sites that participated in the TRUST study, there was twenty-nine on-site monitoring 
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reports created and over 1800 automatic and manual queries were raised through 
centralised monitoring. Further research is necessary to quantify and compare how 
much time, staff resources and trial budget is required to first perform but also to 
deal with the findings generated through on-site and centralised monitoring.   
5.5.1 Strengths and Limitations  
The study has several limitations that should be considered when interpreting the 
results. First the results of this study have been generated from a single clinical trial 
and may not be generalisable to other trials. Furthermore, the SWAT results are 
based on a document analysis and it is important to recognise the limitation of this 
method when drawing conclusions from a single data source reducing the validity 
and reliability of the study results (224). Document analysis is often used in 
combination with other qualitative research methods as a means of triangulation 
which allows for the combination of methodologies in the study of the same 
phenomenon. However, our study only included evidence from one data source; 
monitoring reports. Therefore, is was not possible to corroborate or converge our 
findings with other data sources such as interviews and observation with study 
monitors and the research team.  
 
However, the study has many strengths. Firstly, our study used a SWAT design to 
answer a timely clinical trial methodology question, ‘How should clinical trials be 
monitored using on-site and centralised monitoring?’(149). Researchers and trialists 
face many uncertainties when designing and conducting research. Embedding a 
SWAT within a trial provides a cost-effective and practical way to answer these 
questions.  Secondly, the monitoring reports analysed in this paper had already been 
generated as part of the TRUST Thyroid Trial. Therefore, these documents were non-
reactive and unbiased as they were collected for another purpose(224). Finally, this 
is the first study to use prospective data to compare on-site and centralised 
monitoring. The results of this research will add to the evidence base for clinical trial 
monitoring(29).  
Conclusion  
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This study provides an example of on-site and centralised monitoring activity 
performed simultaneously in a clinical trial. The results of the document analysis 
demonstrate a need for evidence-based guidelines to support the combined use of 
on-site and centralised monitoring in clinical trials.   
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Chapter 6. Introducing Risk-Based Monitoring tools into academic-led clinical trial 
units in Ireland: a quality improvement intervention 
6.1 Abstract 
Background 
Risk based monitoring (RBM) tools provide comprehensive and structured RBM 
guidance. However, evidence supporting their usability is unknown and globally their 
usage among clinical researchers is low. The aim of this quality improvement (QI) 
study was to determine if a brief, educational, interactive, face to face workshop 
would result in increased use of RBM tools by academic clinical researchers in Ireland. 
Additionally, the study tested if RBM tool usability was linked to its use.  
Methods 
This QI intervention was developed by expert researchers and was conducted in four 
publicly funded academic run clinical trial units in Ireland. Each unit assembled a 
Multidisciplinary Testing Team (MDTT) comprised of members who normally 
develop, write, review and approve monitoring plans for trials managed in their 
clinical trial units. In total, the four MDTTs consisted of 12 participants; study doctor 
(n=1), quality and regulatory affair managers (n=4), clinical trial monitors (n=5) and 
research nurses (n=2). The usability of the RBM tools was assessed using the NASA 
Task Load questionnaire (NASA TLX) and the uptake of three RBM tool was measured 
using the Utilization Scale questionnaire. 
Results 
Three of the four MDTTS have implemented one of the three RBM tools in their 
clinical trial unit. All three RBM tools received a combined medium usability score for 
six dimensions of usability measured by the NASA TLX questionnaire; mental 
demand, physical demand, temporal demand, overall performance, frustration level 
and effort. At the six months follow up, results from the Utilization Scale 
questionnaire showed that three of the four MDTTs had taken steps or have fully 
implemented one of the three RBM tools into their clinical trial unit.  
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Conclusion 
The findings of the study show that a brief, face to face, interactive education 
workshop is an effective way to encourage RBM tool usage. This study supports the 
global initiative aimed at increasing use of quality improvement interventions in 
clinical trials to improve clinical trial methodology. 
6.2 Background  
In June 2017, the revised International Conference on Harmonisation Good Clinical 
Practice (ICH GCP) guideline came into effect which endorsed risk-based monitoring 
(RBM)as best practice in clinical trial monitoring (23). RBM is a form of clinical trial 
monitoring (130). It incorporates both centralised monitoring, conducted off-site 
through an examination of electronic data, and on-site monitoring practices that are 
proportional to the risks associated with the clinical trial(23, 24).  Further to the ICH 
GCP guidelines, the Organisation for Economic Co-operation and Development 
(OECD) has instructed clinical researchers to use a RBM tool when developing RBM 
plans (10). These tools have two functions: first, they support the pre-trial risk 
assessment of a clinical trial protocol and second, they provide guidance for 
subsequent on-site and/or centralised monitoring(10). Presently, RBM tools provide 
the most comprehensive and structured guidance for RBM implementation (10, 132). 
A systematic review I published in 2016, identified over twenty RBM tools that fulfil 
the OCED criteria. However, the usability of the RBM tools was not tested, this means 
the extent to which an RBM tool can be used by clinical researchers to conduct RBM 
with effectiveness, efficiency and satisfaction remains unknown (132, 227). To date, 
no gold standard RBM approach has been developed (129). 
Despite the availability of ICH GCP guidelines and RBM tools, challenges still exist with 
respect to clinical researchers establishing a local RBM process and implementing it 
in the desired way(29) (135).The concept of RBM implies that the chosen monitoring 
strategy is adapted to the local and trial-specific context (135). This means that a one-
size-fits-all model is not possible (122). The implementation of RBM, with the 
consequent adjustment or reduction of onsite monitoring visits and source data 
verification (SDV), can only succeed after establishing an appropriate RBM approach 
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(10, 128). The way that risks are identified, evaluated and mitigated through clinical 
trial monitoring requires a change in the mind-set of those who have applied  GCP 
and traditional 100% on-site monitoring since the ICH GCP guidelines were first published 
in 1996(102, 129). In addition, the lack of a gold standard RBM tool makes it difficult 
for clinical researchers to decide which RBM tool they should use to direct their RBM 
plans (208).  A US based survey of Clinical Research Organizations published in 2016, 
found the biggest challenges with implementing RBM are a lack of internal 
knowledge and expertise to perform RBM along with a perceived inability to maintain 
enough quality through RBM and lack of capacity to rapidly adapt to changing RBM 
needs (121). The results of this survey suggest the need for a cultural shift in how 
many clinical trial teams conduct clinical trial monitoring (24). 
With one of the main barriers to RBM implementation being lack of education,  
clinical trial regulators in the US, Europe and Japan have driven initiatives to educate 
their clinical researchers and by doing so support the transition of clinical trial 
monitoring to RBM in their local clinical trial organisations (12, 19, 23, 134).  For 
example, in 2011, the MHRA in the UK developed and published a RBM tool(28). In 
2014, Switzerland became the first European country to introduce a regulation 
adopting risk-based categorization into their clinical trial methodology (135).  In 
contrast, Ireland does not have a national strategy to educate clinical researchers on 
how they should introduce and implement RBM into their publicly funded, academic 
run clinical trial units. In 2017, I conducted a national mix-methods study that 
examined the perceived barriers and facilitators to RBM implementation in 
academic- led clinical trials in Ireland.  The study showed that 14% of participants 
were not familiar with the term RBM. Almost two thirds of these participants 
identified lack of education as a very important barrier with almost 20% of 
participants feeling they did not have the expertise to use a RBM tool (Chapter 4) 
The aim of the current study was to develop, implement and evaluate an educational 
Quality Improvement (QI) intervention to teach academic clinical researchers in 
Ireland about RBM tools and by doing so change their monitoring behaviour and 
support them to use RBM tools when developing monitoring plans for their clinical 
trials.  Educational QI intervention provide an opportunity for participants to increase 
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their knowledge or understanding of a specific topic and by doing so allows the 
mechanism to drive behaviour change(228, 229).  
6.3 Methods 
6.3.1 Study Design 
This study was a QI educational intervention conducted in four, publicly funded, 
academic run clinical trial units in Ireland.  QI interventions aim to support change 
and improve processes by means of an organizational or structural change(147).  
6.3.2 QI Intervention –development  
6.3.2.1 Conceptual framework 
The QI intervention was developed in accordance with the Knowledge to Action 
Framework (KTA). The KTA framework is a conceptual framework for facilitating the 
use of research knowledge by several stakeholders, such as practitioners, 
policymakers, patients, and the public (Figure 9).  
Figure 8: Knowledge to Action Framework 
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The KTA process has two components: (1) knowledge creation and (2) action which 
have seven phases listed below (151) 
1. Identify a problem that needs addressing and select the knowledge or 
research relevant to the problem (e.g. practice guidelines or research 
findings) 
2. Adapt the identified knowledge or research to the local context 
3. Assess barriers to using the knowledge 
4. Select, tailor, and implement interventions to promote the use of 
knowledge (i.e., implement the change) 
5. Monitor knowledge use 
6. Evaluate the outcomes of using the knowledge 
7. Sustain on-going knowledge use 
 
Phase 1- 3 of the KTA framework (problem identification and barriers to knowledge 
use) were discussed in detail in Chapter 3- Risk based monitoring (RBM) tools for 
clinical trials: A systematic review and Chapter 4- Perceived barriers and facilitators 
to Risk Based Monitoring in academic- led clinical trials: a mixed methods study. The 
results of Phase 1-3 of the KTA framework informed the development of the QI 
intervention discussed in this study.  
This study will only focus on Phase 4, 5 and 6 of the KTA process which involves the 
selection, tailoring and implementation of an intervention to promote knowledge 
use, monitor its use and evaluate the outcomes of using this knowledge.  
6.3.2.2 Intervention development team  
Clinical researchers were the target study population for the QI intervention. In 
December 2016, I recruited an expert panel of clinical researchers to direct the 
development of the QI intervention to ensure the intervention would be applicable 
to the target study group. The expert panel consisted of seven clinical trial experts 
which included a trial sponsor (1), principle investigators (2), trial coordinator (1), 
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quality manager (1) and a trial doctor (1) and a clinical trial monitor (1). All panel 
members had a minimum of three years and maximum of twenty years’ experience 
of developing and implementing clinical trial monitoring plans in Clinical Trials of 
Investigational Medicinal Products (CTIMPs).  
 
6.3.2.3 QI development process 
One researcher (CH) carried out data collection and intervention development. The 
intervention development was directed by the Consensus-Oriented-Decision-
Making (CODM) model. The CODM was used to guide the expert panel to reach a 
consensus on the RBM tool intervention (33).  The CODM model is a decision-
making process that includes the following steps: 
1. Framing the topic 
2. Open discussion 
3. Identifying underlying concerns 
4. Collaborative proposal building 
5. Choosing a direction 
6. Synthesizing a final proposal 
7. Closure (33). 
In March 2017, each member of the expert panel was sent a summary of the findings 
from Phase 1 -3 and of the KTA Framework as follows: Chapter 3- ‘Risk based 
monitoring (RBM) tools for clinical trials: A systematic review’ The findings from the 
systematic review found a lack of a gold standard RBM tool as usability of the RBM 
tools had not been tested. However, in the absence of a gold standard RBM tool, the 
systematic review identified criteria that clinical researchers RBM too. The criteria 
are:  
1. ensuring the RBM tool assesses risks in accordance with the Risk Indicator 
Taxonomy for supervision of clinical trials on medicinal products 
2. confirming the RBM tool can direct both on-site and centralised monitoring 
3. checking the tool provides a process for systematic review of the trial's risk 
profile 
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4. ensuring the RBM tool is cost efficient as cost varies significantly between 
tools 
The expert panel were provided with a copy of only three RBM tools that fulfilled the 
four-selection criteria listed above Risk Assessment Tool (RAT) (22), Risk assessment 
for risk adapted monitoring (RARAM) (159) and the Risk Assessment Categorisation 
Tool (RACT) (20) (Table 15). The expert panel were asked to use their experience of 
conducting clinical trials to provide suggestions on how best to introduce these RBM 
tools to an academic clinical trial community in Ireland. The expert panel were asked 
to consider the following points: 
• Intervention participants 
• Duration of the intervention 
• Mode of delivery i.e. online or face to face 
• Frequency of the intervention i.e. once off event or multiple sessions 
• Intervention assessment - required or not necessary 
The expert panel had two weeks to review the findings and to suggest a possible 
educational intervention (through email, telephone or face to face correspondence) 
that would support the introduction of RBM tools into academic run clinical trial units 
in Ireland.  At the end of the review period, CH had received feedback from all seven 
expert panel member. The results were combined using the majority decision rule. 
This meant that a characteristic of the educational intervention was selected if the 
majority decision rule of expert members had suggested it.  
A brief (two hours maximum in duration), once off educational face-to-face 
interactive workshop was identified as the most appropriate way to introduce RBM 
tools into academic led clinical trial units in Ireland. 
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Table 17: RBM tool characteristics 
 Criteria 1 Criteria 2 Criteria 2 Criteria 3 Criteria 4 
Author RBM tool Mode of 
administration 
Risks as mapped to 
risk indicators 
taxonomy for 
supervision of 
clinical trials of 
medicinal products 
Provide 
recommendation 
for onsite 
monitoring 
Provide 
recommendation 
for centralised 
monitoring 
Provides 
recommendations 
for systematic 
review of trial’s risk 
profile 
Cost 
Nordic 
Monitoring 
Network 
(NORM)(27) 
Risk 
Assessment 
Tool (RAT) 
Paper Yes Yes Yes 
 
Yes Free 
Swiss Clinical 
Trial 
Organisation 
(SCTO)(170) 
Risk 
assessment 
for risk 
adapted 
monitoring 
(RARAM) 
Electronic via 
Microsoft 
Excel 
Yes Yes Yes Yes Free 
TransCelerate 
BioPharma 
Inc.(26) 
Risk 
Assessment 
Categorisation 
Tool (RACT) 
Electronic via 
Microsoft 
Excel 
Yes Yes Yes Yes Free 
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6.3.3 QI Recruitment/ Study participants 
The QI intervention was delivered in four academic run clinical trial units in Ireland. 
Each of the four clinical trial units deliver research across numerous clinical 
specialties including oncology, cardiology, neurology, ophthalmology and neonatal 
research in accordance with the EU Clinical Trials Directive and the new ICH GCP 
guideline(64). At the time of QI study, none of the units used a RBM tool and none 
had conducted RBM.  
 
Recruitment took place over 4 weeks from the 7th March to the 4th of April 2017. On 
the 7th of March 2017, I sent an invitation by email to the Quality and Regulatory 
Affairs Managers in each of the four units. The email included a protocol outlining 
the aim and outline of the QI intervention (Appendix E). When the Quality and 
Regulatory Affairs Managers agreed to participate in the QI intervention, they were 
asked to assemble a Multidisciplinary Testing Team (MDTT). For this study, we 
defined a MDTT as a collection of members within each clinical trial unit who 
normally develop, write, review and approve monitoring plans for trials that their 
clinical trial unit manages. In total, the four MDTTs consisted of 12 participants; study 
doctor (n=1), quality and regulatory affair managers (n=4), clinical trial monitors 
(n=5) and research nurses (n=2).  
6.3.4 Implementation of the QI intervention 
Each MDTT arranged a time and date for their members to participate in the 
educational workshop between April and June 2017. Each MDTT selected one clinical 
trial protocol, to which they applied the three RBM tools. The protocol had to pertain 
to a clinical trial of an Investigational Medicinal Products (IMP) that their clinical trial 
unit was managing and all members of the MDTT were familiar with. The phase of 
the clinical trial was not relevant as the three RBM tools can be applied to all clinical 
trial phases from I-IV(132). The characteristics of the protocols are listed in Table 16. 
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Table 18: Characteristics of clinical trial protocols 
MDTT IMP trial Clinical trial 
phase 
Study population Trial 
duration 
Multi-centre 
1 Yes II Adults aged≥ 18 years 2 years Yes 
2 Yes III Men aged ≥ 18 years 3 years Yes 
3 Yes III Adults aged≥ 18 years 2 years Yes 
4 Yes III Neonates 3 years Yes 
 
I facilitated the workshops which all followed the same structure outlined in Table 
17.  At each workshop, I presented the three RBM tools to the MDTT in the same 
sequence. First, each MDTT worked through the Risk Assessment Tool (RAT), then 
through the Risk Assessment for Risk Adapted Monitoring (RARAM) and finally the 
Risk Assessment Categorization Tool (RACT) (see Table 17).  I supported each MDTT 
to apply the three RBM tools to their selected clinical trial protocol.  Throughout the 
workshop, participants were encouraged to ask questions and discuss the RBM tools. 
Each workshop lasted approximately two hours. 
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Table 19: QI intervention schedule 
Stage and purpose Material and rationale for their selection 
 
Physical informational materials used in the 
intervention, including those provided to 
participants or used in intervention delivery 
and in training of intervention providers. 
Mode of delivery Allocated 
time  
Stage 1. Introduction 
To educate participants on the fundamental 
concepts of RBM to ensure they had enough 
baseline knowledge required to work the RBM 
tools 
Three paper based RBM guidelines. Guideline 
used and rationale for its selection are listed 
below:  
 Integrated Addendum to ICH E6(R1): 
Guideline for Good Clinical Practice 
(18) 
This guideline provides the premise for 
RBM and explains what clinical trial 
regulators will expect to see in a RBM 
plan. 
 OECD Recommendation on the 
Governance of Clinical Trials (10) 
This guideline was the first and only 
document to define and explain the 
characteristics of a RBM tool. 
 Risk indicator taxonomy for supervision 
of clinical trials on medicinal products 
(125) 
First peer reviewed paper explaining 
the risk assessment process of 
involved in RBM and identified and 
categorized I risk indicators that may 
Flipped classroom session-flipped learning is a 
teaching approach in which the conventional 
notion of classroom-based learning is inverted, 
so that students are introduced to the learning 
material before class, with classroom time then 
being used to deepen understanding through 
discussion with peers and problem-solving 
activities facilitated by a teacher.  
 
Implementation 
• A week prior to the QI intervention, the 
facilitator sent the MDTT an electronic copy 
of the teaching material. Each member of 
the MDTT and prepare questions to discuss 
at the start of the QI intervention 
• At the start of the QI intervention the 
MDTT together with the facilitator 
discussed the three RBM guidance and how 
they applied to their clinical trials. In 
addition, the facilitator answered questions 
the MDTT had regarding the development 
and implementation of the guidance.  
15 mins 
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present an elevated safety and/or 
ethical risk for participants, and/or for 
data in a clinical trial. 
 
Stage 2: Application of the RBM tools  
The MDTT applied each RBM tool to their 
chosen protocol. The aim of this was for the 
facilitator to engage the participants actively 
in learning how to use the RBM tools. The 
facilitator supported the MDTTs to actively 
use the RBM tools 
The QI intervention included three paper based 
RBM tools the Risk Assessment Tool (RAT) (22), 
Risk assessment for risk adapted monitoring 
(RARAM) (159) and the Risk Assessment 
Categorisation Tool (RACT) (20) 
 
Each of the three RBM tools included in the QI 
intervention fulfilled four criteria for a RBM 
tools. They each assessed risks in accordance 
with the Risk Indicator Taxonomy for 
supervision of clinical trials on medicinal 
products. They supported both on-site and 
centralised monitoring and provided a process 
to systematically review trial's risk profile. 
Finally, each tool was cost efficient as cost as 
they were freely available on the internet.  
 
Interactive workshop 90(30mi
ns 
for each 
RBM 
tool) 
Stage 3: Evaluation 
To evaluate the outcome of the QI 
intervention – first to assess the usability of 
the RBM tools and secondly to determine if 
the intervention supported the participants to 
change their monitoring behaviour and use 
RBM in their clinical trials.  
 
 NASA Task Load (NASA-TLX) 
questionnaire – is a paper-based 
questionnaire that measured the 
measured workload of a task.  
 
Self-administered face to face – traditional 
paper and pencil-based questionnaire 
 
After each MDTT applied the three RBM tools 
to their selected clinical trial protocol, they 
completed three NASA-TLX questionnaires, 
each questionnaire measured the perceived 
workload associated with each RBM tool 
included in the QI intervention. 
 
15 mins 
Stage 4: Follow up 
To measure how much, if any, the MDTT’s had 
Utilization Scale questionnaire - used to 
measure how much, if any, the MDTT’s had 
Self-administered electronic questionnaire  Two 
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used the knowledge they gained in the QI 
intervention and implemented the RBM tools 
in their clinical trial units 
 
used the knowledge they gained in the QI 
intervention and implemented the RBM tools 
in their clinical trial units.  
 
Six months after participating in the QI 
intervention, the four Quality and Regulatory 
Affair Managers from each MDTT, one from 
each clinical trial unit, were asked to complete 
a Utilization Scale questionnaire The Quality 
and Regulatory Affair Managers were the only 
members of each MDTT asked to complete 
this questionnaire because they coordinate 
clinical trial monitoring in their clinical trial 
unit. 
 
weeks to 
complete  
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6.3.5 Data collection and analysis 
Separate data were used to first examine the usability of the RBM tools and then to 
examine if the use of RBM tools had increased among the study population after 
participating in the QI intervention. This occurred in two phases as described in detail 
below and summarised in Figure 8. 
Figure 9: Data collection and analysis 
 
 
6.3.5.1 Phase 1: test usability of RBM tools   
The usability of the RBM tools was assessed using the NASA Task Load (NASA-TLX) 
questionnaire(230, 231). This is a widely used, subjective, multidimensional 
assessment tool that rates perceived workload in order to assess a task, system, or 
team's effectiveness or other aspects of performance(231). Originally developed as 
a questionnaire to measure mental workload, the NASA TLX questionnaire has been 
adopted to measure usability(232).  It was developed by the Human Performance 
Group at NASA's Ames Research Center in the 1980s, over a three year validated 
cycle. It has been cited in over 4,400 studies, in a variety of domains, including 
aviation, healthcare and other complex socio-technical domains(231).  
 
The NASA TLX questionnaire measures the total workload of a task by dividing it into 
six subjective subscales, measured on a 21-point Likert scale (Appendix E). The 
subscales are:  
Phase 1
April -June 2017
• Aim: test usability of RBM tools (secondary aim)
• Method: quantitative (NASA questionnaire)
Phase 2
February 2018 
• Aim: examine RBM tool use (primary aim)
• Method : quantitative (Utilization Scale questionnaire)
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• Mental Demand - how much mental and perceptual activity was 
required? Was the task easy or demanding, simple or complex? 
• Physical Demand - how much physical activity was required? Was the task 
easy or demanding, slack or strenuous? 
• Temporal Demand - how much time pressure did you feel due to the pace 
at which the tasks or task elements occurred? Was the pace slow or rapid? 
• Overall Performance - how successful were you in performing the task? 
How satisfied were you with your performance? 
• Frustration Level- how irritated, stressed, and annoyed versus content, 
relaxed, and complacent did you feel during the task? 
• Effort- how hard did you have to work (mentally and physically) to 
accomplish your level of performance? 
 
NASA TLX questionnaire Analysis 
Each member of the MDTT completed a NASA TLX questionnaire after they used each 
RBM tool. The completed NASA TLX questionnaires were analysed in SPSS version 11 
using the Raw Task Load Index (RTLX) which is a validated scoring system that 
calculates the individual and combined perceived workload of each of the six 
subscales as either low, medium or high(233).  If a subscale receives a score of ≤7 it 
is categorised as having a low perceived workload; if it receives a scores >7 and ≤14 
it is categorised as having a medium perceived workload and if a subscale dimension 
is scored between >14 and ≤21 it is categorised as having a high perceived workload. 
The overall workability score for each RBM tool is the average of the combined 
workability subscale score(233).  
 
6.3.5.2 Phase 2: examine RBM tool use  
The Utilization Scale was used to measure how much, if any, the MDTT had 
implemented the RBM tools in their clinical trial units. The Utilization Scale is a 
validated questionnaire developed by Larsen in 1982. It accesses seven ranked stages 
of knowledge use and non-use(234). The seven stages of knowledge utilisation are:   
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• Nothing done: No action, not even discussion, happened 
• Considered and rejected: Some discussion took place, but the RBM tool was 
rejected 
• Under consideration: RBM tool has not been used but is being discussed and 
considered. 
• Steps toward implementation: Although the RBM tool has not yet been used, 
the decision to do so has been made and initial planning steps have been taken. 
• Partially implemented:  Certain features of the RBM tool have been used, 
whereas others have been disregarded. 
• Implemented as presented: The RBM tool was used in the form in which it was 
originally presented. 
• Implemented and adapted: The RBM tool was modified or adapted to fit our 
local situation 
 
Utilization Scale – data collection 
Six months after participating in the QI intervention, the four Quality and Regulatory 
Affair Managers from each MDTT, one from each clinical trial unit, were asked to 
complete a Utilization Scale questionnaire (Appendix E). The Quality and Regulatory 
Affair Managers were the only members of each MDTT asked to complete this 
questionnaire because they coordinate clinical trial monitoring in their clinical trial 
unit.  
 
6.3.6 Ethical Approval 
Under the Irish Health Service Executive, quality assurance studies and service 
evaluation studies do not require Research Ethics Committee (REC) approval(235). 
They define such studies as having the following characteristics:  
• they are designed to produce information to inform delivery of best practice.  
• they involve an intervention that is not randomly allocated but is selected by 
healthcare professionals.  
• they include the administration of simple interviews and questionnaire(235).  
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Our QI intervention met these criteria and so REC approval was not required. 
However, to ensure participant’s safety and integrity, the QI intervention was 
conducted in accordance with research ethic procedures. Before each educational 
workshop commenced, I explained the aim and purpose of the QI intervention to 
each member of the MDTT. In addition, I informed participants that they could 
withdraw from the study at any time during the workshop or follow up. All 
participants gave verbal consent to participate in the workshop. All participant data 
were anonymized and stored securely.   
6.4 Results 
6.4.1 NASA TLX questionnaire 
The NASA TLX questionnaire results are presented for each of the six subscales of 
workability and then a combined score for each RBM tool was calculated for each 
RBM tool. 
 
6.4.1.1 Workability dimension – MDTT scores  
The results of the NASA TLX questionnaire show that the Risk Assessment Tool (RAT) 
was the only RBM tool to receive a low mental demand score (Table 20). The four 
MDTTs gave each RBM tool a low score for physical demand. The Risk Assessment 
Categorisation Tool (RACT) was the only RBM tool to receive a high score for 
temporal demand. The RAT and the Risk assessment for risk adapted monitoring 
(RARAM) were the only tools to receive a low score for frustration level by MDTT 3 
and 4.  
 
6.4.1.2 Workability dimension per RBM tool  
All RBM tools scored an overall medium workability score besides the RAT which 
received a low overall workability score from MDTT 3 (Table 20).  
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Table 20: NASA TLX questionnaire results for each MDTT  
*Score Rating:   Low = score of ≤7;             Medium= >7 and ≤14;      High= >14 and ≤21 
RBM tool Mental Physical Temporal Performance Frustration Effort Overall 
score 
Average 
score 
MDTT 1   
Risk Assessment Tool (RAT)  10 
 
2 5 8 19 16 60 10 
Medium 
Risk assessment for risk adapted 
monitoring (RARAM)  
16 1 3 15 18 2 55 9 
Medium 
Risk Assessment Categorisation 
Tool (RACT)  
14 1 4 3 17 17 54 9 
Medium 
MDTT 2  
Risk Assessment Tool (RAT)  4 1 4 17 16 4 47 8 
Medium 
Risk assessment for risk adapted 
monitoring (RARAM)  
10 1 6 13 18 21 69 12 
Medium 
Risk Assessment Categorisation 
Tool (RACT)  
 
16 1 13 3 21 12 67 11 
Medium 
MDTT 3  
Risk Assessment Tool (RAT)  5 1 4 8 3 4 25 4 
Low 
Risk assessment for risk adapted 
monitoring (RARAM)  
19 1 11 6 20 19 78 13 
Medium 
Risk Assessment Categorisation 
Tool (RACT)  
 
15 1 18 9 18 13 74 12 
Medium 
MDTT 4  
Risk Assessment Tool (RAT)  5 1 8 15 5 6 40 7 
Medium 
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Risk assessment for risk adapted 
monitoring (RARAM)  
16 1 10 9 3 11 50 8 
Medium 
Risk Assessment Categorisation 
Tool (RACT)  
 
17 2 19 3 18 18 77 12 
Medium 
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6.4.2 Utilisation Scale 
Table 21 outlines the results of the Utilisation Scale questionnaire.  Results show that 
three MDTTs have taken steps or have fully implemented a RBM tool into their 
clinical trial unit. MDTT 1 has taken steps to introduce the Risk assessment for risk 
adapted monitoring (RARAM) into their clinical trial unit. MDTT 3 also adapted the 
RAT to the needs of their clinical trial unit and has implemented the modified version. 
MDTT 4 has implemented the Risk assessment for risk adapted monitoring (RARAM) 
as presented. MDTT 2 was the only clinical trial unit not to implement one of the RBM 
tools into their clinical trial unit.  
 
The Risk assessment for risk adapted monitoring tool (RARAM) had the greatest level 
of uptake as two of the MDTTS have taken steps to introduce this tool into their 
clinical trial unit. The Risk Assessment Tool (RAT) was the only tool to be adapted and 
implemented into a clinical trial unit. Finally, the Risk Assessment Categorisation Tool 
(RACT) was the only tool not to be implemented into a clinical trial unit.  
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Table 21: Utilisation Scale 
*Score Rating:   Low = score of ≤7;             Medium= >7 and ≤14;      High= >14 and ≤21 
RBM tool RBM tool was 
considered but 
rejected 
RBM tool was not 
considered or 
even discussed 
RBM tool in under 
consideration 
Steps have been 
taken towards 
implementing the 
RBM tool 
RBM tool was 
implemented as 
presented 
RBM tool was 
adapted to the 
clinical trial unit’s 
need and then 
implemented 
RAT1 Yes No No No No No 
RARAM2 No No No Yes No No 
RACT3 
 
No Yes No No No N0 
MDTT 2 
RAT1 Yes No No No No No 
RARAM2 Yes No No No No No 
RACT3 
 
No Yes No No No No 
MDTT 3  
RAT1 No No No No No Yes 
RARAM2 No Yes No No No No 
RACT3 
 
Yes No No No No No 
MDTT 4  
RAT1 Yes No No No No No 
RARAM2 No No No No Yes No 
RACT3 
 
Yes No No No No No 
                                                          
1 RAT = Risk Assessment Tool 
2 RARAM = Risk assessment for risk adapted monitoring 
3 RACT = Risk Assessment Categorisation Tool 
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6.5. Discussion 
RBM is now the recommended method of clinical trial monitoring(23). However, at 
present, many clinical researchers are not sufficiently ready, trained, or experienced 
to perform RBM (30, 135, 219). In addition, there is evidence that suggests clinical 
researchers do not have confidence in their ability to adapt and apply RBM in their 
organisations(219).  As far as we are aware, the study reported in this chapter is the 
first Quality Improvement (QI) intervention to support the introduction of RBM into 
academic led clinical trial units. To date, QI interventions have led to changes that 
have produced better patient outcomes, better system performance and better 
professional development(147). However, there is a paucity of evidence 
documenting the value of QI to promote high quality and efficient clinical trials(148). 
Our study supports the global initiative aimed at increasing QI use in clinical trials to 
improve clinical trial methodology (148-150) 
Presently, RBM tools provide the most comprehensive and structured guidance for 
RBM implementation(10, 132).  Our educational workshop included three RBM tools 
that met four pre-defined RBM tool selection criteria(132). Accordingly, all three 
RBM tools assess clinical trial risks that are set out in the Risk Indicator Taxonomy for 
supervision of clinical trials on medicinal products; they direct both on-site and 
centralized monitoring; they provide a process to systematically review a trial's risk 
profile and are all freely available online(132).  
This study used the Utilization Scale questionnaire to assess if and how the MDTTs 
implemented one or more of the RBM tools into their clinical trial unit. The MDTTs 
completed the Utilization Scale questionnaire eight months after the new ICH GCP 
guideline came into effect; and a minimum of six months after they participated in 
the QI intervention. The follow up period was sufficient to allow for an accurate 
assessment of the workshop’s impact (236). The results of the Utilization Scale 
questionnaire show that three of the four MDTTs have taken steps to implement at 
least one of the RBM tools into their clinical trial unit.  With two MDTTs adapting an 
RBM tool to the need of their clinical trial unit and implementing the revised version. 
However, if was not possible to identify how or why the RBM tools were adapted as 
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the Utilization Scale questionnaire did not include open ended questions exploring 
this decision. Only one of the MDTTs (MDTT 2) either considered and rejected or did 
not consider implementing one of the three RBM tools into their clinical trial unit.  
Since three of the four MDTTs implemented one of the RBM tools into their clinical 
trial unit, our findings suggest that the QI intervention was somewhat effective in 
supporting the use of RBM tools in academic-run clinical trial units in Ireland. 
However, this conclusion should be considered with caution. QI interventions lack 
many of the stable characteristics generally assumed for studies of effectiveness(237, 
238).  For example, like many other QI interventions, this study did not have a control 
group and participants were purposely (rather than randomly) sampled(237). The 
differing characteristics of the study participants, the RBM tools and the 
organizations where the interventions were implemented, also makes it difficult to 
predict the effectiveness of a similar QI intervention or whether the effectiveness of 
our QI intervention would be similar in other settings(237). Furthermore, this QI 
study used an educational intervention based on three RBM tools. Conclusions from 
studies of educational interventions cannot be taken in isolation, but also need 
consideration of the characteristics of the knowledge that was being transferred, the 
teacher/facilitator, and participating individuals and organizations(238, 239). For 
instance, a different facilitator, different participants or different RBM tools in a 
similar QI study may have a different effect on the uptake of RBM tools(238, 240).   
Overall there is a need for future studies to evaluate the implementation of the RBM 
tool -QI intervention. Such an implementation evaluation would identify which 
elements were implemented as planned and which were not, discern the 
intervention’s strengths and weaknesses, and study its internal validity by assessing 
the cause and effect relationship. For example the three RBM tools were also 
presented to each MDTT in the same sequence. First, each MDTT worked through 
the Risk Assessment Tool (RAT), then through the Risk Assessment for Risk Adapted 
Monitoring (RARAM) and finally the Risk Assessment Categorization Tool (RACT) .This 
delivery of the RBM tools may have introduced a learning effect into the study, where 
the first RBM tool used by each MDTT may have impacted on their understanding of 
the second and three RBM tool their used(241, 242).  Therefore the usability of each 
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RBM tool may have shrewd by the sequence in which they were presented during 
the QI intervention. 
Finally, we developed this study in February 2017, five months before the new ICH-
GCP came in effect in June of that year(23). Our QI intervention included the three 
RBM tools that employ a standardised, fixed risk assessment process(243). This 
means that these tool assess clinical trial risks using pre-defined risk indicators that 
cannot be modified to for each clinical trial; such risks relate to the study population 
or the investigational medicinal product, (132, 243). For example, these tools provide 
the same standard risk assessment process for a Phase II neonatal trial and a Phase 
III adult trial(27, 170). Since the implementation of our QI intervention, there has 
been significant increase in studies describing and evaluating RBM tools and RBM 
(113, 244). Recently published literature, would suggest that a generic risk 
assessment process may not be appropriate for RBM tools as they don’t 
accommodate the unique risk profile of each clinical trial.(244) Studies now suggest 
that RBM tools should use a dynamic risk assessment process that enables clinical 
researchers to respond to changing clinical trial circumstances (113, 244). Such 
frameworks allow clinical researchers to use their historical experience of managing 
clinical trials in certain disease areas, to develop a data driven risk assessment that 
includes specific risks that pose a potential risk to the integrity of data collected in 
their trial. Then clinical researchers should develop their own suite of operational 
procedures they can employ to mitigate risks as they emerge throughout the lifecycle 
of a trial(244).  Clinical trial units in Ireland should use this dynamic risk assessment 
approach to develop a RBM tool that meets the needs of their organisation. 
To date, evidence supporting the effectiveness of RBM tools in developing an 
effective monitoring plan is lacking (132). This is to be expected, as RBM tools are 
merely an instrument to guide RBM(10). Therefore, their effectiveness will be 
affected by clinical trial variables that are difficult, if not impossible, to control such 
as the experience of the clinical trial team, the IMP, clinical trial budget and the 
unpredictable risks of the study population(26). However, usability provides a marker 
for RBM tool quality as it assesses the extent to which an RBM tool can be used by 
clinical researchers to achieve RBM goals with effectiveness, efficiency, and 
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satisfaction(245).  In essence, a RBM tool designed for use by clinical researchers, 
should be easy to use, easy to learn, easy to remember (the instructions), and helpful 
to users(246).   
The NASA TLX questionnaire measured usability using six dimensions of workability 
which include mental demand, physical demand, temporal demand, overall 
performance, frustration level and effort(231). The results of the NASA TLX 
questionnaire show that none of the three RBM tools received low scores for all six 
dimensions of workability. All three RBM tools received an overall medium score for 
usability.  However, usability is a complex topic and therefore the quantitative survey 
used in this study, by itself does not provide an in depth analysis of the usability of 
RBM tools (247-249). More research is needed to fully understand if characteristics 
of a RBM tool impact on their usability (247-249). For instance, it would be helpful to 
conduct a qualitative study to explore the results of the NASA TLX questionnaire. 
Such a study would explore why the participants graded certain workability 
dimensions as low, medium or high. This information could be used to develop 
barriers and facilitators associated with RBM tool use (219).  
Given the limitations of our study, the generalizability of its findings should be 
interpreted with a degree of caution. However, by disseminating our experiences, we 
are supporting an ancillary recommendation by the Clinical Trials Transformation 
Initiative (CTTI) project on effective and efficient monitoring, to “share knowledge 
and experiences, so that best practices may be established”(29).  
Conclusion 
This is the first quality improvement (QI) intervention to support the introduction of 
RBM tools into academic led clinical trials units.  Our findings show that a brief, face-
to-face, interactive, educational workshop improves the use of RBM tools in clinical 
trials. This study supports the global initiative aimed at increasing QI use in clinical 
trials as one means to improve clinical trial methodology (148-150). 
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Chapter 7. Discussion 
7.1 Introduction 
The overarching aim of this thesis was to develop, implement and evaluate a quality 
improvement intervention to support the introduction of Risk Based Monitoring (RBM) 
into academic-led clinical trials in Ireland.   This research started in 2014, in anticipation 
of the revised ICH-GCP guidelines, which came into effect on 14 June 2017, which 
brought RBM to the forefront of clinical trial monitoring(126). 
This chapter firstly outlines the main findings of this thesis. Secondly, the main 
strengths and limitations of this work are highlighted. Thirdly, implications for practice 
are outlined. Fourthly, areas of future research are proposed. Finally, I provide a brief 
conclusion to the thesis. 
7.2 Summary of findings 
This thesis included four individual pieces of research that were guided by the 
components of the KTA framework (Table 22). The specific objectives of each piece of 
research were informed by the core components of the KTA framework, which are 
knowledge creation and the application of this knowledge into practice(151). This 
meant that at least one of the research elements had to create RBM knowledge, as 
knowledge creation is a core component of the KTA framework. Below is a summary 
of the key findings from each phase of the research(151) 
. 
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Table 22: Application of the KTA framework  
Phase KTA component Objective Study design Key findings 
1 Knowledge creation Examine how should RBM 
be implemented 
Systematic 
review 
Ninety-one potential RBM tools were 
identiﬁed and 24 were eligible for inclusion. 
These tools were published between 2000 
and 2015. Eight tools were paper based or 
electronic questionnaires and 16 operated as 
Service as a System (SaaS). Risk associated 
with the investigational medicinal product 
(IMP), phase of the clinical trial and study 
population were examined by all tools and 
suitable mitigation guidance through on-site 
and centralised monitoring was provided. It 
was possible to identify “best” RBM 
technique or tool as none of the RBM tools 
had been evaluated.  
 
2 Action Cycle 
• Identify problems and 
select knowledge 
• Adapt knowledge to 
local context 
• Assess barriers to 
knowledge use 
Identify the barriers and 
facilitator to RBM 
implementation in 
academic-led clinical trials 
in Ireland? 
Mixed 
methods- 
quantitative & 
qualitative 
study 
Barriers to RBM implementation included 
lack of RBM knowledge/training, increased 
costs caused by greater IT demands, 
increased workload for trial staff and lack of 
evidence to support RBM as an effective 
monitoring approach. Facilitators included 
participants’ legal obligation to perform RBM 
under the new ICH-GCP guideline, availability 
of RBM guidance and perception of cost 
savings by performing RBM in future trials. 
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3 Knowledge creation Investigate the difference 
between on-site and 
centralised monitoring in 
the TRUST study. 
Document 
analysis 
We found that on-site monitoring was used 
more frequently than centralised monitoring 
in the TRUST study. Sixteen of the seventeen 
recommended GCP monitoring activities were 
completed through on-site visits. In contrast, 
only eleven of the seventeen recommended 
monitoring activities were completed through 
centralised monitoring. 
4 Action cycle  
• Select, tailor and 
implement intervention 
• Monitor knowledge use 
• Evaluate outcome 
• Sustain on-going 
knowledge use 
Identify a suitable KT 
strategy to support the 
introduction and on-going 
use of RBM in academic-led 
clinical trials in Ireland 
Mixed 
methods  
The findings of the study show that a brief, 
face to face, interactive education workshop 
is an effective way to encourage RBM tool 
usage in academic led clinical trial units in 
Ireland. 
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7.2.1 Phase 1:  Knowledge creation  
Phase one of the thesis (chapter 3) involved the creation of RBM knowledge through 
the completion of a systematic review of RBM tools. The study was published in  
Contemporary Clinical Trials in 2016(132) and, as of September 2018, has been cited 
in six peer-reviewed papers and downloaded almost two thousand times, and the 
findings have been presented at two international and three local conferences.   
The review identified 24 RBM tools that met the Organisation for Economic Co-
operation and Development (OECD) classiﬁcation of RBM tools(132). These tools were 
published between 2000 and 2015. Eight tools were paper-based or electronic 
questionnaires and 16 operated as Service as a System (SaaS). All tools examined risks 
associated with the investigational medicinal product (IMP), phase of the clinical trial 
and study population and provided suitable mitigation guidance through on-site and 
centralised monitoring.  
However, the review did not identify a gold standard RBM technique or tool because 
none of the tools had been validated (3). It concluded that the lack of a validated 
approach used by RBM tools would make it difficult for clinical researchers to decide 
which RBM tool they should use when developing their RBM plan (3). To overcome 
this challenge, I applied the findings of the review to the ICH GCP’s and the OCED’s 
guideline for RBM and developed four criteria that should be considered when 
choosing a RBM tool (4, 6). These are: 
1. Ensure the RBM tool's baseline risk assessment process examines the risk 
indicators set out in the Risk indicator taxonomy for supervision of clinical trials on 
medicinal products. 
2. Ensure the RBM tool can support both on-site and centralised monitoring. For SaaS 
tools ensure that on-site monitoring data can be entered manually into the 
electronic data capture system. 
3. Ensure the RBM tool provides a process for systematic review of the trial's risk 
profile. 
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4. Ensure the RBM tool is cost efficient i.e. the paper-based tools are available free of 
charge however they need the support of an EDC system to perform centralised 
monitoring. 
The creation of criteria for RBM tool selection, along with the identification of 24 RBM 
tools were the main findings to arise from the systematic review. 
7.2.3 Phase 2- Action cycle 
Phase two of my thesis (chapter 4) was based on the action cycle of the KTA (Table 22). 
The aim of this phase was to complete the first, three subcomponents of the action 
cycle; which are to identify problems and select knowledge, adapt knowledge to local 
context and access barriers to knowledge use. To fulfill these criteria, I conducted a 
mixed methods study, which was published in Trials in 2016 (219) and was accepted 
for oral presentation at the Society for Clinical Trials 39th Annual Meeting in Portland, 
2018.  
The results of the study showed that participant’s inexperience of using RBM tools and 
performing centralised monitoring were the main barriers to RBM 
implementation(219). Most participants in this mixed methods study had never used 
or even knew what a RBM tool was. The study concluded that to increase the use of 
RBM tools, Irish clinical trial regulators should develop or select an approved RBM tool 
at a national level(219).  
Overall, this study confirmed the absence of, and the need for, training and the 
availability of guidelines to support the implementation of RBM in academic-led 
clinical trials through an increased use of RBM tools and centralised monitoring.  
7.2.3 Phase 3 – Knowledge creation  
The results of Phase 2 (chapter 4), mixed methods study showed that academic clinical 
researchers in Ireland had limited experience of conducting centralised monitoring 
and felt ill equipped to perform this monitoring method compared to on-site 
monitoring(219).  This result reflected the lack of centralised monitoring guidelines 
that existed(20). At that time point in my research for this thesis, only two studies had 
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retrospectively compared monitoring practices by testing if on-site monitoring findings 
could have been identified through centralised monitoring(20). Findings, from those 
two studies suggested critical on-site monitoring findings such as incorrect participant 
consent processes and inappropriate IMP dispensing could have been identified 
through central monitoring techniques. However, the results of those studies are 
limited: both used arbitrary criteria to classify monitoring activity and neither reviewed 
all monitoring findings from a completed trial (127, 226).  
To overcome this evidence gap, I conducted a Study Within a Trial (SWAT) to provide 
the first document analysis of on-site and centralised monitoring reports collected 
prospectively in a recent international multi-centre clinical trial - The TRUST Thyroid 
Trial(221).  This study is called “On-site versus centralised monitoring – the TRUST 
Thyroid Trial experience’ and described in detail in Chapter 5. 
The SWAT used deductive qualitative document analysis approach to compare both 
monitoring approaches by examining their use to fulfil ICH GCP’s monitoring guidance. 
Initially, I believed the results of this study would support the development of RBM 
guidelines. However, the external validity of the study results was limited because they 
were generated from a document analysis of a single clinical trial.  
7.2.4 Phase 4 – Action cycle 
The aim of Phase 4 (chapter 6) of the thesis was to complete the last four 
subcomponents of the Action cycle; which are select, tailor and implement a KT 
intervention, monitor its use, evaluate its outcome and sustain on-going knowledge 
use(151). To fulfill these criteria, I conducted a quality improvement (QI) study titled 
‘Introducing Risk-Based Monitoring tools into academic-led clinical trial units in Ireland: 
a quality improvement intervention’. 
The aim of this QI study was to determine if a brief, educational, interactive, face-to-
face workshop would result in increased use of RBM tools by academic clinical 
researchers in Ireland. Additionally, the study tested if RBM tool usability was linked 
to its usage. The results of the study show that a brief, face-to-face, interactive 
education workshop is an effective way to encourage RBM tool usage. This study 
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supports the global initiative aimed at increasing QI use in clinical trials to improve 
clinical trial methodology(237). However, this result should be considered with 
caution. QI interventions lack many of the stable characteristics generally assumed for 
studies of effectiveness(237).  For example, like many other QI interventions this study 
was not controlled, participants were purposely and not randomly sampled (147, 237). 
Due to differing characteristics of the study participants, the RBM tools and the 
organizations where the interventions were implemented, it is difficult to predict the 
effectiveness of a similar QI intervention or suggest its effectiveness would remain 
constant in differing contexts(237). 
7.2.5 Overall findings 
The findings of the thesis show that applying the KTA framework to empirical data 
guided by stakeholder engagement can led to an intervention that is implementable 
in clinical practice and has the potential to positively change clinical researchers 
monitoring practices. This thesis provides critical evidence on the complexities 
associated with implementing RBM in academic-led clinical trials. It provides practical 
recommendations to guide clinical researchers who wish to perform RBM. 
7.3 Strengths and weaknesses 
 Strengths  
This section provides a synopsis of the overall strengths and limitations of this thesis. 
The strengths and limitations of the individual papers have been provided in detail in 
the relevant chapters.   
This thesis has addressed a timely and relevant global research question in the area of 
clinical trial methodology(26). Although the FDA guidance, ‘A Risk-Based Approach’, 
has been final for six years, clinical researchers around the world are still struggling to 
implement monitoring practices that align with RBM(12). My research findings, 
presented in this thesis, include practical recommendations to guide policy makers, 
regulators and clinical researchers in developing strategies to support the 
implementation of RBM in their clinical trials units. The relevance of the findings to 
researchers organising clinical trials is shown by the fact that this work has been 
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presented at several scientific conferences both nationally and internationally 
(Appendix G and H). Furthermore, two of the four original research papers have 
already been published in peer-reviewed scientific journals (Appendix H).  For this 
thesis, at the end of this series of studies, the main product is a carefully developed 
Quality Improvement intervention to support the implementation of RBM.  
The systematic review and mixed methods study were conducted to inform the 
development of a specific intervention. However, the publication of these studies in 
international journals means they will also inform and benefit the work of other 
research groups aiming to follow the ICH-CGP guidelines and introduce RBM in their 
clinical trial units. The systematic review, through the identification and evaluation of 
grey and peer reviewed RBM tools has provided information on available RBM 
methodologies(132). It is the ﬁrst review to systematically identify and compare 
academic and commercial RBM tools for clinical trial monitoring. It makes a major 
contribution to the literature on RBM and provides RBM guidance to the global clinical 
trial community(132). Our ﬁndings support the OECD's goal of ensuring appropriate 
and harmonised understanding of risk assessment (13). 
The mixed methods study provides new insight into the barriers and facilitators that 
encourage or prevent clinical researchers from performing RBM in their clinical 
trials(219). It is the first comprehensive analysis of clinical trialists’ readiness and 
aptitude for RBM and will provide guidance to the international clinical trial 
community who strive to implement RBM. 
A major strength of the thesis was the inclusion of expertise from cross-functional 
areas of a clinical trial team(29). Any clinical trial is the result of the efforts of a diverse 
team including clinicians, monitors, statisticians, trial and data managers, study nurses 
and data managers(29, 170, 250). RBM, as emphasised throughout the TransCelerate 
position paper, is a cross-functional process that requires the skills and knowledge of 
all members of a clinical trial team(26). Similarity  Risk ADApted MONitoring 
(ADAMON) study team call for the perspectives of stakeholders involved in RBM (e.g. 
trial project leaders or principal investigators) to be considered in the development of 
future RBM strategies(29). In this thesis, the mixed methods study and Quality 
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Improvement study included a sample of all the types of researcher who would 
typically work on a clinical trial in an academic setting. These include PIs, nurses, 
doctors, monitors, pharmacists, managers and biostatisticians(23).  The diverse study 
population allowed for the collection of data from all types of clinical trial staff. 
Thus, an effective RBM plan must utilize the strengths of a clinical trial team(29). Every 
member of a clinical trial team has a role to play in ensuring that the trial is robust and 
contributes their personal skills to defining thresholds for unacceptable risk, 
identifying problematic data, investigating underperforming sites or applying 
appropriate interventions to minimize or prevent further issues(29). It is likely that no 
individual team member will be involved in every aspect of RBM, but they should have 
a good understanding of the importance of their role to ensuring the success of the 
overall process(170).   
In 2012, the OCED in their ‘Recommendation on the Governance of Clinical Trials’ said 
that efficient instruction and global training will be a crucial success factor to ensure 
appropriate and harmonised understanding and use of RBM tools(10). As far as I am 
aware, this thesis is the first research study to develop, implement and evaluate an 
educational workshop to support the use of RBM tools. The Quality Improvement 
study will help the global clinical trial community who wish to follow OECD’s 
recommendations and develop training to support RBM tool use(10, 32). 
Finally the thesis was directed by the Knowledge to Action Framework (KTA) (151). This 
framework has been used in practice with varying degrees of completeness(151). This 
thesis is one of the few studies that has completed all seven components of the KTA 
process that include identifying research problems and selecting knowledge ; adapting 
knowledge to local context; accessing barriers to knowledge use; selecting, tailoring 
and implementing intervention; monitoring knowledge use and evaluating outcome 
and sustaining knowledge use.(151). This thesis can be used a guide for other health 
professionals across the globe who face challenges of translating the best available 
evidence into timely health interventions that provide the most effective care and 
service(154). 
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 Limitations  
The thesis also had several limitations, and it should be noted that much of the 
research was conducted before the new ICH-GCP guidelines come into effect on 14 
June 2017.  A future longitudinal study would allow researchers to track the new ICH-
GCP’s effect on RBM uptake over time and explore its impact on clinical trial conduct 
and monitoring outcomes. Such a study could use the mixed methods study results as 
baseline data.  
In addition, as noted above, the results of the brief educational intervention outlined 
in chapter 4, should be considered with caution. Mainly due to the fact that 
conclusions about educational interventions cannot be taken on their own without 
considering the characteristics of the knowledge that was being transferred, the 
teacher/facilitator, participants and organizations(239). For instance, a different 
facilitator or different RBM tools in a similar QI study may increase or reduce the 
uptake of RBM tools(251). 
7.4 Implications for Practice 
Risk assessment and risk management are two key aspects of RBM implementation 
(26, 244). RBM is about taking a holistic approach to assess all possible risks related to 
a clinical trial and then developing an appropriate risk management plan which 
includes systematic monitoring and controlling/mitigating risks throughout the 
conduct of a study(23, 244). The correct identification and assessment of study specific 
risks, categorization and implementation of risk-based study specific monitoring plans 
are critical components the generation of ensure high quality clinical trial data that will 
enhance participant protection, build trial efficiencies and optimise clinical trial 
budgets(110).  
Presently, RBM tools provide the most comprehensive and structured guidance for 
RBM implementation(10, 132).  Our educational workshop included three RBM tools 
that met four pre-defined RBM tool selection criteria(132). Accordingly, all three RBM 
tools assess clinical trial risks that are set out in the Risk Indicator Taxonomy for 
supervision of clinical trials on medicinal products; they direct both confirming on-site 
174 
 
and centralized monitoring; they provide a process to systematically review a trial's 
risk profile and finally they were all freely available online(132).   
To date, evidence supporting the effectiveness of RBM tools is lacking(132). This is to 
be expected, as RBM tools are merely an instrument to guide RBM(10). Therefore, 
their effectiveness will be affected by uncontrollable clinical trial variables such as the 
experience of the clinical trial team, the IMP, clinical trial budget and the unpredictable 
risks of the study population(26). As highlighted in the QI study, clinical researchers 
have different needs and preferences for RBM tools that they choose to use in their 
clinical trials units. 
In the future, clinical researchers who wish to follow the ICH GCP guidelines and 
perform RBM should first either select or develop an RBM tool for their clinical trial 
unit(10, 32). Such a tool should fulfil the OCED’s requirement for an RBM tool. 
Accordingly, ﬁrstly they must support the assessment of risk in a clinical trial protocol 
and secondly, they should provide guidance for subsequent monitoring activity that 
can mitigate the risk identiﬁed (13). It is also important that the usability of an RBM 
tool is considered before it is selected for use in a clinical trial unit. If an RBM tool has 
good usability it can be used by clinical researchers to conduct RBM with effectiveness, 
efficiency and satisfaction.  
Furthermore researchers require training on how to use RBM tools(10).Therefore 
clinical trial units must select the RBM tools that are appropriate for them or develop 
a bespoke one (10, 32). However, whatever RBM technique is ultimately used, an 
emphasis on risk-based approaches will force the sponsor to take a more proactive 
approach to quality through a well-defined protocol, sufficient training and 
communication by highlighting those data most important to patient safety and the 
integrity of the final study results. Furthermore, RBM provides an opportunity for 
clinical researchers to identify the problems early provides the opportunity to refine 
procedures and address shortcomings as the trial is ongoing(213).  
While it may be possible to apply the experience gained in RBM from one trial towards 
another, it may not be as straightforward as applying the same sets of rules and 
programs to a new set of data(244). In many instances what constitutes as high risk 
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depends on several factors related to the disease, sponsor and site experience and the 
characteristics of the clinical trial(133). First-in-human studies, or trials involving 
special patient populations (e.g. paediatrics) or severe disease may have a low 
tolerance for risk among the safety indicators(146, 170). By contrast trials with one or 
more adaptations, many inexperienced sites or new or unfamiliar equipment may have 
stricter thresholds for quality metrics.  Therefore, clinical trial units must select a RBM 
methodology that is appropriate for their organisation. 
7.4.1 Implications for future RBM practice in clinical trial units in Ireland  
The concept of RBM implies that the chosen monitoring strategy is adapted to the local 
and trial-specific context (127). This means that a one-size-fits-all model is not possible 
and despite the availability of RBM guidelines, challenges still exist with respect to 
clinical researchers establishing a local RBM process and implementing it in the 
desired way (24, 127). Generic RBM tool such as the TransCelerate or the Risk 
assessment for risk adapted monitoring (RARAM) discussed in Chapter 6, may not be 
suitable for all clinical trials units. 
For clinical trial units that want to implement RBM in their clinical trial units, I 
recommend that these centers should first develop a RBM tool that is tailored to the 
needs of their clinical trial network and study population. As defined by the OCED and 
discussed in detail in Chapter 3, a RBM tool should fulfil two functions, ﬁrst they must 
support the assessment of risk in a clinical trial protocol and secondly, they should 
provide guidance for subsequent monitoring activity that can mitigate the risk 
identiﬁed (10).  When developing a RBM tool, clinical trial units should follow the six 
steps listed below. 
1. Assembled a Multi-Disciplinary Development Team 
The Multi-Disciplinary Development Team will develop the RBM tool. This team should 
include membership from each functional area in the clinical trial unit such as the 
study monitors, in-house clinical research nurses and PIs, biostatistics, clinical trial 
pharmacists and data management. The team should preferable include patient 
representatives as they play an important role in trial conduct.  
2. Develop a risk assessment process  
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The Multi-Disciplinary Development Team should then develop a risk assessment 
process. To be effective and sustainable, the risk assessment process needs to be 
simple, practical First the team should compile an exhaustive list of risks that they 
believe are associated with their trials. The Multi-Disciplinary Development Team 
should conduct this process through facilitated workshop to prevent siloed thinking. 
Workshops have shown to improve understanding of a risk by bringing together 
diverse perspectives. For example, when considering a clinical trial risk such as 
enrolment of an ineligible participants, workshop participants from Principles 
Investigators, study nurses, data managers, participants and monitors may each bring 
different information regarding causes, consequences, likelihoods. These risks should 
focus on patient safety, data quality and study integrity risks. The risks can be 
identified though a review of the historical experience of the Multi-Disciplinary 
Development Team’s management of clinical trials with a conventional monitoring 
strategy during the preceding years. Along with analysis of known risks associated with 
the population and study procedures/drugs. 
Once the risks have been identified they must be ranked and prioritised.  The risk 
should be ranked as low, medium or high based on their predicated severity and 
probability of occurring. The ranking system should be decided by the Multi-
Disciplinary Development Team.  
3. Develop a risk mitigation / clinical trial monitoring strategy 
 Instructions enable key players to make sure that the clinical trial is conducted, 
recorded and reported in accordance with the protocol, standard operating 
procedures, Good Clinical Practice (GCP) and applicable regulatory requirements. The 
monitoring plan should define what activities will be conducted off-site and 
centralized, as well as those that must be performed.  
4. Construct a RBM Tool template 
Transfer the data risk assessment process and the risk mitigation into one document 
titled ‘Risk Based Monitoring Tool’. Note the Risk Based Monitoring Tool’ may need to 
be tailored for each clinical trial.  
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5 Test for Usability by internal and external stakeholders 
Once the ‘Risk Based Monitoring Tool’ has been developed, the Multi-Disciplinary 
Testing team should test its usability with internal and external stakeholders that 
conduct clinical trials in the clinical trial unit.  Usability testing is a technique used in 
user-centered interaction design to evaluate a product by testing it on users. The 
results of the usability testing will show the effectiveness, efficiency and satisfaction 
with which specific to develop a RBM plan in the clinical trial unit.  There are various 
types of Usability Testing which could involve focus groups or in-depth interviews with 
test users.  
6: Perform routine evaluation and revision 
After completion of the development and validation of the RBM, the Multi-Disciplinary 
Development Team should establish a schedule to review and alter the RBM tool as 
required by the clinical trial unit.  
7.5 Direction for Future Research  
Each phase of this thesis identified areas that require future research. This is 
summarised below: 
• Phase 1: Risk based monitoring (RBM) tools for clinical trials: A systematic review. 
Future research direction: RBM tools for clinical trials are relatively new, their features 
and use vary widely, and they continue to evolve. This makes it difﬁcult to identify the 
“best” RBM technique or tool. Therefore, equivalence testing is required to determine 
if RBM strategies directed by paper based and SaaS based RBM tools are comparable. 
Such research could be embedded within multi-centre clinical trials and conducted as 
a SWAT (Study within a Trial). 
• Phase 2: Perceived barriers and facilitators to Risk Based Monitoring in academic-led 
clinical trials: a mixed methods study 
Future research direction: The cross-sectional nature of the research means that 
estimates of RBM implementation could only be assessed at one time point(214). It 
should also be noted that our study was conducted before the new ICH-GCP guidelines 
comes into effect on 14 June 2017(212). A longitudinal study should be conducted to 
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track RBM uptake over time and explore its impact on clinical trial conduct and 
monitoring outcomes. Such a study could use the results of the mixed methods study 
as baseline data. 
• Phase 3: On-site and centralised monitoring – the TRUST study experience 
Future research direction: ICH GCP’s emphasis on RBM is based on the assumption 
that it prevents wasting clinical trial resources, such as study budget and staff time, on 
monitoring activity that does not improve participant safety or data quality (24, 30, 
131).The results of our document analysis suggest on-site and centralised monitoring 
are being used to complete the same recommended monitoring activities, thus leading 
to research wastage. Our study showed all centralised monitoring activity was being 
completed through on-site monitoring. However, further work is necessary to clarify 
the proportions of both centralised and on-site monitoring necessary to implement 
RBM effectively.   
• Phase 4: Introducing Risk-Based Monitoring tools into academic-led clinical trial units 
in Ireland: a quality improvement intervention 
Future research direction: More in-depth research is needed to fully understand if the 
characteristics of a RBM tool impact on their usability. A qualitative study is needed to 
explore the results of the NASA TLX questionnaire. These results could be used by 
clinical researchers when developing their own RBM tools. 
7.6 Conclusions 
There is increasing recognition of the need to improve the quality and efﬁciency of 
clinical trials so that they can provide reliable and robust evidence needed by 
decision makers in health care who are faced by increasing demands and greater 
pressure on resources(149, 150, 222). This includes work to reduce waste in 
research, improve the selection of outcomes to measure and ensure that patients 
are more involved in all aspects of the trial(149, 222). Alongside this, the resources 
put into the monitoring of a trial need to be proportionate to the risks associated 
with that trial(110). 
Risk-based monitoring (RBM) has disrupted the clinical trial industry, challenging 
conventional monitoring norms(110). It moves away from the traditional approach of 
179 
 
frequent on-site visits and 100% source data verification toward a combination of 
activities, including centralized data collection and monitoring(23). The concept of 
RBM implies that the chosen monitoring strategy is adapted to the local and trial-
specific context(135). This means that a one-size-fits-all model is not possible(130). 
However, despite the availability of RBM tools and guidelines, challenges still exist with 
respect to clinical researchers establishing a local RBM process and implementing it in 
the desired way(29, 135). 
Despite these challenges, RBM is now gaining acceptance as the preferred method of 
choice for monitoring clinical trials(23). Endorsed by regulators and leading industry 
forums, and further driven by escalating drug development costs and enabling 
technology shifts making data available real time, the clinical researchers are moving 
from a mode of resistance to acceptance(12, 141). The effective implementation of 
RBM requires delicately interweaving changes in technology, processes, people, and 
perspectives(141).  
This thesis examined the multiple challenges that exist and proposed potential 
solutions to support RBM implementation.  It adds to the current limited evidence base 
regarding the implementation of RBM into academic led clinical trials by responding 
to the call for interventions, such as the educational workshop, (chapter 4) to support 
RBM implementation(32). The choice of intervention option for this thesis was not 
clear at the outset. However, taking the time to explore the views of clinical 
researchers resulted in the development if QI intervention that was appropriate for 
the study population. 
To conclude, the value of effective monitoring for clinical trials should not be 
underestimated and should be considered at the very early stages of trial design(156). 
Conducting clinical trials in resource-limited settings can be challenging, but careful 
planning and effective, well-conducted risk-based monitoring can assist in ensuring 
reliable and accurate scientific results while adhering to local and international 
guidelines and maintaining patient safety throughout(142, 244). However, there are 
still numerous challenges that lie ahead for RBM(201).  First, individuals will have to 
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get comfortable with risk-based approaches(201). Training in RBM methodologies is a 
good first step, but practical experience will help refine RBM procedures over time. 
 
Clinical researchers must be cautious when implementing RBM. This type of 
monitoring like traditional intensive on-site monitoring cannot correct the inherent 
problems in a clinical trial design or its implementation by a study team. Furthermore, 
the assumption that RBM can replace the need for on-site monitoring and improve 
participant safety or data quality has yet to be proven (26, 121). In 2017, the results of 
the Risk ADApted MONitoring (ADAMON) study were published(142). This study was 
a prospective, stratified, cluster-randomised, controlled study comparing extensive 
on-site monitoring with RBM in eleven clinical trials(142). The study found that 
compared with extensive on-site monitoring, the potential benefit of RBM was small 
and showed limited ability to identify systematic problems in the conduct of clinical 
trials.  This finding is similar to the results of the TEMPER trial published in 2018, which 
retrospectively compared RBM to routine intensive onsite monitoring performed in 
three clinical trial trials(113).  The TEMPER trial like the ADAMON trial, showed that 
RBM may be of potential use but needs improvement and that research into assessing 
the risks of a clinical trial is warranted before a gold standard RBM approach can be 
established. In addition, both the ADAMON study and the TEMPER trial found that that 
no monitoring strategy, be it RBM or traditional monitoring can correct deficiencies in 
a clinical trial design or conduct(113, 142).  Therefore, it is imperative with RBM, that 
the monitoring approach should not exempt the sponsor or investigator from their 
responsibilities to develop and conduct high quality clinical trials. Even if the trial is 
considered ‘low risk’ participant safety must not be neglected, and the integrity of the 
trial must be upheld (129).  
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Appendix 
Appendix A: Supplementary material for Chapter 2. Methods  
Supplementary material 1. Knowledge Translation Frameworks 
Table 23: Knowledge Translation Frameworks 
Knowledge 
Translation 
Framework 
Publication 
year 
Description Suitability 
Coordinated 
Implementation 
Model (CIF) 
1993 Model of research implementation that outlines the overall practice environment to 
capture schematically the competing factors of influence to the implementation process. 
CIF model demonstrates some of the additional and largely unexploited routes through 
which research information could influence clinical care. This model considers the views, 
activities, and available implementation instruments of at least four potential groups. 
Those include community interest groups, administrators, public policymakers, and clinical 
policymakers 
Not suitable. This model 
requires the input of four 
different stakeholders and 
this thesis is only examining 
RBM from a clinical 
researcher’s 
perspective(154) 
The Ottawa Model 
of Research Use 
(OMRU) 
1998 Developed within the context of continuity-of-care innovations. It is a 6-staged approach 
as follows:  
Set the Stage 
Specify the Innovation 
Not suitable. This model 
does not include a process 
to support the sustainable 
of the intervention(252) 
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Assess the Innovation, Potential Adopters and the Environment for Barriers and 
Facilitators 
Select and Monitor the Knowledge Translation Strategies  
Monitor Innovation Adoption 
Evaluate Outcomes of the Innovation 
The Promoting 
Action on Research 
Implementation in 
Health Services 
Framework 
(PARIHS) 
1998 Framework proposes that successful implementation of research in practice is a function 
of the relation between the nature of the evidence, the context in which the proposed 
change is to be implemented and the mechanisms by which the change is facilitated 
The framework is expressed as: 
SI = f (E, C, F) 
where SI=successful implementation, E=evidence, C=context, F=facilitation and f=function 
of. 
Not suitable. Not enough 
evidence on RBM to support 
the implementation of the 
PARIHS framework(253). 
The Knowledge to 
Action 
(KNOWLEDGE TO 
ACTION) Process  
2006 The KNOWLEDGE TO ACTION process has two components: (1) knowledge creation and 
(2) action. Each component contains several phases. The authors conceptualized the 
knowledge to action process to be complex and dynamic, with no definite boundaries 
between the two components and among their phases. The phases of the action 
component may occur sequentially or simultaneously, and the knowledge-creation-
component phases may also influence the action phases. 
Suitable: framework will 
support thesis aim and does 
not require previous RBM 
knowledge or multiple 
stakeholder involvement 
(151) 
Stetler Model of 
Research 
Utilization 
2001 This framework assesses how research findings and other relevant evidence can be applied 
in practice. The Stetler model of Research Utilization consists of five phases that guide:  
Phase 1:  the selection of research evidence;  
Phase 2: formal utilization critique of studies;  
Not suitable. Not enough 
evidence on RBM to support 
Phase 1 of this 
framework(254).  
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Phase 3: consideration of research findings in the context of other forms of evidence, fit 
to the setting that is considering implementation, alignment with current practice and 
feasibility of adoption;  
Phase 4: the type of use decision and specifics of implementation; and  
Phase 5: dynamic evaluation, the details of which depend on the use decision.(254) 
Critical Realism and 
the Arts Research 
Utilization Model 
(CRARUM) 
2009 CRARUM combines critical realism and arts-based methodologies. Critical realism 
facilitates understanding of clinical settings by providing insight into the interrelationship 
between its structures and potentials, and individual action. The arts-based methodology 
fosters reflection on the ways in which contextual factors influence and shape clinical 
practice, and how they may facilitate or impede change. The combination of critical realism 
and the arts within the CRARUM model promotes the successful embedding of 
interventions, and greater impact and sustainability 
Not suitable. Arts –based 
methodology not 
appropriate for study 
population (255). 
Consolidated 
Framework for 
Implementation 
Research (CFIR) 
2009 CFIR is a conceptual framework used to guide the systematic assessment of multilevel 
implementation contexts to identify factors that might influence intervention 
implementation and effectiveness.  
Not suitable-this framework 
is used to support the 
implementation of an 
intervention and not to 
guide its development.(256) 
Theoretical 
Domains 
Framework (TDF) 
2012 The TDF framework consists of 12 theoretical domains) groups of constructs from theories 
of behaviour change) that can be considered when exploring influencing factors and 
designing interventions. 
Not suitable – framework 
based on behavioural 
change theory which is 
beyond the scope of the 
thesis(257) 
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Normalised 
Process Theory 
2010 NPT focuses on the work that individuals and groups do to enable an intervention to 
become normalised. There are four main components to NPT: coherence (or sense -
making); cognitive participants (or engagement); collective action (work done to enable 
the intervention to happen); and reflexive monitoring for formal and informal appraisal of 
the benefits and costs of the intervention 
Not suitable-this framework 
is used to support the 
implementation of an 
intervention and not to 
guide its development(258). 
Diffusion of 
Innovation Theory 
1962 The key elements in diffusion research are: 
Innovation: Any idea, practice, or object that is perceived as new by an individual or other 
unit of adoption could be considered an innovation available for study 
Adopters: individuals, but can also be organizations, within social networks, or countries. 
Communication Channels: Communication channels allow the transfer of information 
from one unit to the other 
Time: The passage of time is necessary for innovations to be adopted; they are rarely 
adopted instantaneously. 
Social system: There are many roles in a social system, and their combination represents 
the total influences on a potential adopter. 
 
Not suitable- this 
framework requires an 
implementation period for 
knowledge users to adopt a 
new idea. The thesis has a 
strict time restriction which 
means this framework 
could not be implemented 
correctly in the thesis(259) 
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Appendix B: Supplementary material for Chapter 3. Systematic review  
Supplementary material 2: Systematic review search results  
 
Search Engine: Pubmed 
Date: 20/02/2016 
Term Results 
1. Clinical Trial[MeSH Major Topic] 43176 
2. trial[Title/Abstract] 419952 
3. randomised trial[Title/Abstract] 6641 
4. randomized trial[Title/Abstract] 33132 
5. randomised controlled trial[Title/Abstract] 13003 
6. randomized controlled trial[Title/Abstract] 39420 
7. control trial[Title/Abstract] 3729 
8. controlled clinical trial[Title/Abstract] 9942 
9. clinical research study[Title/Abstract] 141 
10. clinical protocol[Title/Abstract] 1392 
11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 448763 
12. risk[MeSH Major Topic] 26688 
13. risk assessment[MeSH Major Topic] 21510 
14. "risk assessment tool" 1043 
15. risk factors[MeSH Major Topic] 973 
16. risk analysis[Title/Abstract] 3498 
17. #12 OR #13 OR #14 OR #15 OR #16 30614 
18. monitoring 492712 
19. risk-based monitoring[Title/Abstract] 26 
20. data monitoring[Title/Abstract] 588 
21. remote monitoring[Title/Abstract] 1060 
22. statistical monitoring[Title/Abstract] 48 
23. risk adapted on site monitoring 23 
24. risk proportionate monitoring 30 
25. on site monitoring[Title/Abstract] 168 
26. clinical trial monitoring[Title/Abstract] 26 
27. centralised monitoring[Title/Abstract] 8 
28. centralized monitoring[Title/Abstract] 36 
29. monitoring method[Title/Abstract] 988 
30. monitoring strategy[Title/Abstract] 347 
31. targeted monitoring[Title/Abstract] 56 
32. monitoring technique[Title/Abstract] 816 
33. "quality assurance" 64062 
34. "quality management" 16620 
35. #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR 
#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR 
#34 
565626 
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36. #11 AND #17 1069 
37. #35 AND #36 60 
 
Search engine: Embase  
Date:  20/02/2016 
Term Results 
1. 'clinical trial'/mj ‘  17,113  
2. 'trial':ab,ti 568,568 
3. 'randomised trial':ab,ti 8,767 
4. 'randomized trial':ab,ti 42,869 
5. 'randomised controlled trial':ab,ti 17,651 
6. 'randomized controlled trial':ab,ti 54,705 
7. ' control trial':ab,ti 5,429 
8. 'controlled clinical trial':ab,ti 12,847 
9. 'clinical research study':ab,ti 197 
10. 'clinical protocol':ab,ti 2,124 
11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10  579,595 
12. 'risk'/mj 56,486 
13. 'risk assessment'/mj 30,816 
14. 'risk assessment tool' 1,714 
15. 'risk factor'/mj 40,826 
16. 'risk analysis':ab,ti 5,600 
17. #12 OR #13 OR #14 OR #15 OR #16 131,014 
18. 'monitoring' 706,524 
19. 'risk based monitoring':ab,ti 56 
20. 'data monitoring':ab,ti 1,156 
21. 'remote monitoring':ab,ti 1,781 
22. 'statistical monitoring':ab,ti 74 
23. risk AND adapted AND on AND site AND monitoring 38 
24. risk AND proportionate AND monitoring 46 
25. 'on site monitoring':ab,ti 226 
26. 'clinical trial monitoring':ab,ti 49 
27. 'centralised monitoring':ab,ti 8 
28. 'centralized monitoring':ab,ti 51 
29. 'monitoring method':ab,ti 1,355 
30. 'monitoring strategy':ab,ti 457 
31. 'targeted monitoring':ab,ti 69 
32. 'monitoring technique':ab,ti 1,001 
33. 'quality assurance' 35,784 
34. 'quality management' 41,298 
35. #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR 
#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR 
#34 
774,530 
36. #11 AND #17 6,201 
37. #35 AND #36 321 
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Supplementary material 3: Appraisal Checklist for Grey literature (AACODS) checklist 
Author Authority 
 
Are the authors of 
the article listed? 
 
 
Yes/No 
Accuracy 
 
Does the item have a 
clearly stated aim or 
brief? 
 
Yes/No 
Coverage 
 
Are any limits 
clearly stated? 
 
 
Yes/No 
Objectivity 
 
Does the work seem 
to be balanced in 
presentation? 
 
Yes/No 
Date 
 
Does the item 
have a clearly 
stated date 
related to 
content? 
 
Yes/No 
Significance 
 
Is the item 
meaningful? 
 
 
Yes/No 
Score 
(1-6) 
 
Smith et al(169) 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
6 
 
MRC/DH/MRHA (28) 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
6 
 
Journot et al (260) 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
6 
 
Transcelerate (26) 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
6 
 
Yee et al (173) 
 
Yes 
 
Yes 
 
Yes 
 
No 
 
Yes 
 
Yes 
5 
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Brosteanu et al (261)  
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
6 
Nordic Monitoring 
Network(27) 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
6 
Swiss Clinical Trial  
Organisation(170) 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
6 
Bioclinica(174)  
Yes 
 
Yes 
No Yes Yes Yes 5 
DATATRAK(175) Yes Yes No No Yes Yes 5 
ICON(176) Yes Yes No No Yes Yes 5 
JMP(177) Yes Yes No No Yes Yes 5 
Meditata(262) Yes Yes No No Yes Yes 5 
xClinical(179) Yes Yes No No Yes Yes 5 
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Flex Databases(180) Yes Yes No No Yes Yes 5 
Triumph Research 
Intelligence  
(TRI)(181) 
Yes Yes No No Yes Yes 5 
Cyntegrity(172) Yes Yes No No Yes Yes 5 
CluePoints(182) Yes Yes No No Yes Yes 5 
Remarque 
Systems(183) 
Yes Yes No No Yes Yes 5 
Algorics(184) Yes Yes No No Yes Yes 5 
Kestrel Biologic(185) Yes Yes No No Yes Yes 5 
Clindata(186) Yes Yes No No Yes Yes 5 
Clinerion (187) Yes Yes No No Yes Yes 5 
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ERT(188) Yes Yes No No Yes Yes 5 
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Appendix C: Supplementary material for Chapter 4 
Supplementary material 4: Survey questionnaire 
 
 
 
 
 
 
 
 
 
Clinical trial monitoring is mandatory under ICH-GCP guidelines. In June 2015, the ICH 
published the Integrated Addendum to ICH GCP, which recommends systematic, prioritised, 
risk-based monitoring for clinical trials. 
 
The aim of this survey is: 
- To identify how academic led clinical trials are monitored in Ireland. 
- To better understand the reasons for using the methods identified. 
- To identify any limitations of these methods. 
 
 
1. Please indicate if you consent for your answers to be used for research purposes 
Yes    No  
 
Please enter your contact details below. This information will be used to track the survey's 
response rate 
        2. Name:       
 3. Address:      
 
 
Monitoring Survey 
Welcome to My Survey 
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4.1 Please indicate the University/Clinical trial unit you are affiliated with? 
• University College Cork (UCC)     
• National University of Ireland Galway (NUIG)  
• Wellcome Trust -HRB Clinical Research Facility at St. James Hospital 
• Royal College of Surgeons Ireland (RCSI)  
• University College Dublin (UCD)  
* 4.2 What is your role within a clinical trial? 
• Principal Investigator (PI)    
• Clinical trial nurse 
• Project Manager 
• Quality Manager 
• Study doctor 
• Study Monitor 
• Biostatistics 
• Pharmacists 
 
Other (please specify)       
 
* 4.3 Please identify the Medical Therapeutic area/areas in which you work? (i.e. 
Neurology, Oncology, Geriatrics) 
 
 
 
Demographics 
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4.4 How many years have you been working in clinical trial research? 
 
• <1 
• 1-3 
• 4-6 
• >6 
 
4.5 Please list any specific clinical trial training that you have received? (I.e. 
GCP training, postgraduate training) 
 
4.6 Since the introduction of the European Communities (Clinical Trials on 
Medicinal Products for Human Use) Regulation in 2004, have you conducted 
international multi-site trials? 
                       Yes                          No 
 
4.7 Since the introduction of the European Communities (Clinical Trials on 
Medicinal Products for Human Use) Regulation in 2004, how many of 
the following types of clinical trials have you conducted? ** Regulated 
trials need HPRA approval 
 0 1 2-3 >3 
Industry/commercial-led, regulated clinical trial     
Academic-led, regulated clinical trial     
Non-regulated clinical trials     
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* 4.8 Since 2004, have you participated in a HPRA/ IMB clinical trial inspection? 
 
Yes                          No 
 
 
 
 
 
* 5.1 Do you think the following features of a clinical trial are important to 
consider when deciding the frequency of on-site visits required to monitor 
the trial? 
 Very 
important 
Moderately 
important 
Not 
important 
Investigational Medicinal Product (IMP)    
Budget    
Study population    
Phase of trial (I, II, III, and IV)    
Experience of clinical trial team    
 
5.2 Which of the following factors would you use to trigger an onsite monitoring visit? 
(Select all that apply)? 
Several protocol deviations  
Incidence of adverse events  
Upcoming regulatory inspection  
Low recruitment rate  
Inexperience of clinical trial site  
High subject drop-out rate  
             
        Other (please specify)       
  
On-site monitoring  
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**Centralised monitoring is also known as remote monitoring. This monitoring system 
allows clinical researcher to remotely monitor clinical trial activity such as recruitment 
trends, data entry etc. 
 
6.1 Does your clinical research unit have a SOP for centralized monitoring? 
Yes  
No 
Not sure 
 
6.2 Since 2004, have you used centralised data monitoring for the following quality 
management activities in a clinical trial? 
 
 
 
 Yes No Not 
sure 
To assess protocol compliance    
To completely replace on-site monitoring     
To supervise study recruitment     
To record pharmacovigilance information (I.e. adverse events, 
SAEs) 
   
To organise sampling and material logistics (e.g. specimen 
collection, storage and shipment) 
   
To inspect the informed consent process     
To identify missing data     
Centralised monitoring  
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* 6.3 Please indicate how important you consider the following factors to be as 
a barrier to implementing centralised monitoring in clinical t r ia l s? 
 Very 
important 
Moderately 
Important 
Not 
important 
Lack of education and training in centralised 
monitoring 
   
Cost associated with centralised monitoring    
IT demands of centralised monitoring    
Workload associated with centralised 
monitoring 
   
 
 
 
  7.1 Please name the most clinical trial you worked on? 
                   
7.2   In this clinical trial did you or your study team complete an assessment of risk prior to 
developing the monitoring plan? 
Yes - if Yes please only answer questions 8.1-8.4 
No - if No please only answer questions 9.1-9.3 
Not sure - if Not sure please only answer questions 10.1-10.2 
 
 
Note: These questions are only relevant to participants that answered ‘Yes’ to question 7.2 In 
this clinical trial did you or your study team complete an assessment of risk prior to developing 
the monitoring plan? 
 
8.1 Did you or your study team use a risk assessment tool when assessing the risks in your 
clinical trial? **a risk assessment tool is used to identify the risks within an approved clinical 
trial protocol that can be mitigated through monitoring. For example, a risk assessment tool 
could be an in-house SOP, a checklist     or a computer programme** 
Risk Based Monitoring 
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Yes 
No  
Not sure 
 
8.2 Please indicate why you or your study team performed a risk assessment? (Select all that 
apply) 
 
To fulfil HPRA/IMB requirements  
To improve patient safety  
To improve data accuracy  
To reduce monitoring costs  
To determine a schedule for on-site monitoring visits  
To fulfil GCP requirements  
Not sure 
 
 
 
Other           
 
8.3 Do you think the following are important features of a risk-assessment tool? 
 
 Very 
important 
Moderately 
Important 
Not 
important 
It is GCP compliant    
Training is required to operate the tool    
It is approved by the HPRA    
It requires specialised software to operate    
It is paper based    
It contains less than 20 risk assessment 
questions 
   
It has been formally validated for precision 
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It clearly defines risk and appropriate 
monitoring guidelines 
   
 
8.4 Since 2004, have you implemented a risk-based monitoring plan in a clinical trial? 
 
Yes  
 
No 
 
I am not familiar with the term risk-based monitoring  
 
 
 
Note: These questions are only relevant to participants that answered ‘No’ to question 7.2 –
In this clinical trial did you or your study team complete an assessment of risk prior to 
developing the monitoring plan?’ 
 
* 9.1 Please indicate why you or your study team did not perform a risk assessment? (Select 
all that apply) 
 
It is not a GCP requirement  
Do not have the expertise to perform a risk assessment  
It is too time consuming  
It is too expensive   
It will not improve patient safety  
Not sure   
 
Other            
 
 
9.2 Do you think the following are important features of a risk-assessment tool? **a risk 
assessment tool is used to identify the risks within an approved clinical trial protocol that can 
be mitigated through monitoring.  For example, a risk assessment tool could be an in-house 
SOP, a checklist or a computer programme** 
 
 Very 
important 
Moderately 
Important 
Not 
important 
It is GCP compliant    
Training is required to operate the tool     
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It is approved by the HPRA     
It requires specialised software to operate    
It is paper-based     
It contains less than 20 risk assessment questions    
It has been formally validated for precision    
It clearly defines risk and appropriate monitoring 
guidelines 
   
 
 
9.3 Since 2004, have you implemented a risk-based monitoring plan in a clinical trial? 
 
Yes  
 
No 
 
I am not familiar with the term risk-based monitoring  
 
 
 
 
Note: These questions are only relevant to participants that answered ‘Not sure’ to question 
7.2 –‘In this clinical trial did you or your study team complete an assessment of risk prior to 
developing the monitoring plan? 
 
10.1 Do you think the following are important features of a risk-assessment tool? **a risk 
assessment tool is used to identify the risks within an approved clinical trial protocol that can 
be mitigated through monitoring.  For example, a risk assessment tool could be an in-house 
SOP, a checklist or a computer programme** 
 
 Very 
important 
Moderately 
Important 
Not 
important 
It is GCP compliant    
Training is required to operate the tool     
It is approved by the HPRA     
It requires specialised software to operate    
It is paper-based     
It contains less than 20 risk assessment questions    
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It has been formally validated for precision    
It clearly defines risk and appropriate monitoring 
guidelines 
   
 
 
10.2 Since 2004, have you implemented a risk-based monitoring plan in a clinical trial? 
 
Yes  
 
No 
 
I am not familiar with the term risk-based monitoring  
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Supplementary material 5: Topic guide for semi structured questionnaires  
 
Study: Implementation of risk-based monitoring in academic led Irish clinical trials   
 
Document: Interview Topic Guide  
Hi (participant’s name) , thank you for completing the Monitoring Survey. The questions 
I will ask you today will further explore your view and opinions on risk-based monitoring. There 
are no right answers so please stop me if you want me to clarify any question.  
            
1. To start could you tell me about the most recent clinical trial you worked on and your 
role in that trial? 
2. At what stage is that trial- recruitment, close out?  
3. How is/was that trial monitored?  
4. Did you/team use on-site and/or centralised monitoring?  Did you use an electronic 
clinical report form eCRF? 
5. Who developed the initial monitoring plan? (You, monitor, PI) 
6. Were you involved in the development of the monitoring plan?   
7. Why did you/they choose this type of monitoring? (Cost, IT, staff)  
8. Was the monitoring plan reviewed and changes during the trial duration?  
9. In November 2016, the ICH-GCP will launch the updated version of GCP which will 
recommend clinical trial Sponsors use risk based monitoring. Are you familiar with the 
new guideline?  
10. If no, we can review paragraph from ‘participant sheet’? 
11. Are you familiar with the term risk-based monitoring?  
12. Have you ever conducted risk-based monitoring in a clinical trial?  
13. Do you think risk based monitoring will change you monitor a clinical trial in the future? 
14. Do you feel there are benefits associated with RBM? 
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15. Do you think there are limitations associated with RBM?  
16. In future trials you work on, would you consider using risk-based monitoring? 
17. In these trials, would you like to be involved in the development of a monitoring plan? 
18. Do you feel you have the skills and knowledge base to conduct RBM?  
19. What intervention or support would help you conduct risk-based monitoring? 
20. Who should lead this intervention? 
21. How much commitment would you give to the intervention?  
22.   Do you have any additional information you would like to add? 
23. Do you have any questions for me?  
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Appendix D: Supplementary material for Chapter 5 
Supplementary material 6: Automatic and manual central monitoring queries 
from the TRUST Thyroid Trial  
 
Table 24. Automatic and manual queries 
Automatic data queries 
1. Participants concomitant medication 
2. Participants eligibility   
3. Missed or delayed participant visits 
4. Data entry errors 
5. Dispense Medication  
6. Participant withdrawal procedure  
7. Delayed study tests such as blood samples 
8. Missing barcodes on blood work  
9. Inaccurate study test results  
Manual data queries  
9. Missed or delayed participant visits 
10. Data entry errors 
11.  concomitant medication 
 
  
204  
 
 
 
Appendix E: Supplementary material for Chapter 6 
 
Supplementary material 7: Protocol for quality improvement study 
Protocol - RBM tool usability study 
 
 
Factors that determine the selection of a Risk Based Monitoring (RBM) tool in 
academic (Investigator led) clinical trials 
Aim: Select an operational Risk Based Monitoring (RBM) tool for use in academic led 
clinical trials  
Background 
In November 2016, the ICH published the integrated addendum to ICH-GCP E6 (R2), 
advising Sponsors to develop a systematic, prioritised, risk-based approach to 
monitoring clinical trials. This process is more commonly known as risk-based 
monitoring (RBM). It incorporates both centralised monitoring conducted off-site 
through an examination of electronic trial data and on-site monitoring practices that 
are proportional to the risks associated with the clinical trial. These risks relate to the 
Investigational Medicinal Product (IMP), the study population and the robustness of 
the study design. For example, in high-risk trials RBM may involve 100% source data 
verification (SDV) onsite monitoring while for low-risk trials it may include 80% SDV 
through centralised and on-site monitoring practices. Moreover, once a trial starts, 
sponsors must continuously review the risk profile of a trial while it is on-going and 
modify monitoring practices accordingly. In 2013, the Organisation for Economic Co-
operation and Development (OECD) published guideline which advised clinical 
researchers to use a RBM tool when developing their RBM plan. Such tools should 
have two functions, firstly they must support the assessment of risk in a clinical trial 
Version 1 – 27/02/2017 
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protocol and secondly, they should provide guidance for subsequent monitoring 
activity that can mitigate the risk identified.  
Project Context  
In 2016, I published a systematic review which identified 24 RBM tools that met the 
OECD’s criteria: https://www.ncbi.nlm.nih.gov/pubmed/27641969  .They differed in 
terms of mode of administration (paper based versus software as a system (SAAS), 
baseline risk assessment process and guidance for on-site and centralised 
monitoring. However, I did not find a gold standard or validated RBM approach.  
To help overcome this challenge, I applied the findings of my systematic review to 
the ICH-GCP and OECD guideline to develop four criteria to consider when choosing 
a RBM tool.  
These are: 
1. Ensure the RBM tool's baseline risk assessment process examines the risk 
indicators set out in the Risk indicator taxonomy for supervision of clinical trials on 
medicinal products. 
2. Ensure the RBM tool can support both on-site and centralised monitoring. For SaaS 
tools ensure that on-site monitoring data can be entered manually into the system  
3. Ensure the RBM tool provides a process for systematic review of the trial's risk 
profile 
4. Ensure the RBM tool is cost efficient i.e. the paper-based tools are available free 
of charge however they need the support of an Electronic Data Capture (EDC) system 
to perform centralised monitoring. 
Subsequently three of the 24 RBM tools I identified fulfilled my 4 recommendations 
listed above.  These tools are freely available for use my clinical researchers. 
RBM tools include: 
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Nordic Monitoring Centre - Risk Assessment Tool  
Swiss Clinical Trial Organisation – Risk Assessment Form 
TransCelerate – Risk Assessment and Categorisation Tool (RACT) 
Note: Each tool must be completed by a clinical trial team including quality and 
clinical staff.  
Project Aim: To test the usability of the three RBM tools listed above and select a 
suitable one for use in academic led trials in UCC, NUIG and RCSI.  
Methods  
Study Design: Usability testing 
* N.B Usability testing refers to evaluating a product or service by testing it with 
representative users. It is more commonly used in software development  
Data Collection:  
Quantitative data:  Results from the NASA Task Load Index (NASA-TLX) questionnaire, 
the time taken to complete each RBM tool. 
NASA-TLX is a widely used, subjective, multidimensional assessment tool that rates 
perceived workload in order to assess a task, system, or team's effectiveness or other 
aspects of performance. It was developed by the Human Performance Group at 
NASA's Ames Research Center over a three-year development cycle that included 
more than 40 laboratory simulations.  
NASA-TLX originally consisted of two parts: the total workload is divided into six 
subscales that are represented on a single page https://en.wikipedia.org/wiki/NASA-
TLX#/media/File:NasaTLX.png 
 Six subscales are: Mental Demand, Physical Demand, Temporal Demand, 
Performance, Effort and Frustration. Each subscale is rated for each task within a 100-
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points range with 5-point steps. These ratings are then combined to the task load 
index. Providing descriptions for each measurement can be found to help 
participants answer accurately. These descriptions are as follows: 
• Mental Demand 
How much mental and perceptual activity was required? Was the task easy or 
demanding, simple or complex? 
• Physical Demand 
How much physical activity was required? Was the task easy or demanding, slack or 
strenuous? 
• Temporal Demand 
How much time pressure did you feel due to the pace at which the tasks or task 
elements occurred? Was the pace slow or rapid? 
• Overall Performance 
How successful were you in performing the task? How satisfied were you with your 
performance? 
• Frustration Level 
How irritated, stressed, and annoyed versus content, relaxed, and complacent did 
you feel during the task? 
• Effort 
How hard did you have to work (mentally and physically) to accomplish your level of 
performance? 
Setting: The study will be conducted in four academic Clinical Research Facilities in 
Ireland  
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Study population: Quality Managers, Monitors, Research Nurses, Sponsor medic, 
data manager, biostatistician- staff usually involved in developing monitoring plans. 
Usability Testing – Standard Operating Procedure (SOP) 
Procedure 
1. Assemble your ‘MDTT’.  This is the team who normally develop, write, review 
and approve monitoring plans at your institution.  The MDTT may include 
Monitors, Quality Managers, Research Nurses, Sponsor Medic Data 
Managers, biostatisticians – the composition of the MDTT may be different at 
different sites depending on local practice.  Document the members of your 
MDTT indicating their role (e.g. monitor, quality manager etc.). 
 
2. Select a clinical trial protocol you wish to use for the Usability testing. These 
protocols should pertain to clinical trials of Investigational Medicinal Products 
(IMP) that are or were sponsored by your organisation. The clinical trial phase 
is not significant. However, where possible please use the version of the 
protocol that was in use at study start-up. Document the protocol version, 
name, clinical trial phase, and IMP for each protocol. 
 
3. Arrange a time and date for the members of your MDTT to meet and 
collectively apply the 3 RBM tools to each of the three clinical trial protocols. 
This gives a total of 3 assessments. This step will involve the MDTT completing 
the RBM tools with data from the respective protocol. This process will result 
in the identification of a risk classification for each clinical trial and 
corresponding monitoring guideline on how each risk should be mitigated 
through on-site and/or centralised monitoring.  
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4. After you have applied each of the 3 RBM tools independently to each 
protocol, please complete a NASA TLX questionnaire to record the usability 
of each RBM tool. 
 
5. In February 2018, MDTTs will be asked to complete a short questionnaire to 
establish if they have introduced one or more of the RBM tools into their 
organisation. 
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Supplementary material 8: NASA Task Load Index (NASA TLX) 
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        Supplementary material 9: The Template for Intervention Description and Replication (TIDieR) checklist 
 
Item 
no. 
Item QI Intervention  
              Brief name  
1. Provide the name or a phrase that describes the 
intervention. 
Introducing Risk-Based Monitoring tools into academic-led clinical trial units in 
Ireland: a quality improvement intervention 
 
              Why  
2. Describe any rationale, theory, or goal of the 
elements essential to the intervention 
At the time the intervention was developed and implemented, the use of RBM tools 
by academic clinical researchers in Ireland was low and lack of education and training 
was the main barrier to RBM tool use. The intervention is an education QI 
intervention. The aim of this study was to develop, implement and evaluate an 
educational Quality Improvement (QI) intervention. Educational QI intervention 
provide an opportunity for participants to increase their knowledge or understanding 
of a specific topic and by doing so allows the mechanism to drive behaviour change. 
The educational QI intervention in this study aimed to teach academic clinical 
researchers in Ireland about RBM tools and by doing so change their monitoring 
behaviour and support them to use RBM tools when developing monitoring plans for 
their clinical trials.    
 
              What 
3 Materials: Describe any physical or 
informational materials used in the 
The physical material used in the intervention included paper based RBM guidelines, 
RBM tools and paper-based outcome questionnaires.  
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intervention, including those provided to 
participants or used in intervention delivery or 
in training of intervention providers. Provide 
information on where the materials can be 
accessed (e.g. online appendix, URL). 
 
1. Paper based RBM guidelines  
 
• Purpose: To educate participants on the fundamental concepts of RBM to ensure 
they had enough baseline knowledge required to work the RBM tools.  
 
• Guideline used and rationale for its selection 
 
 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice (18) 
This guideline provides the premise for RBM and explains what clinical trial 
regulators will expect to see in a RBM plan. 
 
 OECD Recommendation on the Governance of Clinical Trials (10) 
This guideline was the first and only document to define and explain the 
characteristics of a RBM tool. 
 Risk indicator taxonomy for supervision of clinical trials on medicinal products 
(125) 
First peer reviewed paper explaining the risk assessment process of involved 
in RBM and identified and categorized I risk indicators that may present an 
elevated safety and/or ethical risk for participants, and/or for data in a 
clinical trial. 
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2. RBM tools  
Purpose:  interactive education session to educate the participants on the 
components of a RBM tool and how to apply the RBM tool to a study protocol to 
develop a RBM plan 
 
 RBM tool and rationale for its inclusion in the QI intervention 
The QI intervention included three paper based RBM tools the Risk Assessment Tool 
(RAT) (22), Risk assessment for risk adapted monitoring (RARAM) (159) and the Risk 
Assessment Categorisation Tool (RACT) (20) 
 
Each of the three RBM tools included in the QI intervention fulfilled four criteria for a 
RBM tools. They each assessed risks in accordance with the Risk Indicator Taxonomy 
for supervision of clinical trials on medicinal products. They supported both on-site 
and centralised monitoring and provided a process to systematically review trial's risk 
profile. Finally, each tool was cost efficient as cost as they were freely available on the 
internet.  
 
3. Outcome questionnaires 
 
Purpose: To evaluate the outcome of the QI intervention – first to assess the 
usability of the RBM tools and secondly to determine if the intervention supported 
the participants to change their monitoring behaviour and use RBM in their clinical 
trials.  
 
Questionnaires and their selection 
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 NASA Task Load (NASA-TLX) questionnaire – is a paper-based questionnaire that 
measured the measured workload of a task.  
After each MDTT applied the three RBM tools to their selected clinical trial 
protocol, they completed three NASA-TLX questionnaires, each questionnaire 
measured the perceived workload associated with each RBM tool included in 
the QI intervention. 
 Utilization Scale questionnaire - used to measure how much, if any, the MDTT’s 
had used the knowledge they gained in the QI intervention and implemented 
the RBM tools in their clinical trial units.  
Six months after participating in the QI intervention, the four Quality and 
Regulatory Affair Managers from each MDTT, one from each clinical trial unit, 
were asked to complete a Utilization Scale questionnaire The Quality and 
Regulatory Affair Managers were the only members of each MDTT asked to 
complete this questionnaire because they coordinate clinical trial monitoring 
in their clinical trial unit. 
 
4 Procedures: Describe each of the procedures, 
activities, and/or processes used in the 
intervention including any enabling or support 
activities. 
The procedures in the QI intervention were rolled out in four stages listed below. 
Stage 1: Introduction / baselined RBM education session - face to face workshop 
Stage 2: RBM tool application - face to face workshop 
Stage 3: Evaluation 
Stage 4: Follow up 
               Who provided 
5 For each category of intervention provider (e.g. 
psychologist, nursing assistant), describe their 
expertise, background and any specific training 
given. 
The intervention was developed by an expert panel of clinical trial experts. The expert 
panel consisted of seven clinical trial experts which included a trial sponsor (1), 
principle investigators (2), trial coordinator (1), quality manager (1) and a trial doctor 
(1) and a clinical trial monitor (1). All panel members had a minimum of five years and 
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maximum of twenty years’ experience of developing and implementing clinical trial 
monitoring plans.  
               How 
6 Describe the modes of delivery (e.g. face-to-face 
or by some other mechanism, such as internet 
or telephone) of the intervention and whether it 
was provided individually or in a group. 
The QI intervention was delivered through a face to face intervention workshop. The 
Intervention was facilitated by one researcher who delivered the intervention in the 
same format for each of the four Multi -Disciplinary Testing Teamss (MTDDs).  
              Where 
7 Describe the type(s) of location(s) where the 
intervention occurred, including any necessary 
infrastructure or relevant features 
The QI intervention was delivered in four academic run clinical trial units 
in Ireland based in publically funded hospitals. Each of the four clinical 
trial units deliver research across numerous clinical specialties including 
oncology, cardiology, neurology, ophthalmology and neonatal research 
in accordance with the EU Clinical Trials Directive and the new ICH GCP 
guideline (56). At the time of the QI study, none of the units used a RBM 
tool and none had conducted RBM.  
 
Each clinical trial unit assembled a Multidisciplinary Testing Team 
(MDTT). For this study, we defined a MDTT as a collection of members 
within each clinical trial unit who normally develop, write, review and 
approve monitoring plans for trials that their clinical trial unit manages. In 
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total, the four MDTTs consisted of 12 participants; study doctor (n=1), 
quality and regulatory affair managers (n=4), clinical trial monitors (n=5) 
and research nurses (n=2). 
              When and How Much 
8 Describe the number of times the intervention 
was delivered and over what period including 
the number of sessions, their schedule, and their 
duration, intensity or dose. 
The intervention was delivered once to each of the four MDTTs. The intervention 
lasted approximately two hours.  
              Tailoring  
9 If the intervention was planned to be 
personalised, titrated or adapted, then describe 
what, why, when, and how. 
All MDTTs received the same intervention  
              Modifications  
10 If the intervention was modified during the 
course of the study, describe the changes (what, 
why, when, and how). 
The intervention was not modified during the study.  The intervention was delivered 
in the same sequence for each of the MDTTs.  
              How Well 
11 Planned: If intervention adherence or fidelity 
was assessed, describe how and by whom, and if 
any strategies were used to maintain or improve 
fidelity, describe them. 
The trial fidelity was not formally assessed however, the intervention was delivered as 
planned Facilitated by the fact that the intervention was a simple and not a complex 
intervention The members of each MDTTs were comparable in terms of academic 
background and clinical trial experience. Thus, the intervention did not have to be 
tailored to address the needs of individual MDTTs. Therefore, the objectives of the 
intervention was consistent for each MDTT and delivered as planned.  
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12 Actual: If intervention adherence or fidelity was 
assessed, describe the extent to which the 
intervention was delivered as planned. 
N/a – see comment above  
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Appendix F. Research training undertaken during doctoral research 
 
Postgraduate courses 
June 2017 Postgraduate Diploma in Clinical Trials 
University of Edinburgh (online)  
May 2017 Certificate in Biomedical Device Manufacture Cork Institute of 
Technology (CIT)     
May 2015 Postgraduate Certificate in Clinical Trials 
University of Edinburgh (online) 
UCC Postgraduate modules  
2015 PG6003:  Teaching and Learning assignment 
2015 PG6009: Graduate Information Literacy Skills 
2015 PG6001: STEPS - Scientific Training for Enhanced Postgraduate 
Study 
2016 PG7021:  An Introduction to the Ethics of Health Research 
2016 PG6025: Community - Based Participatory Research 
2016 PG6008:  Qualitative Data Analysis and Computer Assisted 
Qualitative Data Analysis Software for the Social Sciences and 
Humanities 
Clinical trial courses 
April 2017 Clinical investigation of medical devices for human subjects –ISO 
14155 
HRB Clinical Research Facility Cork 
December 2016 Good Clinical Practice (GCP) Course 
HRB Clinical Research Facility Cork 
  
Appendix G. Prizes and awards relating to doctoral research 
 
September 2016 Best speaker award at the Irish Centre for Fetal and Neonatal 
Translational Research (INFANT) Research Day 2016 
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Appendix H. Dissemination of doctoral research 
Supplementary material 9: Peer reviewed PhD publications and links to 
papers  
• Hurley C, Shiely F, Power J, Clarke M, Eustace JA, Flanagan E, et al. Risk 
based monitoring (RBM) tools for clinical trials: A systematic review. 
Contemporary clinical trials. 2016;51:15-27. 
https://www.ncbi.nlm.nih.gov/pubmed/27641969 
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• Hurley C, Sinnott C, Clarke M, Kearney P, Racine E, Eustace J, et al. 
Perceived barriers and facilitators to Risk Based Monitoring in academic-
led clinical trials: a mixed methods study. Trials. 2017;18(1):423. 
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-
2148- 
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Conference proceedings – oral presentation  
 
September 2015 Risk based monitoring. The Health Research Board- Trial 
Methodology Research Network – 3rd Annual Trial 
Methodology Symposium, Dublin  
 
September 2016 Best speaker award at the Irish Centre for Fetal and Neonatal 
Translational Research (INFANT) Research Day 2016 
 
October 2017 Risk based monitoring. The Health Research Board- Trial 
Methodology Research Network – 3rd Annual Trial 
Methodology Symposium, Dublin  
 
May 2018 Perceived barriers and facilitators to Risk Based Monitoring 
in academic-led clinical trials: a mixed methods study. Society 
for Clinical Trials, 39th Annual Meeting, Oregan USA 
 
 
 
 
Conference proceedings: poster presentations 
2015 HRB Trials Methodology Research Network (HRB-TMRN), Cork 
 
2015 3rd International Clinical Trials Methodology Conference, Glasgow 
2016 SCT 37th Annual Meeting (2016) - Society for Clinical Trials (SCT), 
Montreal 
 
2016 Irish Research Nurses Network, Dublin 
 
2016 SPHeRE ‘Structured Population and Health-services Research 
Education’ Conference, Dublin  
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Appendix I. Additional academic activity during the conduct of this research 
 
Webinar  
September 2016 Risk based monitoring and the introduction of the new ICH-GCP 
guideline for the Health Research Board – Trial Methodology 
Research Network (HRB-TMRN) 
 
 
Teaching 
2015 Tutor for Introduction to Health Statistics module on the BSc in 
Public Health Sciences UCC  
2015 Tutor on the Data Management for Public Health module as 
part of the BSc in Public Health Science 
2016 Tutor for Introduction to Health Statistics module on the BSc in 
Public Health Sciences UCC 
2016 Tutor on the Data Management for Public Health module as 
part of the BSc in Public Health Science  
2016 Thesis Tutor for the Master’s in Public Health (MPH) 
 
Research funding awards 
September 2014 Strategic Research Fund PhD Scholars Programme, University 
College Cork 
Awarded €45000 to pay for my student fees and stipend 
 
September 2015 Doctoral Travel Bursary, University College Cork 
Awarded €1000 to attend the conference in Montreal 
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May 2016 Study Within a Trial Study (SWAT) funding, Health Research 
Board-Trial Methodology Network (co-applicant) 
Project awarded €10000 to conduct a conduct a SWAT titled - 
Patients’ perspectives and preferences on clinical trial 
dissemination: the TRUST Thyroid trial experience 
 
Peer reviewer   
2016 BMC Medical Research Methodology, journal 
2017 Trials – journal  
 
Co-author papers on clinical trial and clinical trial methodology 
• Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RG, Mooijaart SP, Hurley 
C et al. Thyroid hormone therapy for older adults with subclinical 
hypothyroidism. New England Journal of Medicine. 2017. 
https://www.nejm.org/doi/full/10.1056/NEJMoa1603825 
 
• Stott DJ, Gussekloo J, Kearney PM, Rodondi N, Westendorp RG, Mooijaart S, 
Hurley C et al. Study protocol; Thyroid hormone Replacement for Untreated 
older adults with Subclinical hypothyroidism-a randomised placebo controlled 
Trial (TRUST). BMC endocrine disorders. 2017;17(1):6. 
https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-017-
0156-8 
 
• Racine E, Hurley C et al. Study within a trial (SWAT) protocol. Participants' 
perspectives and preferences on clinical trial result dissemination: The TRUST 
Thyroid Trial experience. Contemporary Clinical Trials Communications. 2017. 
https://www.sciencedirect.com/science/article/pii/S2451865417300479 
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• Racine E, Hurley C, Cheung A et al. Participants’ perspectives and preferences 
on clinical trial result dissemination: The TRUST Thyroid Trial experience. HRB 
Open Res 2018, 1:14  
https://hrbopenresearch.org/articles/1-14/v1 
Poster 
• Siobhan Browne, Kenneth Burns, Rebecca Dennehy, Ruth Hally, Caroline 
Hurley, Blazej Kauca, Aine Kearns, Catherine O’Mahony, Katarzyna Pyrz, Sarah 
Robinson, Kieran Walsh. Building RRI Proficiency through a Community-Based 
Participatory Research Module. 7th Living Knowledge Conference. 
https://www.researchgate.net/publication/304659058_Building_RRI_Proficiency_thr
ough_a_Community-Based_Participatory_Research_Module 
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